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1.  Introduction  
 
 
 
“Before you believe the results from any study, always say to them  
LIAR, LIAR, LIAR!! 
See if you can prove them wrong”. 
Mahomed Patel. 
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Overview of MAE experience  
My MAE placement was a joint position between Queensland Children’s Medical 
Research Institute (QCMRI) and the Communicable Diseases Branch (CDB) of 
Queensland Health (QH) both located at Herston in Brisbane. 
 
During my placement at QCMRI, formerly located on the grounds within the old Royal 
Children’s Hospital at Herston, Brisbane, we moved offices at least three times. The 
Edith Cavell building was a two-story beautiful old heritage listed building that used to 
be the nurses quarters. Unfortunately storm season damaged the building on a regular 
basis to the point where it became uninhabitable. At the same time, construction of 
the new Lady Cilento Children’s Hospital at South Brisbane was underway with the 
Centre for Children’s Health Research (CCHR) on the same campus. The CCHR, where 
QCMRI is now located, is a beautiful new building with spectacular views over South 
Bank and the Brisbane River. And storm proof, hopefully. 
 
My QCMRI placement was within the Respiratory Infection Outreach And Research 
team (RiOAR), not to be confused with the Brisbane Roar soccer team. My supervisor 
for this placement was Dr Kerry-Ann O’Grady who was the group leader. Within our 
team were many other students, all with different research projects underway which 
was an exciting space to be. My supervisor for my QH placement was A/Prof Stephen 
Lambert who was also located in Edith Cavell and then CCHR building once we moved. 
 
During my placement I was able to spend a short time at one of the busiest public 
health units in South Brisbane for my outbreak investigation project. This was a fun, 
dynamic unit with a very experienced team of public health epidemiologists and I 
learned a great deal in a short period of time there. 
 
Kerri Viney was my academic supervisor through the National Centre for Epidemiology 
and Population Health (NCEPH) located at the Australian National University in 
Canberra. Kerri was a great fit for me. She was a grounded, supportive helpful 
supervisor and never made me feel like my questions were stupid when in hindsight 
they probably were!   
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Summary of public health experience 
Epidemiological study (Chapter 2) 
 
In Australia, influenza vaccination is recommended for all pregnant women. Evidence 
to date suggests influenza vaccination has not been associated with adverse birth 
outcomes, however there are still concerns about safety and risks of receiving a 
vaccine during pregnancy.  This chapter describes a nested retrospective cohort study 
comprising 7,121 mother-infant pairs in Australia from 2012-2014. The study focussed 
on whether mothers who had received an influenza vaccination during pregnancy had 
poorer birth outcomes compared to unvaccinated women in pregnancy. Birth 
outcomes examined were infant birthweights and prematurity. I found there were no 
differences in birth outcomes between the vaccinated and unvaccinated groups. This 
was the first Australian study examining birth outcomes of influenza vaccination during 
pregnancy and as such, results will make an important contribution to the literature on 
this topic. 
 
Analysis of a public health dataset (Chapter 3) 
 
Morbidity and mortality of pertussis is highest in infants under six months of age. 
Control efforts focus on preventing disease in this age group by minimizing exposure 
by other infected cases. This project presents results from a retrospective case series 
analysis of all valid and probable pertussis notifications in Queensland from 1997-2014 
by age group. Over this 18 year observation period, amongst children less than three 
years of age, notifications of pertussis were most common amongst infants <4 months 
of age. Increases in pertussis notifications from 2009 coincided with a substantial 
increase in the number of cases diagnosed by PCR. The results in this case series are 
consistent with that of overseas literature. It will important to monitor the outcomes 
of the implementation of the Queensland maternal pertussis vaccination program 
which commenced on 01 August 2014 regarding pertussis notifications in infants less 
than four months of age. 
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Outbreak investigation (Chapter 4) 
 
This chapter describes an outbreak investigation of 85 confirmed cases of Salmonella 
Typhimurium (MLVA 03-12-11-12-524 and MLVA 03-13-11-12-524) in South-East 
Brisbane in January 2015. Cases experienced gastrointestinal illness following the 
consumption of Kim Bap (Korean style sushi). The descriptive study involved 
epidemiological, laboratory and environmental investigations. Twenty-two cases were 
hospitalised, seven of these (32%) were children. The likely vehicle of transmission of 
infection for this outbreak (Kim Bap sushi) was distributed by one producer to multiple 
food retail outlets in South-East Brisbane. Once supply of this product had ceased 
there were no further reported cases of illness. I was unable to determine any 
associations between food exposures and illness due to the absence of a comparison 
group. 
 
Evaluation of a surveillance system (Chapter 5) 
 
Hepatitis A virus (HAV) in Australia remains a nationally notifiable disease and control 
is considered to be a high public health priority. This evaluation of the current 
surveillance system for HAV in Queensland examined acceptability and timeliness. A 
detailed retrospective case series data analysis and genotype analysis was also 
conducted to determine sensitivity, representativeness and data quality. Age and sex 
data were complete, however risk factor data were largely incomplete. Data quality for 
travel history, post exposure prophylaxis vaccination, Indigenous status, mechanism of 
infection and hospitalisations were poor. Most cases of HAV are now acquired as a 
result of overseas travel or exposure to a returning overseas traveller. The timeliness 
of all aspects of the current system is reassuring however there needs to be a 
sustained improvement in completeness of data at every step, particularly for 
identification of Aboriginal and Torres Strait Islander people and for risk factor data.  
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2. Epidemiology project: Birth outcomes for 
Australian mother-infant pairs who self-reported 
receiving an influenza vaccine during pregnancy, 
2012-2014. 
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Prologue 
I had been employed as the national coordinator of the prospective cohort study 
‘FluMum’ when I was accepted into the MAE program. My main career interest is in 
perinatal epidemiology so I was very keen to remain involved in the study and examine 
birth outcomes for my epidemiology project. Being involved from the conception of 
this study to the final delivery has been very rewarding. 
My Role 
My part in this project involved developing a nested dataset to analyse national birth 
outcomes of the FluMum study. It involved; writing a protocol and adapting a study 
participant questionnaire, attending chief investigator meetings and conducting data 
linkage of laboratory confirmed influenza for six study sites through the state health 
departments. I was invited to present preliminary results of this study to my peers at 
the NCEPH seminar series during March 2015 courseblock. I was also accepted to give 
an oral presentation at the 2015 Communicable Disease Control conference in 
Brisbane which fulfilled a core component of the MAE program. A draft paper of the 
results from this study is in preparation for submission to a scientific journal which also 
fulfils a core component of the MAE program. 
Lessons Learned 
One very unexpected but grateful outcome that arose from this project was data 
analysis skills. I never dreamed I would be someone who could use the statistical data 
analysis program ‘Stata’. Really use it. Having gone from someone who was scared of 
do-files to creating my very own ‘sophisticated’ (not my words) do-file to perform the 
analysis component of this project makes me feel very proud. I would like to 
acknowledge Ross Andrews for his limitless patience and lightning quick responses to 
my ‘tiny’ opportunistic Stata queries. I hope I have taught him something too. Another 
unexpected outcome was finding myself using terminology such as ‘compared to 
what?’, ‘it depends’ and ‘within cohort comparisons’ and thinking to myself ‘what’s my 
denominator’…I am finally starting to feel like a real epidemiologist. 
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Public Health Implications 
Maternal influenza vaccine uptake is a public health policy initiative that has been 
advocated for more than a decade without any systematic initiatives to monitor 
implementation or birth outcomes.1 Providing further evidence around the safety of 
receiving a vaccine during pregnancy, particularly infant birthweights and prematurity 
may help increase uptake of the vaccine. This may reduce the morbidity and mortality 
that results from influenza infection when it occurs during pregnancy.2  
Acknowledgements 
I would like to acknowledge the FluMum investigator team for their support of me 
doing this project as well as the study coordinators at each of the ‘FluMum’ sites 
around the country who were responsible for the excellent quality of data collected. 
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Abstract 
Introduction 
Influenza vaccination is recommended for women who will be pregnant during the 
influenza season. Safety and effectiveness are key influences of vaccine uptake for 
both vaccine providers and parents. While the evidence to date suggests influenza 
vaccination has not been associated with adverse birth outcomes, there are still 
concerns about safety and risks of receiving a vaccine during pregnancy.  To date there 
have been no studies or systematic reviews that have been large enough to exclude 
risks of relatively rare adverse events. My epidemiology project is part of an ongoing 
national cohort study ‘FluMum’ and comprised over 7, 120 participants. To date it is 
the largest cohort of mother-infant pairs in Australia. I aimed to assess the relationship 
between receiving an influenza vaccination during pregnancy and prematurity and 
infant birthweight. 
Methods 
I conducted a nested retrospective cohort study using data collected between 01 April 
2012 and 31 December 2014 from the overarching ‘FluMum’ study. These data were 
from mother-infant pairs at time of enrolment. The primary exposure of interest for 
this nested study was self-reported receipt of an influenza vaccination during 
pregnancy. The primary outcomes of interest were birthweights in grams of infants 
and gestations in weeks of the mother at time of birth of the infant. The primary 
analyses were comparisons of these birth outcomes between mothers who received 
an influenza vaccine during pregnancy with unvaccinated mothers. Maternal co-
morbidities and risk factors for influenza infection were also examined  
Results 
I found there were no differences in birth outcomes between the vaccinated and 
unvaccinated groups. Of the 7,121 mother-infant pairs who were enrolled in the study, 
the mean maternal age was 31.7 years. The mean gestation at birth was 38.7 weeks 
for both groups; mean birthweight was 3332 grams whilst 52% of infants were male. 
The ratio of maternally vaccinated:unvaccinated participants was 1:1.9 (34% v 66%) 
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Conclusion 
This is the first Australian study examining birth outcomes of influenza vaccination 
during pregnancy and as such, these results will make an important contribution to the 
literature on this topic. The birth outcomes results arising from this study are 
reassuring. In relation to the safety of receiving a maternal influenza it can be deemed 
appropriate to offer the vaccine to all pregnant women in accordance with the current 
recommendations in Australia. 
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Introduction 
Influenza is an acute viral illness affecting the respiratory tract and can be highly 
infectious.3 There are three major strains; influenza A, B and C. The A and B strains 
cause significant seasonal morbidity and mortality but are potentially vaccine 
preventable.4 Severity of symptoms vary but influenza generally causes fever, 
headache, dry cough, fatigue and sore throat.3 The disease severity is highest in 
infants, the elderly and pregnant women.4 
 
Worldwide, influenza infection during pregnancy causes increased morbidity and 
higher rates of hospitalisation than those of the general population, especially for 
women with pre-existing respiratory conditions like asthma and bronchitis.4 During 
influenza pandemics, 50% of the deaths that occurred among women of child-bearing 
age were amongst pregnant women.2 Elevated morbidity and mortality rates were 
evident during the 2009 (H1N1) influenza pandemic, which increased the emphasis on 
pregnant women being deemed a priority group for vaccination both in Australia and 
overseas.5-8 
 
Influenza vaccination is recommended for women who will be pregnant during the 
influenza season.8 Safety and effectiveness are key influences of vaccine uptake for 
both vaccine providers and parents.9 While the evidence to date suggests influenza 
vaccination has not been associated with adverse birth outcomes,10-14 there are still 
concerns about safety and risks of receiving a vaccine during pregnancy.9  A systematic 
review on the safety of maternal vaccination did not find evidence of increased risks of 
adverse birth outcomes following vaccination.14 Other studies infer the same message 
regarding safety of maternal vaccination and birth outcomes however there have been 
no studies or systematic reviews that have been large enough to exclude risks of 
relatively rare adverse events.11-13,15-18 
 
In Australia, maternal influenza vaccination during pregnancy is recognised as the 
primary strategy to prevent influenza illness during pregnancy. It is a public health 
policy initiative that has been advocated for more than a decade by Commonwealth 
and State Governments.8 However despite this, there have been no systematic 
initiatives employed to monitor its implementation or assess birth outcomes.1 I 
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conducted a nested study which focussed on the safety of receiving an influenza 
vaccine during pregnancy with respect to infant birthweights and prematurity. If there 
is evidence that antenatal vaccination is safe in terms of these birth outcomes in the 
Australian context, this may facilitate increased uptake of the vaccine during 
pregnancy. 
 
Literature review 
Description of search methods 
I conducted a literature search of SCOPUS and PubMed databases using the search 
terms “Safety of influenza vaccine in pregnancy” AND “Birth Outcomes” AND 
“Australia”. This yielded zero results. I then removed “safety of” to broaden the search. 
This also produced no results. After I removed “Australia”, the modified search then 
yielded a total of 161 articles (Figure 2.1).  
 
I then refined the search terms and restrictions. This involved excluding; articles in 
another language other than English, laboratory based studies, case reports, letters, 
comments, editorials and book chapters. This search yielded 96 results. Given that new 
and emerging research is being conducted in maternal vaccination, I further limited 
the search to publication dates since the year 2007. I scanned these for duplicates and 
relevance, then produced a shortlist of six unique articles, which I subsequently 
evaluated and synthesized (Table 2.1). 
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Figure 2.1:  Literature review flowchart with number of results for searches of birth 
outcomes and influenza vaccine in pregnancy in Australia in PubMed and 
Scopus, 2015. 
 
 
 
  
PubMed 
“Influenza vaccine in 
pregnancy” AND 
“Birth outcomes” AND 
“Australia” 
N=0 
SCOPUS 
“Influenza in pregnancy” 
AND 
“Birth outcomes” AND 
“Australia” 
N=0 
PubMed 
“Influenza vaccine 
in pregnancy” AND 
“Birth outcomes”  
N= 79 
SCOPUS 
“Influenza vaccine 
in pregnancy” AND 
“Birth outcomes”  
N= 82 
Limits 
English articles only 
NO book chapters, 
letters, comments, 
notes, editorials or 
conference papers 
SCOPUS 
N= 53 
articles 
PubMed 
N= 43 
articles 
Abstract titles 
scanned and reviewed 
for relevance and 
duplicates- post 2007 
N= 6 unique articles 
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Table 2.1:  Summary of research articles on maternal vaccination safety, 2007-2015 
 
Author, 
Year  
Study Design Sample 
Size 
Country Study Objective Key results 
Tamma 
et al., 
2009 
Systematic 
review 
11 studies, 
96,027 
participants 
USA Safety of 
maternal 
vaccination 
No increased risk of 
adverse birth 
outcomes  
Bratton 
et al., 
2014 
 
Meta-
analysis 
7 studies, 
116,001 
participants 
USA Birth outcomes-
safety 
No differences in 
stillbirths or 
spontaneous 
abortions 
Sheffield 
et al., 
2012 
Retrospective 
cohort 
10,225 
participants 
USA Birth outcomes-
safety of 1st 
trimester 
influenza 
vaccination 
No differences in 
birth outcomes 
Legge  
et al., 
2014 
Retrospective 
data analysis 
12,223 
participants 
Canada Safety of 
maternal 
influenza 
vaccination-
neonatal 
outcomes 
No increased risk of 
adverse birth or 
neonatal outcomes. 
Stillbirth data not 
included in the 
analysis 
Omer  
et al., 
2011 
Retrospective 
cohort 
analysis 
4,168 
participants 
USA Birth outcomes-
safety 
Immunisation 
provided protection 
against prematurity 
and low birthweight 
Pasternak 
et al., 
2012 
Registry 
based data 
analysis 
53,432 
participants 
Denmark Birth outcomes-
safety of 2009 
H1N1 pandemic 
vaccine 
No differences in 
adverse birth 
outcomes with 
influenza vaccination 
during pregnancy 
 
A systematic review by Tamma et al.,11 found no adverse birth outcomes using data 
pooled from eleven studies following maternal influenza vaccination during pregnancy. 
The birth outcomes examined in this review included prematurity, birthweights of 
infants, rates of caesarean sections, congenital anomalies and neonatal morbidity and 
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Apgar scores. A large proportion of the studies included in the systematic review were 
greater than ten years old however, and sample sizes were small with one study 
having no control group. All of the studies included in this systematic review occurred 
before the 2009 H1N1 influenza pandemic and none of the studies were conducted in 
the Southern hemisphere.  
 
Bratton et al.,14 conducted a systematic review and meta-analysis using seven studies 
and found no increased risk of stillbirth or spontaneous abortion in women who 
received an influenza vaccine during their pregnancy compared to unvaccinated 
pregnant women. The study design for six out of seven of these articles reviewed were 
cohort studies with large sample sizes and hence power to detect an association 
between receipt of vaccination during pregnancy and fetal loss on an individual study 
basis. However, power was diminished when these studies were pooled for the meta-
analysis and only one study adequately captured potential confounding factors. There 
were no validation data collected for trimester of pregnancy for receipt of influenza 
vaccination which is important when assessing risk and determining whether the 
vaccine was given prior to, or following fetal loss. The analyses were heavily based on 
one specific vaccine used during the 2009 H1N1 influenza pandemic and not seasonal 
influenza vaccines, therefore comparisons cannot reliably be made nor conclusions 
drawn.19 Stated limitations by authors of both the systematic review and meta-analysis 
included the use of databases as well as population registries with potential high risks 
of selection and measurement biases.  
 
A retrospective cohort study by Sheffield et al., in the USA assessed the safety of first 
trimester receipt of an influenza vaccination on birth outcomes such as stillbirths, 
neonatal deaths, prematurity and congenital malformations.12 There was no evidence 
of differences in birth outcomes between the vaccinated and unvaccinated pregnancy 
cohort. This study was well powered due to the large sample size and a comprehensive 
list of potential confounding factors were collected from the participants and included 
in the analyses. There were large numbers of high-risk participants in this study who 
would normally be targeted for influenza vaccination during pregnancy due to 
increased risks of complications. Also, this study offered influenza vaccination free to 
all enrolled participants, further increasing potential selection bias. Vaccination status 
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was obtained from hospital records at the recruitment site, which may have resulted in 
some women being incorrectly classified as unvaccinated if an influenza vaccination in 
pregnancy was received from a source other than the hospital. Due to the large sample 
size though, any difference in significance would have been minimal. 
 
Population-based retrospective data analysed by Legge et al.,13 examined birth and 
neonatal outcomes of influenza vaccinated and unvaccinated women in pregnancy 
from one province in Canada. This was a large sample size (12,233) and therefore well 
powered. The results found a protective effect of receiving an influenza vaccine during 
pregnancy in relation to birthweights, prematurity and babies that were small for 
gestational age which is consistent with the literature. Legge et al. collected data on 
livebirths and stillbirths but excluded stillbirths from the analysis.13 For safety statistics, 
it may have been useful to know the proportions of mothers who had birthed a 
stillborn baby and received influenza vaccine during pregnancy compared to those 
who delivered a stillbirth and not received a vaccination though numbers would have 
been small. Dates of receipt of maternal vaccination were also unavailable for this 
study so validation of influenza vaccine being administered and trimester of pregnancy 
was unable to be determined. Again as with other studies, absence of trimester of 
vaccination status hinders the ability to establish whether influenza vaccine was 
administered prior to, or following any adverse fetal or maternal outcomes, or assess 
whether there are differences in perinatal outcomes depending on the trimester of 
vaccination given.  
 
Consistent with other studies presented in this literature review, safety studies in the 
US by Omer et al.,6,18 and in Denmark by Pasternak et al.,20 analysed birth outcomes 
such as prematurity, birth defects and birthweights. These studies found no increased 
risk of adverse outcomes from receiving an influenza vaccination during pregnancy and 
indeed showed a protective effect of receiving the vaccine during pregnancy in relation 
to low birth weights, prematurity and rates of stillbirth. This is also consistent with 
current literature available. 
 
Whilst there is evidence from the Northern hemisphere that maternal influenza 
vaccination during pregnancy is not associated with adverse birth outcomes such as 
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prematurity, low birthweight and stillbirth,14 there are no Australian data on this topic. 
A limitation of the studies from Europe and the US has been inadequate availability of 
data on the timing of maternal influenza vaccination during pregnancy, specifically the 
trimester of vaccination.  
Aims 
This study aims to inform maternal influenza vaccination policy and strategies by 
demonstrating whether women in Australia who self-reported receiving an influenza 
vaccine during any stage of pregnancy were: 
a) more likely to birth smaller infants compared to mothers who did not receive an 
influenza vaccine during pregnancy and, 
 
b) more likely to birth infants who were more premature compared to mothers who 
self-reported they did not receive an influenza vaccine during pregnancy.  
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Objectives 
Amongst mother-infant pairs in Australia, the primary objectives of my study were to 
compare birth outcomes between the exposed (infants born to mothers who self-
reported they had received influenza vaccination during any stage of their pregnancy) 
and the unexposed (infants born to mothers who did not self-report receipt of 
influenza vaccination during their pregnancy) where the primary outcomes of interest 
were: 
a) infant birthweight (grams); and 
b) gestation at birth (weeks) 
 
The secondary objectives were to: 
a) compare maternal characteristics between women who self-reported receipt of 
an influenza vaccine during pregnancy with those who did not 
b) compare maternal risk factors for influenza between women who self-reported 
receipt of an influenza vaccine during pregnancy with those who did not 
c) compare birth outcomes (birthweight and gestation) by trimester of 
vaccination within the exposed group (that is women who reported receipt of 
an influenza vaccine during pregnancy), compared to women who did not 
receive an influenza vaccination during pregnancy. 
 
Methods  
Study design and population 
The study design for this FluMum birth outcomes project was a retrospective nested 
cohort study. The methods for the overarching study, called ‘FluMum’, have been 
published.1 In brief, ‘FluMum’ is an ongoing national prospective cohort study where 
mother-infant pairs were recruited at or soon after birth (when vaccine exposure 
during pregnancy was ascertained) with the mother-infant pairs followed through until 
infants reached six months of age. Participants were enrolled from public and private 
maternity units, immunisation centres and/or maternal and infant health centres in six 
participating Australian cities; Darwin, Brisbane, Sydney, Melbourne, Adelaide and 
Perth. My study was nested within that overarching study as a retrospective cohort, 
utilising the data collected at or soon after delivery. 
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Ethical considerations 
Written informed consent encompassing all aspects of this nested study was obtained 
from all enrolled participants of the original FluMum cohort study. Data were kept in a 
de-identified format in a password protected computer within a locked facility. No 
identifiable information has been or will be presented in any aspect of the study 
results. Participant confidentiality and privacy was maintained at all times.  
 
The results for participants who identify as Aboriginal and or Torres Strait Islander, 
under the variable ‘Indigenous status’, have been presented at a state and territory 
level only, rather than at a local, regional or remote community level. This is to protect 
identity and ensures confidentiality is maintained as numbers of Aboriginal and or 
Torres Strait Islander peoples are small in this study.   
 
The FluMum study was approved by all state and territory ethics committees at the 
sites involved, as well as unconditional ethics approval from the Australian National 
University. 
 
My nested study involved no physical risks to any participant as there were no blood 
tests, specimen collections or injections involved. There was no further contact with 
any participants at any stage of the nested project beyond the initial questionnaire and 
6 month follow-up conducted by trained study staff as a component of the overarching 
study. All data will be archived and then destroyed after 5 years. 
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Figure 2.2:  Study design of FluMum nested retrospective cohort study (by outcome) and 
self-reported receipt of influenza vaccine during pregnancy in mother-infant 
pairs, Australia (2012-2014). 
 
For my study, I only included data collected between 01 April 2012 and 31 December 
2014 on the mother-infant pairs at time of enrolment in FluMum given that study was 
not due to finish recruitment until October 2015. As an existing dataset, the number of 
enrolled participants was pre determined and dependent on the number of enrolled 
participants in the overarching FluMum study at 31 December 2014.  
 
Inclusion criteria 
The study population came from formally consented mothers who were over the age 
of 17 years, able to understand and speak sufficient verbal English, and had birthed a 
live born infant.  
 
Exclusion criteria 
For my study, I excluded mothers from the dataset if they had received an influenza 
vaccine 14 days or less prior to the birth of their infant. Mothers who had birthed a 
stillborn infant were not approached to be in the study. This was a requirement by 
most of the participating sites’ ethics committees. 
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Multiple births were recorded in the original dataset of the overarching FluMum study 
but were excluded from this analysis due to outcome variables only being recorded on 
the first born child. Multiple pregnancies are also a potential confounding factor for 
both birthweight and gestation at birth as these infants are generally smaller in grams 
and often do not go to full term.21  
 
Primary exposure of interest 
The primary exposure of interest for this nested study was self-reported receipt of an 
influenza vaccination during pregnancy. The ratio of exposed:unexposed participants 
within the nested study was expected to be 1:2 based on preliminary analyses of the 
national FluMum data suggesting approximately 30% of women enrolled reported 
receipt of an influenza vaccine during pregnancy (Andrews, unpublished data, personal 
communication, 2014) .   
 
Primary outcomes of interest 
The primary outcomes of interest were: 
a) infant birthweight in grams, and; 
b) number of weeks gestation at delivery of the infant.  
 
Based on definitions from the Australian Institute of Health and Welfare (AIHW) 
Mother’s and babies report,22 prematurity was defined as any infant born before 37 
completed weeks of gestation and low birthweight was defined as any infant born less 
than 2500 grams.  
 
A singleton infant born before 35 completed weeks gestation was defined as being 
‘very premature’, whilst a singleton infant born before 30 completed weeks gestation 
was defined as ‘extreme prematurity’.22 
 
‘Very low’ birthweight, and ‘extremely low’ birthweight, as defined by the World 
Health Organization (WHO) were infants weighing less than 1500 grams at birth and 
infants weighing less than 1000 grams at birth respectively.4  
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Gestation in weeks at birth of the infant and birthweight in grams of the infant were 
self-reported by the mother. Where data were available on the variable ‘last normal 
menstrual period’ (LNMP), this was used to cross check against self-report of the 
gestation (in weeks) at birth of the infant. To cross check these data, I calculated the 
difference between the infant date of birth and the LNMP date to give weeks gestation 
at birth. Where illogical differences in dates were found, research staff at relevant 
study sites were asked to review the original questionnaire to cross check dates. This 
also provided an opportunity to correct data entry errors at the study sites.     
 
Data collection and storage 
Data were collected and entered on all maternal and infant characteristics by trained 
researchers. The researchers conducted face to face interviews using a detailed, 
structured participant questionnaire (Appendix 2.1). All FluMum study data were 
stored electronically in a de-identified format in a purpose-built, password protected 
Filemaker Pro Advanced V13 (Filemaker, Inc. Santa Clara, USA) relational database. 
 
Data included in the analysis 
Table 2.2 contains the variables collected for analysis. These variables were chosen to 
compare baseline demographic characteristics of the mother as well as to capture risk 
factor data and potential confounders. A number of maternal comorbidities and risk 
factors for acquiring influenza infection are listed in the Australian Immunisation 
Handbook.8 These factors, outlined in Table 2.3, were all included in our analysis. The 
variable on diabetes mellitus included type one, type two and gestational diabetes. 
Data were recorded collectively for this variable and not analysed separately for each 
individual type of diabetes. Baseline characteristics assessed for the infant were sex 
and whether the baby had been identified as being of Aboriginal or Torres Strait 
Islander origin. 
 
  
Chapter 2                                                                                   Epidemiological Study   
25 
 
Table 2.2:  Variables included in data collection for FluMum analysis 
 
Variable Workbook 
(Appendix 2.1) 
Maternal age in years at birth of infant Q2.03,12.01 
Aboriginal and Torres Strait Islander status Q18.01 
Country of birth of mother Q18.04 
English as a primary language spoken at home Q18.06 
Gestation in weeks when mother 1st received antenatal care Q4.02 
Any previous influenza vaccinations received Q10.01,11.01 
Maternal respiratory illness during pregnancy Q4.06-6.11 
Maternal smoking status during pregnancy Q17.13 
Exposure to indoor tobacco smoke during pregnancy Q18.16 
Exposure to household tobacco smoke during pregnancy Q18.15 
Household occupancy- how many people usually live in the house Q18.08 
Lives in household with other children who attend daycare, preschool or 
kindergarten (excluding the birth infant) 
Q18.14 
Educational qualifications of mother Q19.01 
Place of birth of infant- public hospital or private hospital Screening 
Form 
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Table 2.3:  Maternal co-morbidities and risk factors for influenza infection examined in the 
FluMum study participants, Australia, 2012-2014. 
 
Co-morbidities and risk factors for influenza infection Workbook 
(Appendix 2.1) 
Heart disease Q17.01 
High blood pressure or hypertension* Q17.02 
Any severe pneumonia requiring hospitalisation Q17.03 
Chronic respiratory conditions† Q17.04 
Immunosuppressive conditions‡ Q17.05 
Cancer requiring treatment Q17.09 
Diabetes mellitus§ Q17.10 
Regular use of immunosuppressive medication Q17.11 
ANY co-morbidity/risk factors║   As above 
* Including essential hypertension, gestational hypertension and pre- eclampsia 
† Including emphysema or severe asthma requiring frequent hospital visits 
‡ Including HIV/AIDS 
§ Including type 1, type 2 and gestational diabetes 
║ Results of pooled risk factors and comorbidities  
 
Statistical methods 
Primary analysis 
The primary analyses were comparisons of birth outcomes between mothers who self-
reported receiving an influenza vaccine during pregnancy with those mothers who self-
reported not receiving an influenza vaccine during pregnancy. 
 
Secondary analysis 
Maternal comorbidities and risk factors for influenza were assessed individually to 
determine whether there were any differences between women who self-reported 
influenza vaccination in pregnancy compared to women who self-reported that they 
did not have an influenza vaccine in pregnancy. If a woman was unsure of her 
vaccination status during pregnancy then she was excluded from these analyses. These 
co-morbidities and risk factors were then grouped together as a new variable called 
‘ANY comorbidity/risk factor’. This was to determine whether there were any within 
cohort differences between the two groups as any person with any of these co-
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morbidities and risk factors listed in the 2013 Australian immunisation handbook are 
recommended to receive an influenza vaccination annually (regardless of their 
pregnancy status).8  
 
Data cleaning 
Data were extracted from the Filemaker Pro Advanced relational database for analysis. 
Missing data were coded as such, and data cleaning, recoding, labelling and analyses 
were conducted and documented in my Stata do-file (see Appendix 2.2). The data 
were analysed using StataCorp v.12.1 (StataCorp, Texas).  
 
Analysis 
Baseline characteristics 
Demographic data on all remaining eligible participants were examined to determine 
whether there were any differences between the vaccinated and unvaccinated group. 
Results were presented as descriptive statistics (means, proportions and their 
corresponding 95% confidence intervals (CI).  
 
Univariable analysis 
Two-sample t-tests were calculated for continuous variables to determine whether 
there were any differences in mean birthweights and mean gestations at birth of the 
infants. Means were calculated instead of medians due to the distribution of the data. 
Differences in means were calculated and 95% CI’s for the differences between these 
means. Chi-squared tests were calculated for binary and categorical variables and a 
Fisher’s exact test was conducted on cells that had less than five expected cases. 
Relative risks, 95% CI’s and risk differences were performed on the binary and 
categorical variables in order to determine whether there were any statistically 
significant and clinically relevant differences between the two groups. Differences 
were considered to be statistically significant if the corresponding p-values were less 
than 0.05 and 95% CI’s did not cross 1.  
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Multivariable analysis 
Regression analyses, interactions, subgroups and sensitivity analyses were proposed as 
part of the analysis plan. However, these have not been conducted as yet. 
Multivariable analyses will plan to examine for the presence of potential confounding 
factors known to cause reduced birthweights and preterm births. Specifically, these 
will include the variables ‘hypertension’, ‘diabetes mellitus’, ‘ANY comorbidity/risk 
factor’ and smoking exposures during pregnancy.  
Results 
Between 01 April 2012 – 31 December 2014, there were 10,398 women screened for 
eligibility to participate in the FluMum study. Of these, 3229 (31%) were deemed 
ineligible and/or declined participation. Amongst those participants who were eligible 
and provided consent (n = 7,169), 48 (0.7%) were withdrawn either because the 
participant withdrew consent or because of a death of the baby or the mother. The 
final dataset included 7,121/10,398 (68%) women for analysis. Participants were 
evenly distributed between the six participating Australian sites (Figure 2.3). 
Participant characteristics were similar between women who did and did not provide 
consent however data on maternal age was not collected routinely from all sites if 
participants did not provide consent.  
 
Figure 2.3:  Total number of participants screened and enrolled in the FluMum cohort study 
(by site of enrolment) and self-reported receipt of influenza vaccine during 
pregnancy, Australia (2012-2014). 
 
 
Darwin  
n= 1179 (17%) 
Brisbane  
n= 1192 (17%) 
Sydney 
n= 1287 (18%) 
Melbourne 
n= 1248 (17%) 
Adelaide 
n= 1078 (15%) 
Perth 
n= 1137 (16%) 
Participants screened 
N= 10,398 
Participants ineligible 
or declined   
N= 3229 
Self-reported receipt of a 
maternal influenza vaccine during 
pregnancy  
N=2394 (34%)  
 
NO Self-reported receipt of a 
maternal influenza vaccine during 
pregnancy  
N=4727 (66%)  
Participants enrolled  
N=7,121 (68%) 
Participants consented  
N=7169  
Participants withdrawn  
N=48  
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Of the 7,121 mother-infant pairs who were enrolled in the study, the mean maternal 
age was 31.7 years and 203 (3%) of mothers were of Aboriginal and/or Torres Strait 
Islander origin. The mean gestation at birth was 38.7 weeks, mean birthweight was 
3332 grams whilst 52% of infants were male. The ratio of maternally 
vaccinated:unvaccinated participants was 1:1.9 (34% v 66%). There were:  
 4,302 (60%) women recruited through public hospitals, 1,986 (28%) through 
private hospitals and 819 (12%) recruited outside the hospital system or where 
the place of birth of the infant was not specified. 
o Amongst the vaccinated group, the distributions were 58% public, 33% 
private, 9% other. 
o Amongst the unvaccinated group, the distributions were 62% public, 
25% private, 13% other 
 
Baseline maternal characteristics by vaccination status 
Maternal characteristics at enrolment were similar between the vaccinated and 
unvaccinated cohorts (Table 2.4). There were a range of variables that showed 
statistically significant results as summarised below but the differences were neither 
substantive nor clinically meaningful. In the vaccinated group, 53% of women reported 
educational qualifications as having a degree or higher. In the unvaccinated group, this 
was 45%.  
 
Maternal co-morbidities and risk factors  
With regards to maternal co-morbidities and risk factors for influenza infection, there 
were no statistically significant or clinically meaningful results between the two groups 
apart from diabetes and the variable ‘ANY co-morbidity/risk factor’(Table 2.5). Women 
with any form of diabetes were 20% more likely to report receiving a maternal 
influenza vaccination in pregnancy compared to women without diabetes (RR 1.2, 95% 
CI 1.06-1.46, p 0.006). Women reporting ‘ANY co-morbidity or risk factor’ were 10% 
more likely to have received a maternal influenza vaccination compared to mothers 
without any co-morbidity or risk factor (RR 1.1, 95% CI 1.04-1.25, p 0.007). 
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Table 2.4:  Baseline characteristics of the FluMum study participants, by self-reported influenza vaccine in pregnancy status,  
Australia (2012-2014) 
 
Characteristics Vaccinated  
N (34%) 
Unvaccinated  
N (66%) 
Total  
N=7121  
Relative Risk 
(RR) 95% CI 
p value  
 
Difference 
95% CI 
Maternal age (mean, in years)    32.1 
 
31.5 
 
31.7  
 
NA 0.000 
 
- 0.7 
-0.92,-0.40 
Mothers who identify as Aboriginal and or Torres Strait 
Islander 
75/2393  
(3%) 
128/4720  
(3%) 
203/7118 
(3%) 
RR 1.16 
0.87,1.53 
0.31 
 
0.4% 
-0.42%,1.26% 
Gestation (mean, in weeks) when 1st received antenatal 
care 
8.2  
 
8.8  
 
8.6 NA 0.000 
 
0.6 
0.25,0.88 
Self-reported maternal respiratory illness during 
pregnancy 
426/2393 
(18%) 
743/4724 
(16%) 
1169/7117 
(16%) 
RR 1.1 
1.02,1.3 
0.03 
 
2% 
0.22%,3.92% 
Self-reported maternal smoking in pregnancy  142/2392 
 (6%) 
383/4726 
(8%) 
524/7118 
 (7%) 
RR 0.73 
0.69,0.92 
0.001 
 
-2% 
-3.40%,-0.95% 
Exposure to indoor tobacco smoke during pregnancy 57/2392 
 (2%) 
152/4712 
(3%) 
209/7104 
 (3%) 
RR 0.74 
0.55,1.00 
0.047 
  
-0.8% 
-1.63%,-0.05% 
Exposure to household tobacco smoke during pregnancy 403/2393 
 (17%) 
1023/4721 
 (22%) 
1426/7114 
(20%) 
RR 0.78 
0.70,0.86 
0.000 
 
-5% 
-6.73%, -2.92% 
English primary language spoken at home 1906/2308 
 (83%) 
3692/4575 
 (81%) 
5602/6883 
(81%) 
RR 1.02 
0.99,1.05 
0.07 
 
1.8% 
-0.14,%, 3.70% 
Lives with other children who attend daycare/preschool 
(excludes the birth infant)  
577/2391 
(24%) 
1210/4721 
 (26%) 
1784/7112 
(25%) 
RR 0.94 
0.86,1.02 
0.16 
 
-1.5% 
-3.65%, -0.58% 
Note: denominators differ due to missing data, RR refers to the relative risk of the vaccinated cohort compared with the unvaccinated cohort 
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Table 2.5:  Co-morbidities of 7121 FluMum study participant mothers, by self-reported 
maternal influenza vaccine in pregnancy status, Australia, 2012-2014. 
 
Characteristics Vaccinated  
N (%) 
Unvaccinated  
N (%) 
RR  
95% CI  
Difference 
95% CI 
p-
value 
Heart disease 21/2394 
 (0.9%) 
32/4721 
 (0.7%) 
RR 1.3 
0.75,2.24 
0.2% 
-0.24%, 0.64% 
0.62 
 
Hypertension*  271/2394 
 (11%) 
473/4721 
 (10%) 
RR 1.1 
0.98,1.30 
1.3% 
-0.23%, 2.83% 
0.09 
 
Severe pneumonia 
requiring hospn. 
45/2392 
 (1.8%) 
72/4720 
 (1.5%) 
RR 1.2 
0.85,1.78 
 0.4% 
-0.29%, 1.00% 
0.27 
 
Chronic respiratory 
condition† 
50/2391 
 (2%) 
81/4721 
 (2%) 
RR 1.2 
0.86, 1.73 
0.4% 
-0.31%, 1.06% 
0.27 
 
Immunosuppressive 
condition‡ 
20/2392 
 (1%) 
33/4721 
 (1%) 
RR 1.2 
0.69,2.08 
0.1% 
-0.30%, 0.57% 
0.53 
 
Cancer requiring 
treatment 
14/2389 
 (1%) 
39/4719 
 (1%) 
RR 0.8 
0.47,1.44 
-0.2% 
-0.59%, 0.27% 
0.48 
 
Diabetes mellitus§ 231/2393 
 (10%) 
366/4721 
 (8%) 
RR 1.2 
1.06,1.46  
2%  
0.49%, 3.31% 
0.006 
 
Regular use of immune 
medication 
38/2392 
 (1.6%) 
48/4720 
 (1.0%) 
RR 1.6 
1.02,2.38 
0.6% 
-0.01%,1.15% 
0.11 
 
ANY co-morbidity/risk 
factor║   
558/2393 
 (23%) 
969/4721  
(21%) 
RR 1.1 
1.04,1.25 
3% 
0.74%, 4.84% 
0.007 
 
Note: denominators differ due to missing data, RR refers to the relative risk of the vaccinated cohort 
compared with the unvaccinated cohort 
* Including essential hypertension, gestational hypertension and pre- eclampsia 
† Including emphysema or severe asthma requiring frequent hospital visits 
‡ Including HIV/AIDS 
§ Including type 1, type 2 and gestational diabetes 
║ Results of pooled risk factors and comorbidities  
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Infant characteristics 
Sex and Indigenous status  
There were no differences in either the sex of the infant or of the Indigenous status of 
the infant between the vaccinated and unvaccinated cohort (Table 2.6). 
 
Table 2.6:  Sex and Indigenous status of 7121 infants born to participants enrolled in the 
FluMum study, by self-reported maternal influenza vaccine in pregnancy status, 
Australia, 2012-2014. 
 
Characteristics Vaccinated  
N (%) 
Unvaccinated  
N (%) 
RR 
95% CI 
Difference p-
value 
Sex (n, %)  
Male 
1249/2391  
(52%) 
2447/4723  
(52%) 
RR 0.99 
0.94-1.04 
0 0.73 
 
Indigenous * 
(n, %) 
100/2393 
 (4%) 
194/4717  
(4%) 
RR 1.02 
0.80- 1.29 
0 0.89 
* Infants who have been identified by a parent as being Aboriginal and/or Torres Strait Islander. 
  
Trimester of receipt of influenza vaccination 
There were 1009 mothers for whom a date of receipt of an influenza vaccination 
during their pregnancy had been ascertained. Of these, 142 (14%) received the 
influenza vaccine during the first trimester, 471 (47%) in the second trimester and 396 
(39%) in the third trimester (Table 2.7).  
 
Table 2.7:  Breakdown of maternal influenza vaccine by trimester of pregnancy 
 
Trimester mother received vaccination  N=1009 
1st trimester 142 (14%) 
2nd trimester 471 (47%) 
3rd trimester 396 (39%) 
 
Mothers who received a maternal influenza vaccination in their first trimester gave 
birth to infants at a mean of 38.3 weeks gestation, compared to a mean of 38.7 weeks 
in mothers who were not vaccinated. Although this is a statistically significant 
difference (0.4 weeks, 95%CI 0.01 to 0.80 weeks, p 0.04), the difference is minimal and 
not clinically relevant, even at the upper confidence limit of 0.8 weeks given the mean 
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gestation under those circumstances would still be considered as full-term. The mean 
birthweight in grams was no different between the women vaccinated during the first 
trimester compared with those who were not vaccinated. 
 
Table 2.8:  Birth outcomes of mothers who received an influenza vaccine in their 1st 
trimester of pregnancy compared to mothers who did not receive an influenza 
vaccine in pregnancy, Australia 2012-2014. 
 
Characteristics Vaccinated 1st trim. 
(3%) 
Unvaccinated  
(97%) 
Difference 
95% CI 
p 
value 
Gestation (mean, in weeks) 
at birth of infant 
38.3 38.7 0.4 
0.01,0.80 
0.04 
 
Birthweight of infant (mean, 
in grams) 
3258 3336 78 grams 
-36.0,191.0 
0.18 
 
 
Weeks in gestation and birthweight 
There were no statistically significant differences between vaccinated and 
unvaccinated mothers in relation to weeks’ gestation at birth of the infant and infant 
birthweights (Table 2.9). Gestation in weeks at birth of the infant was 38.7 for the 
cohort as a whole and for both the vaccinated and unvaccinated group (Table 2.9). 
There was an 11 grams difference in birthweight between infants born to mothers in 
the vaccinated group (3325 grams) compared to infants born to mothers in the 
unvaccinated group (3336 grams, p-value 0.52). 
 
  
Chapter 2                                                                                   Epidemiological Study   
34 
 
Table 2.9:  Birth outcomes of 7121 FluMum study participants by self-reported (SR) 
maternal influenza vaccine in pregnancy status, Australia (2012-2014). 
 
Study outcomes  Vaccinated  
N (%) 
Unvaccinated  
N (%) 
RR &  
95% CI 
Difference 
95% CI 
P-value  
   
Gestation at birth 
(mean, in weeks)    
 
38.7  
 
38.7  
 0.04 
-0.07,0.16 
 
0.43 
Preterm infants*  
(n, %) 
436/2391  
(18%) 
751/4712 
 (16%) 
1.14 
1.03-1.27 
2.3% 
0.43,4.16 
 
0.014 
Very premature infants† 
(n, %) 
69/2019 
 (3%) 
128/4086 
(3%) 
1.09 
0.82-1.45 
0.3% 
-0.67,1.24 
 
0.55 
Extremely premature 
infants‡ (n, %) 
11/1961  
(0.6%) 
23/3981 
 (0.6%) 
0.97 
0.47-2.00 
-0.02 
-0.42,0.39 
 
0.97 
Birthweight of infant  
(mean, in grams)  
 
3325 
 
3336 
 10.5 
-21.68,42.78 
 
0.52 
Normal infant 
birthweight (2500g- 
3999g), (n=, %)  
1977/2382 
(83%) 
3909/4699 
(83%) 
0.98 
0.98-1.02 
-0.19% 
-2.03,1.66 
 
0.84 
Low birthweight infants§ 
(n, %) 
158/2393 
(6.6%) 
 305/4721 
(6.5%) 
1.02 
0.85-1.23 
0.14% 
-1.08,1.40 
 
0.82 
Very low birthweight 
infants ║ (n, %) 
14/2381 
(0.6%) 
35/4693  
(0.7%) 
0.79 
0.43-1.46 
-0.16% 
-0.55,0.24 
 
0.45 
Extremely low 
birthweight infants¶(n, %) 
1/2380 
(0.04%) 
11/4693  
(0.2%) 
0.18 
0.02-1.39 
-0.19% 
-0.35,-0.33 
 
0.06 
Large for gestational age 
infants** (n=, %) 
253/2381 
 (11%) 
494/4199 
 (11%) 
1.01 
0.87-1.16 
0.10% 
-1.42,1.62 
 
0.90 
Note: denominators differ due to missing data 
* Infants born before 37 completed weeks’ gestation 
† Infants born before 35 completed weeks’ gestation 
‡ Infants born before 30 completed weeks’ gestation 
§ Infants weighing less than 2500 grams at birth 
║Infants weighing less than 1500 grams at birth 
¶Infants weighing less than 1000 grams at birth 
** Infants weighing greater than 4000 grams at birth 
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Infants born to vaccinated mothers were 14% more likely to be born preterm (RR 1.14, 
95% CI 1.03-1.27, p-value 0.014, 18% versus 16%). Most importantly though, from a 
clinical perspective (Table 2.9), there were no observed differences between the 
vaccinated and unvaccinated cohorts with respect to very premature births (3% in 
each group) or extremely premature births (0.6% in each group). There were no 
observed differences with regards to birthweight.  
 
Discussion 
In this study of 7,121 mother-infant pairs from multiple sites across Australia over 
three consecutive years, there was no evidence of clinically meaningful differences in 
birth outcomes (birthweight or gestation) for women who received an influenza 
vaccination during pregnancy compared with those who were not vaccinated in 
pregnancy (Table 2.9). In addition, there was no evidence to suggest any increased risk 
of having an adverse birth outcome from receiving an influenza vaccine during the first 
trimester when compared with receiving the vaccine during the second or third 
trimester of pregnancy. In this large sample size, we did find that infants born to 
vaccinated mothers were 14% more likely to have a preterm birth than infants born to 
unvaccinated mothers (RR 1.14, 95% CI 1.03-1.27, p-0.014). Whilst the difference was 
statistically significant, the absolute difference in the proportion of preterm infants 
between the two groups was only 2% (18% amongst maternally vaccinated versus 16% 
amongst maternally unvaccinated). This difference was not of major clinical 
importance given these infants were neither extremely premature nor very premature 
(two serious categories of prematurity for which there were no differences between 
the vaccinated and unvaccinated cohort).  
 
Others have found evidence suggesting receipt of an influenza vaccination during 
pregnancy reduces the risk of preterm births and reduces the risk of having a low birth 
weight infant.11,12,15,17 Legge et al., found infants with low birthweights occurred less in 
the vaccinated group (adjusted odds ratio [aOR] 0.73, 95% CI 0.56–0.95) compared to 
the unvaccinated group, and preterm births occurred less in the vaccinated group 
compared to the unvaccinated group (adjusted odds ratio 0.75, 95% CI 0.60–0.94).13 A 
similar study by Sheffield et al.,12 showed no differences in mean birthweights 
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between the vaccinated and unvaccinated group and found less preterm births in the 
vaccinated group (5%) compared to the unvaccinated group (6%) with a p-value of 
0.004.  
 
Study outcomes 
Preterm births and infant birthweights 
Infants who are born prematurely are known to be at much higher risk of adverse 
neonatal outcomes than those infants who are born at term.20 These outcomes can 
include long term physical and developmental difficulties as well as higher risks of 
acquiring co-morbidities.21  
 
The results of my study are reassuring with regards to the safety and birth outcomes 
for gestation. There was no evidence to suggest that receiving an influenza vaccine in 
pregnancy was associated with preterm births. Mothers in the vaccinated and 
unvaccinated group both gave birth at 38.7 weeks gestation which was also the 
recorded mean duration of pregnancy for Australian women as a whole in 2014.21 
 
Infant birthweight is an important indicator of health.20The mean birthweight of all live 
born infants in the Australian population in 2012 was 3367 grams 21which is similar to 
the mean birthweight in grams of infants in our study population as a whole which was 
3331 grams. There was only 11 grams difference in birthweight between babies born 
in the vaccinated group compared to babies born in the unvaccinated group. This 
suggests there is no evidence receiving an influenza vaccine in pregnancy is related to 
low birthweight of infants or infants born large for gestational age. The proportion of 
infants born within the normal weight range of 2500g-4000g in my study for the 
vaccinated and unvaccinated group was 85% for both groups. This is the same 
proportion of infants born within the normal weight range for the Australian 
population for 2012.20 
 
On closer examination of infant’s birthweights, there were no differences between the 
vaccinated and unvaccinated groups in relation to proportions of infants who were 
born of low birthweight, very low birth birthweight, extremely low birth weight or 
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large for gestational age. The proportions of the infants in these categories for the 
vaccinated and unvaccinated groups were the same as those for infants in the 
Australian population in 2012.21 These data are encouraging regarding the support of 
receiving an influenza vaccine during any stage of pregnancy and are substantiated by 
safety studies presented in overseas literature.11,12 
 
There were minor differences in demographics between the unvaccinated and 
vaccinated group, with many of the statistically significant differences being very small 
in real terms, a reflection of the large sample size. The mean age in years of 
participants was 31.7 which was similar to the mean age in years of women giving birth 
in Australia in 2012.21 The proportion of Aboriginal and Torres Strait Islander women in 
the total cohort was 3%. This was slightly lower than the national data, of which 4% of 
births in 2012 were to Aboriginal and Torres Strait Islander women;20 likely a reflection 
of study participants recruited from large inner city hospitals from the major capital 
cities. 
 
Maternal co-morbidities and risk factors for influenza infection 
Influenza vaccination is recommended for pregnant women who will be pregnant 
during the influenza season.8 Other potential at-risk groups that should receive an 
influenza vaccination are those with pre-existing co-morbidities and those who are at 
risk of acquiring influenza infection.  
 
In our study, we found no statistically significant or clinically important differences in 
the proportions of mothers with co-morbidities or risk factors for acquiring influenza 
infection when comparing the vaccinated and unvaccinated groups. This was surprising 
considering current recommendations in Australia specifically target these high-risk 
women for annual influenza vaccination (regardless of their pregnancy status).8 
 
Pregnant women with diabetes showed a statistically significant result in the analysis 
(RR 1.2, 95% CI 1.06-1.46, p-0.006). The difference between the groups was small at 
2%, and this finding could be a consequence of a large sample size, however 
considering the high public health importance and clinical significance of diabetes in 
Chapter 2                                                                                   Epidemiological Study   
38 
 
pregnancy these results should be reflective rather than dismissive. Overseas 
literature5,12 however found no statistically significant differences in preterm births or 
low birthweights between the vaccinated and unvaccinated groups of mothers who 
had diabetes in pregnancy. 
 
Trimester of pregnancy received influenza vaccine  
Where a date of influenza vaccination in pregnancy was ascertained, most participants 
were vaccinated during the second and third trimesters of pregnancy (86%) compared 
to the first trimester (14%). Our data found no differences in birth outcomes between 
mothers who received an influenza vaccine during the first trimester of pregnancy 
compared to mothers who were confirmed as having received an influenza vaccine 
during the second or third trimesters of pregnancy. These results suggest it is safe to 
receive an influenza vaccine at any stage during pregnancy which is supported by other 
emerging overseas literature.12 
 
Strengths 
The strength of the project lies in the design of the original FluMum prospective cohort 
study. Although the study population is not a random sample, all eligible participants 
in this nested cohort arise from the original FluMum study where the exposure 
(maternal vaccination status) and outcomes of interest (birth weight and gestation at 
birth) were not known by the investigators at the time of recruitment and unlikely to 
have been a factor in participant consent since the primary outcome of interest for the 
overarching FluMum study was laboratory confirmed influenza in infancy (which had 
not yet occurred). Data quality was of a high standard with minimal missing data for 
variables. As a retrospective cohort, internal validity is provided by between cohort 
comparisons (vaccinated versus unvaccinated). The large sample size does provide 
precision around the estimates of effect. As a non-random sample of women giving 
birth in urban centres, who are predominantly first language English speakers, there 
are potential biases that may limit generalisability of the findings. Of note however, 
the study sample had very similar mean birthweight and gestational age at birth 
almost identical to published Australian data on perinatal outcomes as discussed in 
selection bias below. 
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There is a lack of rural and remote representativeness of pregnant women in the study 
population as all participating sites are major Australian capital cities. Generalisability 
of these results to the wider population should therefore be treated with caution. 
Influenza vaccine uptake by pregnant Aboriginal and Torres Strait Islander women in 
my study was 37% which is consistent with the overall vaccine uptake in the cohort. It 
must be noted that apart from the Darwin site, participant numbers in this study were 
small for Aboriginal and Torres Strait Islander women and therefore results for these 
women may not be reflected in the birth outcomes of this study. 
 
We know that pregnant women who present for antenatal care before 16 weeks 
gestation for their first pregnancy have better birth outcomes than pregnant women 
who present later.22 My study shows an overall sample of pregnant women who 
attended antenatal care early at 8.4 weeks. This early presentation for antenatal care 
is reflective of pregnant women from the Australian population as a whole.20 
 
Limitations 
Selection bias 
The recruitment selection strategy for this nested cohort study was pre-determined by 
the overarching FluMum study, which is a non-random sample.1 Whereas the original 
study recruited participants before their outcome of interest was known (laboratory 
confirmed influenza in infants in the first 6 months of life), the nested cohort is 
effectively a retrospective cohort design since the primary outcomes have already 
occurred at the time of recruitment. As such, we cannot know whether there are any 
differences in non-responders compared to those who consented to be in this study. 
Apart from place of birth of the infant; private versus public hospital, we cannot know 
whether eligible participants who declined consent to be in the FluMum cohort study 
have certain demographic, behavioural and health characteristics which may be 
potentially quite different to the consenting cohort. 
 
Women were required to be >17 years old to be considered eligible to consent to this 
study. This excluded a large demographic of young mothers from being in the cohort. 
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This in turn made it more likely that a larger proportion of Aboriginal and Torres Strait 
Islander mothers were excluded from being in the study as these women tend to have 
their first child at a younger age than Non-Indigenous women.20 Traditionally 
Aboriginal and Torres Strait Islander women have much higher rates of prematurity 
and lower birthweight infants than non-Indigenous women,21 so it is possible the birth 
outcomes of these women will not be reflected in the birth outcomes of my study. 
 
Women needed to be able to speak fluent English to be eligible to consent to this 
study. This excluded a large urban migrant population who may not speak fluent 
English from being part of the cohort. Again this requirement also potentially excluded 
some Aboriginal and Torres Strait Islander women whose first language is not English. 
As a result we will not know whether these groups of women are more or less likely to 
access or be offered maternal influenza vaccination in pregnancy and if they are 
offered a vaccine whether they would be more or less likely to accept the offer of 
vaccination. We also will not know if these subgroups have or have not received an 
influenza vaccine during pregnancy and whether there are any subsequent differences 
in birth outcomes between these groups. However, a study by Sheffield et al.,12 
examined birthweights and preterm births in vaccinated and unvaccinated groups of 
pregnant women that included women; under 17 years of age as well as non-English 
speaking and those in minority groups. Their results remained consistent with the 
results from this study showing no differences in preterm births or birthweights 
between vaccinated and unvaccinated pregnant women.  
 
Women must have birthed a live baby to be eligible to be in this study. This prevented 
us from knowing an element of safety around maternal vaccination in pregnancy 
related to birth outcomes as we have no data on stillbirths or late spontaneous 
abortions. There are however, encouraging data from a systematic review looking at 
stillbirths and spontaneous abortions that showed there were no differences between 
women who had an influenza vaccine in pregnancy compared to women who did 
not.14 
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Although there was a statistically significant difference in the analysis of maternal age 
in years at birth of the infant between vaccinated mothers compared to unvaccinated 
mothers in pregnancy, this difference was only six months and unlikely to have clinical 
implications for public health practice.  
 
Minimising selection bias 
There is a clearly defined eligibility criterion for the original FluMum cohort study as 
well as a well-defined protocol as to how data are to be collected.1 
 
A feature of the original cohort study attempted to recruit a mix of participants from 
public and private hospitals. This is not reflected in these data as there are twice as 
many participants recruited from public hospitals than private hospitals.   
 
Participant loss to follow up within this nested study was minimised by nature of the 
study design. Any loss to follow up will have already occurred in the original 
prospective cohort prior to analysis. The analysis plan for the nested cohort study 
focused on within cohort comparisons. Collecting demographic and risk factor data 
enabled an assessment of influences between the vaccinated and unvaccinated 
cohorts. A review of published Australian data on perinatal outcomes from the AIHW 
national perinatal statistics data was used to compare national demographic and risk 
factor data with the demographic and risk factor data from my study. This was to 
identify whether there could be potential biases such as volunteer or in this case 
‘healthy vaccinee effect’ bias.20 
 
Potential measurement error for study exposure and outcome factors  
Misclassification of exposure is possible if some participants were labelled as having 
had an influenza vaccine in pregnancy (exposed) when they did not (unexposed), and 
vice versa.  
 
This was a consequence of using self-reporting of receipt of an influenza vaccination 
during pregnancy. Validation studies on self-reporting of receiving an influenza vaccine 
by age group demonstrate high reliability,18 however data on self-reporting in 
Chapter 2                                                                                   Epidemiological Study   
42 
 
pregnancy is scant. Misclassification of outcome is also possible if some participants 
were labelled as having had an infant born prematurely or of low birth weight 
incorrectly however validation studies conducted on self-reporting of birth outcomes 
by mothers,18 show a high reliability so this is unlikely. 
 
There is potential measurement bias for the study outcome gestation in weeks at birth 
of the infant. Data for this variable were self-reported by the mother and subsequently 
collected by the researcher and then entered into the database. Other studies state 
the use of self-reported gestation in weeks by the mother in their research.13 These are 
supported by the same validation study above demonstrating high reliability of 
maternal self-reporting of gestation at birth of the infant and infant birthweights.17 
Other literature has not stated how gestation was calculated in their studies.11,12 
 
Minimising measurement error for study exposure and outcome factors 
The original FluMum study questionnaire is a detailed form where trained health 
researchers collected information. It was piloted by research staff at each site prior to 
the commencement of the study in 2012. There were revisions to the questionnaire 
over the course of the study however this would not have influenced data used in this 
analysis. Data entry error is inevitable, though coding the Stata .do file in preparation 
for data analysis enabled cross checking of questions such as gestation at birth of 
infants to determine whether participants were potentially misclassified or not. Data 
were examined for logic and consistency. Illogical outliers were individually checked at 
the point of data cleaning for dates of birth of infant and where available LNMP.  
 
Effort was also made to reduce measurement bias in the study outcome variable 
‘gestation in weeks at birth of the infant’. Where data were available, gestations in 
weeks were calculated if the date of the LNMP was collected. Although dates, 
birthweights of infants and gestations at birth of the infants were self-reported by the 
mother, again validation studies on self-reporting with regards to these birth outcomes 
have verified moderate to high reliability of the self-reported results when compared 
with medical records.18 
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Public Health Implications 
Maternal influenza vaccine uptake is a public health policy initiative that has been 
advocated for more than a decade without any systematic initiatives to monitor 
implementation or birth outcomes.1 Providing further evidence around the safety of 
receiving a vaccine during pregnancy, particularly infant birthweights and preterm 
births may help increase uptake of the vaccine. This may reduce the morbidity and 
mortality that results from influenza infection when it occurs during pregnancy. We 
know historically that during previous influenza pandemics, 50% of the deaths that 
occur among women of child-bearing age are amongst pregnant women.2,16 
 
Current policy and Recommendations 
In Australia, the influenza vaccine is recommended for all pregnant women who will be 
pregnant during the flu season.8 
 
The primary focus is preventing serious consequences for the mother from influenza 
infection during pregnancy.23 Women who are at higher risk of acquiring influenza 
infection due to reduced immunity or due to the presence of co-morbidities are 
targeted for immunisation with the influenza vaccine.15,2,22 
 
Conclusion 
The birth outcomes results arising from this first Australian study are reassuring. In 
relation to the safety of receiving a maternal influenza vaccination during pregnancy, 
based on these findings, health care providers can confidently promote the influenza 
vaccine for all pregnant women and reassure them and their families regarding the 
safety of receiving the vaccine during any stage in pregnancy. Finally it can be deemed 
appropriate to offer the vaccine to all pregnant women in accordance with the current 
recommendations in Australia. 
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Appendix 2.1.  FluMum study participant questionnaire 
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1. Participant entry into FluMum nested study 
  Note: 
i. This form is an excerpt from the original FluMum cohort study questionnaire 
(which was developed by Ross Andrews) showing questions that I have used in 
the nested cohort study.  
Question numbers are based on the original form and it will appear some are 
missing or out of order , however this is intentional as it will assist with data 
analysis in stata (where the do file is written based on question numbers 
labelled in the original form). 
*I will not be able to see any of the participant’s identifiable information in the 
nested dataset therefore I have excluded the variables ‘Contact details’ and ‘Baby’s 
name’ from this questionnaire. 
ii. All dates are dd/MMM/yyyy format, ie 02/FEB/2011 
iii. Yes/No questions may also include “Unk”, which = Unknown/Unsure/Don’t 
know 
 
  
1.02 Informed consent obtained from the 
participant[Consent]  
Must be seen by YOU (signed by the person AND by a Team member)  … 
No 
0 
Yes 
1 
If No  
do not 
proceed 
  
                      STOP       
1.03 Sufficient verbal English demonstrated in consent 
process to allow questionnaire completion[English1]                             
… 
No 
0 
Yes 
1 
If No  
do not 
proceed 
  
                      STOP       
1.04 Interview date for participant questionnaire 
[DateSEQ]                                               dd/mmm/yyyy   
… 
/         / 
  
                            
1.05 Interview being conducted within the specified 
window period (38wks gest - 8 wks post delivery)?[FUWindow]                     
… 
No 
0 
Yes 
1 
Unk 
9 
If No  
do not 
proceed 
  
Note:Although the protocol allows enrolment from 38wks gest, sites are now focussing on postnatal 
recruitment 
  
STOP 
      
 
  
2. Confirmation of eligibility 
Shaded boxes indicate mum is ineligible – if so, do not include in study 
2.03 Could you please tell me your date of 
birth?[MaternalDOB]: 
   dd/mmm/yyyy    … 
/          / 
Dcl 
10 
              
2.04 Confirm participant is aged 17 years or more at 
enrolment?   [Age17]:  … 
No 
0 
Yes 
1 
If No  
do not 
proceed 
 
  
  
STOP 
   
 
  
4. Mum’s health 
 
     
4.02 How many weeks pregnant were you when you first started 
receiving antenatal care during your pregnancy? [Antenatal]  … 
  
weeks 
Unk 
99 
Dcl 
100 
 (enter 0 if not attended any antenatal care)  
 
 
 
 
  
4.06 During your pregnancy, did you ever have a respiratory      
 illness with symptoms like fever, chills, cough, aches 
and pains, that caused you to see a doctor? [MatILI]              
… 
No 
0 Yes 
1 
Unk 
9 
Dcl 
10 
    7.01    7.01  
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5. Episodes of respiratory illness during your pregnancy that caused you to see a doctor 
 Thinking now about the 1st episode of respiratory illness during your pregnancy that caused you to see a doctor, can you tell 
me … 
5.01 Tests done 
[Mat1Test] 
No 
0 
Blood 
1 
Nose 
2 
Throat 
3 
Unk 
9 
Dcl 
10 
  
  
          5.06         5.06   5.06                     
    5.04 How many weeks pregnant 
were you? [Mat1FluWks]                       
… 
  
weeks 
Unk 
99 
Dcl 
100 
                     
 
5.06 
 
Did you have a 2nd episode of respiratory illness in pregnancy that caused you to see a doctor? [Mat2ILI]                
… 
No 
0 
Yes 
1 
            7.01  
5.07 Tests done 
[Mat2Test] 
No 
0 
Blood 
1 
Nose 
2 
Throat 
3 
Unk 
9 
Dcl 
10 
    
          6.01         6.01   6.01                     
    5.10 How many weeks pregnant 
were you? [Mat2FluWks]                       
… 
  
weeks 
Unk 
99 
Dcl 
100 
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6. Further episodes of respiratory illness during your pregnancy that caused you to see a doctor 
 
6.01 
 
Did you have a 3rd episode of respiratory illness in pregnancy that caused you to see a doctor? [Mat3ILI]                 
… 
No 
0 
Yes 
1 
            7.01  
6.02 Tests done 
[Mat3Test] 
No 
0 
Blood 
1 
Nose 
2 
Throat 
3 
Unk 
9 
Dcl 
10 
  
  
          7.01         7.01   7.01                     
  
  
6.05 How many weeks pregnant 
were you? [Mat3FluWks]                       
… 
  
weeks 
Unk 
99 
Dcl 
100 
6.07  
Did you have a 4th episode of respiratory illness in pregnancy that caused you to see a doctor? [Mat4ILI]                 
… 
No 
0 
Yes 
1 
            7.01  
6.08 Tests done 
[Mat4Test] 
No 
0 
Blood 
1 
Nose 
2 
Throat 
3 
Unk 
9 
Dcl 
10 
  
  
          7.01         7.01   7.01                     
  
  
6.11 How many weeks pregnant 
were you? [Mat4FluWks]                       
… 
  
weeks 
Unk 
99 
Dcl 
100 
Appendix 2.1 FluMum Participant Workbook                    STUDY ID #: |__|__|__|__|__| 
Chief Investigator Lisa McHugh (l.mulhearn1@uq.edu.au). 
Team Member Initial: |__.__|           Date (dd/mmm/yyyy): __ __ / __ __ __ /__ __ __ __ 
 
LisaMcHughBV_Master_FINAL – CONFIDENTIAL - Page 50 
7.09 Did you get a flu vaccine during this 
pregnancy?[FluvaxPreg]  
If NO or Unknown go to 9.01                                        … 
No 
0 
Yes 
1 
Unk 
9 
Dcl 
10 
            
9.01 
 
  9.01   9.01 
10. Flu vaccine during the 12 months BEFORE you became pregnant 
10.01 Some people have had the flu vaccine BEFORE they got pregnant.  
Thinking about the 12 months before you became pregnant, 
 did you get a flu vaccine during that time?[Fluvax12mths] 
        If No or Unknown go to 11.01                  … 
No 
0 
Yes 
1 
Unk 
9 
Dcl 
10 
11. More vaccine history questions 
11.01 We have already asked about your pregnancy and the  
 12 months prior to becoming pregnant, other than 
these times, have you EVER had a flu vaccine?[FluvaxEver]             
… 
No 
0 
Yes 
1 
Unk 
9 
Dcl 
10 
    11.06  
  
11.06   11.06 
PART B – 12. Birth of your baby 
12.01 What date did you deliver (give birth to your baby or 
baby)?  
[DeliveryDate]:                                dd/mmm/yyyy      … 
/         / 
Dcl 
10 
              
          
12.03 Study site[Site]  
 (If Darwin, go to 12.05 = do NOT stop)  ... 
Dwn 
1 
Brb 
2 
Syd 
3 
Mel 
4 
Adl 
5 
Per 
6 
 
         
12.05       
12.04 Birth 
month[Bmth] 
          
 Jan 
1 
Feb 
2 
Mar 
3 
Apr 
4 
May 
5 
Jun 
6 
Jul 
7 
Aug 
8 
Sep 
9 
Oct 
10 
Nov 
11 
Dec 
12 
 
   
STOP   
  
STOP 
  
STOP 
  
STOP  
12.05 Live birth/s?[LiveBirth]  
… 
No 
0 
Yes 
1 
If No 
do not 
proceed 
              
 
12.07 How many weeks pregnant were you at the time of  
delivery?[Gestation]                                                          
… 
  
weeks 
Unk 
99 
Dcl 
100 
       
12.08 What was the date of your last menstrual 
period prior to your pregnancy? [LMPdate]:    
dd/mmm/yyyy       … 
/         / 
Unk 
9 
Dcl 
10 
    
  
12.10 
  
12.10 
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14.03 Birthweight (g) [B1Wgt] 14.04 Gender[B1Sex] note: Ind=Indeterminate 
 …     
grams 
Unk 
9 
Dcl 
10 
 … Ind 
0 
M 
1 
F 
2 
Dcl 
10 
 
14.06 
 
Live Birth(cross checking with Q12.05) 
 [B1Live] 
  … 
No 
0 
Yes 
1 
Dcl 
10 
      17.01  
14.08 Since birth, has your baby been diagnosed with a 
condition that suppresses the immune system? 
[B1Immune] 
No 
0 
Yes 
1 
Unk 
9 
Dcl 
10 
            14.10   14.10 
  
14.10 
14.09 If yes, what is the name of that condition?
 [B1ImmuneName]
 
 
Unk 
9 
Dcl 
10 
 
14.10 Has your baby been given any steroids or 
medications since birth that suppress the immune 
system? [B1Steroids] 
No 
0 
Yes 
1 
Unk 
9 
Dcl 
10 
            14.12   14.12 
  
14.12 
14.11 If yes, why was he/she given these medications?
[B1Steroid_reason] Unk 
9 
Dcl 
10 
 
14.12 Has your baby been diagnosed with any illnesses 
requiring medical follow-up (on a regular basis) or 
hospitalisations? 
No 
0 
Yes 
1 
Unk 
9 
Dcl 
10 
 [B1HighRisk]          17.01   17.01 
  
17.01 
14.13 If yes, what is the name of that condition?
 [B1HighRiskName] Unk 
9 
Dcl 
10 
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17. Some general questions about your own health 
 Note: 17.01-17.11 list medical conditions pre-disposing to severe influenza as specified in the Immunisation Handbook, 10
th 
edition 
 Have you EVER been told by a doctor that you have had 
any of the following conditions 
Ask each one 
17.01 …Heart disease 
 [Heart] 
No 
0 
Yes 
1 
Dcl 
10 
17.02 …High blood pressure or hypertension  
(including gestational hypertension and pre 
eclampsia)[Hypertension] 
No 
0 
Yes 
1 
Dcl 
10 
17.03 …Severe pneumonia (requiring hospitalisation) 
[Pneumonia]
 
No 
0 
Yes 
1 
Dcl 
10 
17.04 …Chronic respiratory condition (including emphysema or 
severe asthma requiring frequent hospital visits) [Bronchitis]  
No 
0 
Yes 
1 
Dcl 
10 
17.05 …Immunosuppressive condition (inc HIV/AIDS)  
[Immune] 
No 
0 
Yes 
1 
Dcl 
10 
     
 During your pregnancy or the 12months before you were 
pregnant, have you been told by a doctor that you have 
had any of the following conditions 
Ask each one 
 
    
17.09 …Cancer (requiring treatment) 
[Cancer] 
No 
0 
Yes 
1 
Dcl 
10 
17.10 … Diabetes (type 1 or 2, including gestational diabetes)  
requiring hospitalisation or medical follow-up [Diabetespreg] 
No 
0 
Yes 
1 
Dcl 
10 
17.11 Regular use of immunosuppressive medications 
[ImmuneMedspreg]   
No 
0 
Yes 
1 
Dcl 
10 
     
 
17.12 
 
How many cigarettes do you usually smoke in a day? [Smokes]       
… 
  
cigs 
Dcl 
 
    900 
17.13 Did you smoke any cigarettes during your most recent 
pregnancy? [PregSmoker] (includes before you knew you were pregnant)                        
… 
No 
0 
Yes 
1 
Dcl 
10 
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18. Now to finish with some general questions 
18.01 Are you of Aboriginal or Torres Strait Islander 
origin? [ATSIMum]                                                                                                
… 
No 
0 
AB 
1 
TSI 
2 
Both 
3 
Dcl 
10 
              
18.02 Is your baby of Aboriginal or Torres Strait 
Islander origin? [ATSIBaby]                                               … 
No 
0 
AB 
1 
TSI 
2 
Both 
3 
Dcl 
10 
              
18.03 Were you born in Australia? [AustralianBorn] 
    … 
No 
0 
Yes 
1 
Dcl 
10 
              18.06 
18.04 Country of birth? 
[BirthCountry] 
 
Dcl 
10 
 
18.06 Is English the main language you usually speak at home? 
[English2] 
    … 
No 
0 
Yes 
1 
Dcl 
10 
              18.08 
18.07 What is the main language you speak at home? 
[Language]  Dcl 
10 
              18.08 
 
18.08 
How many people usually live at your house? [Occupancy]  
counting the new baby (babies)                              … 
   Unk 
99 
Dcl 
100 
 
18.14 Do any of the children who usually live at your house also 
attend child-care or day-care? [DayCare]                                                
… 
No 
0 
Yes 
1 
Dcl 
10 
 
18.15 How many of the people who live at your house, smoke 
cigarettes? [HouseholdSmoker]                                                     … 
   Unk 
99 
Dcl 
100 
 
18.16 Were you regularly exposed to indoor tobacco smoke during 
your pregnancy, including before you found out you were pregnant? [IndoorSmoke]  
No 
0 
Yes 
1 
Dcl 
10 
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19. Last page of the Study Entry Questionnaire 
19.01 Which of the following describes the highest 
educational qualification you have obtained 
[Education] 
Did not finish high 
school 
1 
Dcl 
10 
  High School 
2
 
 
  Certificate 
3 
 
  Diploma 
4 
 
  Degree 
5 
 
  Postgraduate degree 
6
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Appendix 2.2.  Stata do-file for FluMum data analysis 
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*cr_FluMum_epiproject_Dec2014.do was written by Lisa McHugh 
*last updated 15Nov 2015 and last run 15November 2015. 
*This do file creates a FluMum nested dataset called 
FluMum_epiproject_Dec2014.dta  
*based on Flumum_all.xls export from FileMaker Pro 
*The do file labels, cleans and, where necessary,  
*recodes the data set in preparation for data analysis. 
  
* Change working directory in STATA, for me that's 
*"C:\MAE for uni\FluMum epi project\Data analysis\Do files\FluMum nested study 
export 12Dec2014.csv", case 
capture log close 
version 12.1 
clear 
set more off 
log using cr_FluMum_epiproject_Dec2014.log,replace 
 
******************************************************************************
**** 
** 1. FluMum_all.xlsx -> FluMum_all.dta 
******************************************************************************
**** 
*import excel "S:\QCMRI-RiOAR\FluMum Study National\MAE for uni\FluMum epi 
project\Data analysis\Do files\FluMum nested study dataset 20Nov2014.xls", 
firstrow 
*insheet using "C:\MAE for uni\FluMum epi project\Data analysis\Do 
files\FluMum nested study export 12Dec2014.csv", case 
******************************************************************************
**** 
**      - code below could be run off server to create FluMum_nested.dta 
**      - this can then be re-run off a future export for any subsequently 
cleaned data meeting future requirements 
**       (would just need an extra command like keep if DeliveryDate > xxx & 
DeliveryDate< XXX eg infant birth <31dec2014??) 
******************************************************************************
**** 
*To activate these edits 
* 1. Turn off the insheet command above 
* Turn on the following commands before the next double line break of "***** 
*(depending on whether using C drive or S drive) 
 
*insheet using "S:\QCMRI-RiOAR\FluMum Study National\Data exports\Database 
Exports 2014\FluMum 12Dec2014.csv", case 
insheet using "C:\MAE for uni\FluMum epi project\Data analysis\Do files\FluMum 
12Dec2014.csv", case 
 
*keep StudyID ID Site PlaceScreened Consent Enrolled FluvaxPreg DateSEQ 
MaternalDOB LMPDate DeliveryDate ScreenDate /// 
*Antenatal MatILI Mat2iLi Mat3iLi Mat4iLi FluvaxPreg Fluvax12mths FluvaxEver 
B1Live B1Immune B1Steroids LiveBirth /// 
*Mat1Test Mat2Test Mat3Test Mat4Test Mat1FluWeeks Mat2FluWeeks Mat3FluWeeks 
Mat4FluWeeks Bmth  /// 
*Gestation ScreeningNum B1Wgt SiteCity B1Sex B1HighRisk Heart-ImmuneMedspreg 
PregSmoker AustralianBorn English2 /// 
*DayCare IndoorSmoke ATSIMum ATSIBaby HouseholdSmoker Education 
ReasonWithdrawn vpflupregdate 
******************************************************************************
**** 
******************************************************************************
**** 
 
save FluMum_nested.dta, replace 
 
*NOTE: all participants must be >17yrs to be eligible to consent to be in this 
study   
*NOTE: all participants must be able to speak English to be eligible to 
consent to be in this study 
*NOTE: Fields containing potentially identifiable data and/or no values or 
relevance have been deleted 
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*STUDY ID 
codebook StudyID 
*all missing data here for StudyID, now check ID 
codebook ID 
* confirm ID is a unique number 
bysort ID: assert [_N]==1 
 
*STUDY SITE Q12.03  
codebook Site 
tab Site, miss 
sort Site ID 
*NOTE:Sites 1-6  
label define labelSite  1 "Darwin" 2 "Brisbane" 3 "Sydney" 4 "Melbourne" 5 
"Adelaide" 6 "Perth" 
numlabel, add 
label values Site labelSite 
tab Site, miss 
 
*PLACE SCREENED (Screening log) 
codebook PlaceScreened 
replace PlaceScreened = "1" if PlaceScreened == "Private Hospital" 
replace PlaceScreened ="0" if PlaceScreened =="Public Hospital" 
replace PlaceScreened="2" if PlaceScreened =="Community Health Centre" 
replace PlaceScreened="3" if PlaceScreened =="Postnatal Clinic" 
replace PlaceScreened="4" if PlaceScreened =="Antenatal Clinic" 
replace PlaceScreened="5" if PlaceScreened =="Other" | PlaceScreened 
=="Birthing Centre" 
replace PlaceScreened="5" if PlaceScreened =="Oher" 
destring PlaceScreened, replace 
label define labelPlaceScreened 0 "Public Hospital" 1"Private Hospital" 2 
"Community Health Centre" 3 "Postnatal Clinic" /// 
4 "Antenatal Clinic" 5 "Other" 
label values PlaceScreened labelPlaceScreened 
tab PlaceScreened, miss 
bysort PlaceScreened: tab FluvaxPreg 
*Create a categorical variable for "Place of birth" that differentiates 
"Public hospital" from "Private hospital" 
gen PlaceBirth=0 if PlaceScreened==0 
replace PlaceBirth=1 if PlaceScreened==1 
replace PlaceBirth=2 if PlaceScreened>1 & PlaceScreened<.  
label var PlaceScreened "Place of birth of infant" 
label define labelPlaceBirth 0 "Public hosp" 1 "Private hosp" 2 
"Other/unspecified" 
label values PlaceBirth labelPlaceBirth 
* now cross check recoding makes sense 
tab PlaceScreened PlaceBirth, miss 
 
*CONSENT Q1.02 
codebook Consent 
label var Consent "Informed consent obtained" 
replace Consent="0" if Consent =="No" 
replace Consent="1" if Consent =="Yes" 
destring Consent, replace 
label define labelYesNo 0 "(0)No"  1 "(1)Yes" 9 "(9)Unk" 10 "(10)Dcl" 
label values Consent labelYesNo 
tab Consent, miss 
tab Consent Site, miss 
 
codebook ReasonNotEnrolled 
 
*RECODING YES/NO Q's & DESTRINGING 
*MATERNAL RESPIRATORY ILLNESS Q's 
foreach var of varlist MatILI Mat2iLi Mat3iLi Mat4iLi FluvaxPreg Fluvax12mths 
FluvaxEver B1Live B1Immune B1Steroids LiveBirth English1 StaySix Age17 
FUWindow{ 
 codebook `var' 
 replace `var'="0" if `var'=="No" 
 replace `var'="1" if `var' =="Yes" 
 replace `var'=".u" if `var' =="Unknown" | `var'=="Unk" 
 replace `var'=".d" if `var'=="Declined" | `var'=="Dcl"  
 destring `var', replace 
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 label values `var' labelYesNo 
 codebook `var' 
 tab `var',miss 
} 
label var MatILI "Maternal resp illness during pregnancy" 
label var Mat2iLi "2nd maternal resp illness during pregnancy" 
label var Mat3iLi "3rd maternal resp illness during pregnancy" 
label var Mat4iLi "4th maternal resp illness during pregnancy" 
label var FluvaxPreg "Maternal flu vaccine during pregnancy" 
label var Fluvax12mths "Maternal flu vaccine 12 months prior to pregnancy" 
label var FluvaxEver "Ever had a flu vaccine?" 
label var B1Live "Live birth this pregnancy" 
label var B1Immune "Infant diagnosed with immunosuppressive condition" 
label var B1Steroids "Infant given steroids since birth (1st 8 weeks)" 
label var LiveBirth "Live birth this pregnancy" 
label var English1 "English speaking" 
label var Age17 "Participant over 17 years of age" 
label var StaySix "Eligibility 6 months" 
label var FUWindow "Elligibility within follow up window" 
 
*This section on heirarchy for consent/consort code is written by Ross Andrews 
*make a hierarchy so Consent minus Withdrawn = Active, then Complete6mth_pc = 
0 if Lost to follow-up, 1 if Status=Complete  
gen Withdrawn=0 if Consent==1 
replace Withdrawn=1 if Status=="Withdrawn" 
tab ReasonWithdrawn Withdrawn 
replace Withdrawn=0 if (substr(ReasonWithdrawn,1,4)=="Loss" | 
substr(ReasonWithdrawn,1,4)=="Lost" | /// 
substr(ReasonWithdrawn,1,4)=="lLos") & Withdrawn==1 
replace Withdrawn=0 if (substr(ReasonWithdrawn,1,11)=="Other - con") & 
Withdrawn==1 
label var Withdrawn "Withdrawn (recoded)"  
*bysort Consent: tab Withdrawn Status, miss 
gen Active=0 if Withdrawn==0  
replace Active=1 if Status=="Active" & Active==0 
label var Active "Active (recoded 0=Eligible participant no longer active)" 
*bysort Consent: tab Active Status, miss 
  
tab ReasonWithdrawn  
label define labelReasonWithdrawn 0 "Not Withdrawn" 1 "OutsideStudyWindow" 2 
"WithdrewConsent" 3 "MovedOverseas" 4 "LostToFollow-up" /// 
5 "DeathBaby" 6 "DeathMother" 7 "Insufficient English" 8 "Other" 9 "Unknown" 
88 "DataEntryError" 
 
gen ReasonWithdrawn_calc=0 if Withdrawn==0 
replace ReasonWithdrawn_calc=1 if substr(ReasonWithdrawn,1,7)=="Outside" 
replace ReasonWithdrawn_calc=2 if (substr(ReasonWithdrawn,11,7)=="Consent" | 
substr(ReasonWithdrawn,11,7)=="consent") 
replace ReasonWithdrawn_calc=2 if (substr(ReasonWithdrawn,10,7)=="Consent" | 
substr(ReasonWithdrawn,10,7)=="consent") 
replace ReasonWithdrawn_calc=3 if (substr(ReasonWithdrawn,1,5)=="Moved" | 
substr(ReasonWithdrawn,1,5)=="moved") 
replace ReasonWithdrawn_calc=4 if (substr(ReasonWithdrawn,1,4)=="Loss" | 
substr(ReasonWithdrawn,1,4)=="Lost" | /// 
substr(ReasonWithdrawn,1,4)=="lLos") 
replace ReasonWithdrawn_calc=5 if (substr(ReasonWithdrawn,1,10)=="Death of B" 
| substr(ReasonWithdrawn,1,10)=="Death of b")  
replace ReasonWithdrawn_calc=6 if (substr(ReasonWithdrawn,1,10)=="Death of M" 
| substr(ReasonWithdrawn,1,10)=="Death of m")  
replace ReasonWithdrawn_calc=7 if (substr(ReasonWithdrawn,1,6)=="Insuff")  
replace ReasonWithdrawn_calc=8 if (substr(ReasonWithdrawn,1,5)=="Other" | 
substr(ReasonWithdrawn,1,5)=="other")  
*"Other contact details not current" = lost to follow-up 
replace ReasonWithdrawn_calc=4 if (substr(ReasonWithdrawn,1,11)=="Other - 
con")  
 
replace ReasonWithdrawn_calc=9 if (substr(ReasonWithdrawn,1,3)=="Unk" | 
substr(ReasonWithdrawn,1,3)=="unk")  
replace ReasonWithdrawn_calc=88 if (substr(ReasonWithdrawn,1,5)=="Error")  
*Note 5 records from Brisbane with no analysable data 
replace ReasonWithdrawn_calc=88 if ID=="DC5981CA-9F78-9149-B991-1815B1B06C0B" 
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replace ReasonWithdrawn_calc=88 if ID=="7A55F94F-5EA3-8F4E-97B8-12BBB253CE20" 
replace ReasonWithdrawn_calc=88 if ID=="E4F97F80-1DD2-CD4F-B682-33DBB6181FFD" 
replace ReasonWithdrawn_calc=88 if ID=="B5FC3ED0-9893-B046-B6E8-590A2ADD2D13" 
replace ReasonWithdrawn_calc=88 if ID=="833D2434-F69F-45E6-BD14-0148E5986AE1" 
 
replace ReasonWithdrawn_calc=9 if Status=="Withdrawn" & Consent==1 & 
Withdrawn==1 & ReasonWithdrawn_calc==. 
 
*Some records coded as LostToFollow-up but had not consented and had not 
completed eligibility criteria 
bysort Site: l ScreeningNum MaternalDOB DeliveryDate ScreenDate DateSEQ /// 
Consent English1 FUWindow StaySix Age17 Health FluvaxPreg Withdrawn 
ReasonWithdrawn_calc if /// 
ReasonWithdrawn_calc==4 & Consent~=1 & English1~=1 & FUWindow~=1 & StaySix~=1 
& Age17~=1, noobs 
 
replace ReasonWithdrawn_calc=. if ReasonWithdrawn_calc==4 & Consent~=1 & 
English1~=1 & FUWindow~=1 & StaySix~=1 & Age17~=1  
replace Withdrawn=. if Withdrawn==0 & ReasonWithdrawn_calc==. & Consent~=1 & 
English1~=1 & FUWindow~=1 & StaySix~=1 & Age17~=1  
 
*Some records coded as WithdrewConsent but appear to have completed Part A. 
Assume LTFU unless advised otherwise by Site 
tab ReasonWithdrawn_calc FluvaxPreg if ReasonWithdrawn_calc==2, miss 
 
label values ReasonWithdrawn_calc labelReasonWithdrawn 
label var ReasonWithdrawn_calc "Reason Withdrawn or LTFU (calculated)" 
 
sort Site DateSEQ 
bysort Site ReasonWithdrawn_calc: l ScreeningNum ScreenDate MaternalLastName 
MaternalDOB DeliveryDate /// 
DateSEQ Consent English1 FUWindow StaySix Age17 Health FluvaxPreg /// 
Withdrawn  if (ReasonWithdrawn_calc==2 | ReasonWithdrawn_calc==8 | 
ReasonWithdrawn_calc==9) /// 
 & (FluvaxPreg==0 | FluvaxPreg==1), noobs 
 
gen chkReasonWithdrawn=1 if (ReasonWithdrawn_calc==2 | ReasonWithdrawn_calc==8 
| ReasonWithdrawn_calc==9) /// 
 & (FluvaxPreg==0 | FluvaxPreg==1) 
label var chkReasonWithdrawn "Check if reason withdrawn should be Lost to 
Follow-up"   
replace Withdrawn=0 if chkReasonWithdrawn==1 & Withdrawn==1 
replace ReasonWithdrawn_calc=4 if chkReasonWithdrawn==1 & /// 
(ReasonWithdrawn_calc==2 | ReasonWithdrawn_calc==8 | ReasonWithdrawn_calc==9) 
* Coding written by Ross Andrews complete 
 
**DATES 
*DATESEQ Q1.04, MATERNAL DATE OF BIRTH Q2.03, LMP Date Q12.08 
codebook MaternalDOB 
*1. Create a variable to calculate the maternal age at delivery 
*Format string date variables (note DeliveryDate & ScreenDate were numeric, 
others were strings) 
*Note-dates are MDY in excel dataset,need to change these so they look like 
DMY 
foreach var of varlist DateSEQ MaternalDOB LMPDate DeliveryDate Date1Given 
ScreenDate{ 
 codebook `var' 
 replace `var'="" if `var'=="?" 
 replace `var'="10Oct1010" if `var'=="9/09/0909" | `var'=="10/10/1010" 
 gen `var'f=date(`var', "DMY") 
 format `var'f %td 
 drop `var' 
 rename *f *  
 replace `var'=.u if `var'==d(10Oct1010) 
 codebook `var' 
} 
drop if Withdrawn==1 
tab Site FluvaxPreg if Consent==1 
 
*ENROLLED 
codebook Enrolled 
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tab Enrolled Site, miss 
tab Enrolled Site if Consent==1 
bysort Enrolled: tab Site FluvaxPreg, col 
 
foreach var of varlist MatILI Mat2iLi Mat3iLi Mat4iLi Fluvax12mths FluvaxEver{ 
tab `var' FluvaxPreg, col 
} 
gen MatAge=(DeliveryDate-MaternalDOB)/365.25 if MaternalDOB>d(10oct1010)& 
MaternalDOB<. 
*Then create histogram to determine whether data are normally distributed for 
maternal age at delivery. 
hist MatAge 
*Data are normally distributed 
codebook MatAge 
*sort MatAge by FluvaxPreg 
tabstat MatAge, by (Site) stat (n mean min p25 p50 p75 max) 
tabstat MatAge, by (FluvaxPreg) stat (n mean min p25 p50 p75 max) 
 
*ANTENATAL (WEEKS PREGNANT AT FIRST ANTENATAL VISIT) Q4.02 
codebook Antenatal 
tab Antenatal, miss 
label var Antenatal "Wks @ 1st antenatal care" 
* Q4.02 says enter 0 if not attended any antenatal care 
*Create a categorical variable for antenatal care that differentiates "no 
care" from "early care" & "late care" 
gen AntenatalBy16=0 if Antenatal==0  
replace AntenatalBy16=1 if Antenatal<17 
replace AntenatalBy16=2 if Antenatal>16 & Antenatal<99 
replace AntenatalBy16=.u if Antenatal==99 
replace AntenatalBy16=.m if Antenatal==100 
label var AntenatalBy16 "Self-reported antenatal care by 16wks (<17wks)" 
label define labelAntenatalBy16 0 "No antenatal care" 1 "1st antenatal care by 
16wks" 2 "1st antenatal care after 16wks" /// 
.u "unk wks preg@1st antenatal care" .d "declined wks preg@1st antenatal care" 
label values AntenatalBy16 labelAntenatalBy16 
* now cross check recoding makes sense 
tab Antenatal AntenatalBy16, miss 
gen MeanGest=Antenatal if Antenatal>0 & Antenatal<99 
*tabstat MeanGest, by (FluvaxPreg) stat (n mean min p25 p50 p75 max)is 
performed at the end 
 
* MATERNAL INFLUENZA LIKE ILLNESS (ILI) IN PREGNANCY 
tab MatILI 
*some mum's have had more than one ILI in pregnancy-how to account for this? 
tab FluvaxPreg if MatILI==1 
tab MatILI if FluvaxPreg==1 
 
*TESTS DONE FOR RESP ILLNESS Q5.01, Q5.07, Q6.02, Q6.08 
*Current data export on tests not easily analysable 
 
foreach var of varlist Mat1Test Mat2Test Mat3Test Mat4Test{ 
 codebook `var' 
 tab `var',miss 
} 
*generate categorical variable for maternal tests for 1st resp illness  
gen RespTest1=0 if Mat1Test==0  
replace RespTest1=1 if Mat1Test==1 | Mat1Test==2 | Mat1Test==3 
replace RespTest1=2 if Mat1Test>10 & Mat1Test<. 
replace RespTest1=.u if Mat1Test==9 
replace RespTest1=.d if Mat1Test==10 
label var RespTest1 "Type of 1st TEST for resp illness in pregnancy" 
label define labelRespTest1 0 "No test" 1 "Blood test, nose OR throat swab" 2 
"More than 1 test" .u "Unknown" /// 
.d "Missing data" 
label values RespTest1 labelRespTest1 
* now cross check recoding makes sense 
tab RespTest1, miss 
tab RespTest1 if MatILI==1 
 
*generate categorical variable for maternal tests for 2nd resp illness  
gen RespTest2=0 if Mat2Test==0  
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replace RespTest2=1 if Mat2Test==1 | Mat2Test==2 | Mat2Test==3 
replace RespTest2=2 if Mat2Test>10 & Mat2Test<. 
replace RespTest2=.u if Mat2Test==9 
replace RespTest2=.d if Mat2Test==10 
label var RespTest2 "Type of 2nd TEST for resp illness in pregnancy" 
label define labelRespTest2 0 "No test" 1 "Blood test, nose OR throat swab" 2 
"More than 1 test" .u "Unknown" /// 
.d "Missing data" 
label values RespTest2 labelRespTest2 
* now cross check recoding makes sense 
tab RespTest2, miss 
tab RespTest2 if MatILI==1 
 
*generate categorical variable for maternal tests for 3rd resp illness  
gen RespTest3=0 if Mat3Test==0  
replace RespTest3=1 if Mat3Test==1 | Mat3Test==2 | Mat3Test==3 
replace RespTest3=2 if Mat3Test>10 & Mat3Test<. 
replace RespTest3=.u if Mat3Test==9 
replace RespTest3=.d if Mat3Test==10 
label var RespTest3 "Type of 3rd TEST for resp illness in pregnancy" 
label define labelRespTest3 0 "No test" 1 "Blood test, nose OR throat swab" 2 
"More than 1 test" .u "Unknown" /// 
.d "Missing data" 
label values RespTest3 labelRespTest3 
* now cross check recoding makes sense 
tab RespTest3, miss 
tab RespTest3 if MatILI==1 
 
*generate categorical variable for maternal tests for 4th resp illness  
gen RespTest4=0 if Mat2Test==0  
replace RespTest4=1 if Mat4Test==1 | Mat4Test==2 | Mat4Test==3 
replace RespTest4=2 if Mat4Test>10 & Mat4Test<. 
replace RespTest4=.u if Mat4Test==9 
replace RespTest4=.d if Mat4Test==10 
label var RespTest4 "Type of 4th TEST for resp illness in pregnancy" 
label define labelRespTest4 0 "No test" 1 "Blood test, nose OR throat swab" 2 
"More than 1 test" .u "Unknown" /// 
.d "Missing data" 
label values RespTest4 labelRespTest4 
* now cross check recoding makes sense 
tab RespTest4, miss 
tab RespTest4 if MatILI==1 
 
*I want to create categorical variables to separate out the trimesters and 
display the results in a table by trimester. 
*WEEKS PREGNANT IF VISITED THE DOCTOR FOR AN ILI & HAD A TEST Q5.04, Q5.10, 
Q6.05, Q6.11 
*generate new variable to create categories for trimesters 
foreach var of varlist Mat1FluWeeks-Mat4FluWeeks{ 
 codebook `var' 
} 
*generate categorical variable for trimester at 1st visit to Dr for flu 
gen GestTest=0 if Mat1FluWeeks==0  
replace GestTest=1 if Mat1FluWeeks<=13 
replace GestTest=2 if Mat1FluWeeks>=14 & Mat1FluWeeks<=28 
replace GestTest=3 if Mat1FluWeeks>=29 & Mat1FluWeeks<=43 
replace GestTest=.u if Mat1FluWeeks==99 
replace GestTest=.d if Mat1FluWeeks==100 
label var GestTest "Trimester in which 1st test for flu occurred" 
label define labelGestTest 1 "1st trimester test for flu" 2 "2nd trimester 
test for flu" 3 "3rd trimester test for flu" /// 
.u "unknown trimester when visited for flu" .d "declined" 
label values GestTest labelGestTest 
* now cross check recoding makes sense 
codebook GestTest 
*cross tab against MatFluWeeks to see if new variable matches as intended (it 
does!) 
tab Mat1FluWeeks GestTest, miss 
tab GestTest FluvaxPreg, col 
tab Mat1FluWeeks if Mat1FluWeeks <99 & Mat1FluWeeks >0 
replace Mat1FluWeeks=.m if Mat1FluWeeks==0 
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replace Mat1FluWeeks=.u if Mat1FluWeeks==99 
replace Mat1FluWeeks=.d if Mat1FluWeeks==100 
tab Mat1FluWeeks 
 
*generate categorical variable for trimester at 2nd visit for flu  
gen GestTest2=0 if Mat2FluWeeks==0  
replace GestTest2=1 if Mat2FluWeeks<=13 
replace GestTest2=2 if Mat2FluWeeks>=14 & Mat2FluWeeks<=28 
replace GestTest2=3 if Mat2FluWeeks>=29 & Mat2FluWeeks<=43 
replace GestTest2=.u if Mat2FluWeeks==99 
replace GestTest2=.m if Mat2FluWeeks==100 
label var GestTest2 "Trimester in which 2nd test for flu occurred" 
label define labelGestTest2 1 "1st trimester test for flu" 2 "2nd trimester 
test for flu" 3 "3rd trimester test for flu" /// 
.u "unknown trimester when tested for flu" .m "missing data" 
label values GestTest2 labelGestTest2 
* now cross check recoding makes sense 
tab Mat2FluWeeks GestTest2, miss 
tab GestTest2 FluvaxPreg, col 
 
*generate categorical variable for trimester at 3rd visit for flu  
gen GestTest3=0 if Mat3FluWeeks==0  
replace GestTest3=1 if Mat3FluWeeks<=13 
replace GestTest3=2 if Mat3FluWeeks>=14 & Mat3FluWeeks<=28 
replace GestTest3=3 if Mat3FluWeeks>=29 & Mat3FluWeeks<=43 
replace GestTest3=.u if Mat3FluWeeks==99 
replace GestTest3=.m if Mat3FluWeeks==100 
label var GestTest3 "Trimester in which 3rd test for flu occurred" 
label define labelGestTest3 1 "1st trimester test for flu" 2 "2nd trimester 
test for flu" 3 "3rd trimester test for flu" /// 
.u "unknown trimester when tested for flu" .m "missing data" 
label values GestTest3 labelGestTest3 
* now cross check recoding makes sense 
tab Mat3FluWeeks GestTest3, miss 
tab GestTest3 FluvaxPreg, col 
 
*generate categorical variable for trimester at 4th visit for flu  
gen GestTest4=0 if Mat4FluWeeks==0  
replace GestTest4=1 if Mat4FluWeeks<=13 
replace GestTest4=2 if Mat4FluWeeks>=14 & Mat4FluWeeks<=28 
replace GestTest4=3 if Mat4FluWeeks>=29 & Mat4FluWeeks<=43 
replace GestTest4=.u if Mat4FluWeeks==99 
replace GestTest4=.m if Mat4FluWeeks==100 
label var GestTest4 "Trimester in which 4th test for flu occurred" 
label define labelGestTest4 1 "1st trimester test for flu" 2 "2nd trimester 
test for flu" 3 "3rd trimester test for flu" /// 
.u "unknown trimester when tested for flu" .m "missing data" 
label values GestTest4 labelGestTest4 
* now cross check recoding makes sense 
tab Mat4FluWeeks GestTest4, miss 
tab GestTest4 FluvaxPreg, col 
 
*DATE OF DELIVERY Q12.01 (dd/mmm/yyyy) 
*create year and month of delivery 
gen Birthyear = year(DeliveryDate) 
label var Birthyear "Year infant born" 
gen Birthmonth = month(DeliveryDate) 
label var Birthmonth "Month infant born" 
label define labelmonth 1 "Jan" 2 "Feb" 3 "Mar" 4 "Apr" 5 "May" 6 "Jun" 7 
"Jul" 8 "Aug" 9 "Sep" 10 "Oct" 11 "Nov" 12 "Dec" 
label values Birthmonth labelmonth 
gen Birthyrmth = Birthyear + (Birthmonth*0.01) 
label var Birthyrmth "Year month infant born"  
tab Birthyrmth, miss 
 
*BIRTHMONTH Q12.04 
codebook Bmth 
tab Bmth, miss 
tab Bmth Site, col  
 
*LIVEBIRTHS Q12.05 
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codebook LiveBirth 
tab LiveBirth, miss 
tab LiveBirth 
label var LiveBirth "Live Birth" 
label values LiveBirth labelYesNo 
tab Site LiveBirth, miss 
tab LiveBirth 
 
*GESTATION IN WEEKS AT DELIVERY (Q12.07) 
*Definition/reference came from AIHW website accessed 18Dec2014 babies are 
preterm if born before 37 completed wks 
codebook Gestation 
tab Gestation, miss 
br if Gestation<25 | (Gestation>42 & Gestation<.) 
list ScreeningNum StudyID Site Gestation if Gestation<25 | (Gestation>42 & 
Gestation<.), noobs 
bysort Site: list ScreeningNum StudyID Site Enrolled Consent DeliveryDate 
Gestation if Gestation<25 | (Gestation>42 & Gestation<.), noobs 
tab Gestation if Gestation <38 & Gestation >10  
gen Gest37comp=1 if Gestation>20 & Gestation<38 
replace Gest37comp=0 if Gestation>=38 & Gestation<. 
label var Gest37comp "Gestation <37 completed weeks" 
tab Gest37comp FluvaxPreg, col 
cs Gest37comp FluvaxPreg 
tabstat Gestation, by (FluvaxPreg) stat (n mean min p25 p50 p75 max) 
tabstat Gestation, by (Site) stat (n mean min p25 p50 p75 max) 
 
*PREMATURITY 
*generate categorical variable for gestation =<38 weeks & >=38 weeks (that is 
less than 37 completed weeks & > 37 completed weeks) 
gen GestWeeks=0 if Gestation==0  
replace GestWeeks=1 if Gestation>24 & Gestation<=29  
replace GestWeeks=2 if Gestation>29 & Gestation<=34 
replace GestWeeks=3 if Gestation>34 & Gestation<=37 
replace GestWeeks=4 if Gestation>37 & Gestation<43 
replace GestWeeks=.u if Gestation==99 
replace GestWeeks=.d if Gestation==100 
label var GestWeeks "Gestation at delivery-preterm birth" 
label define labelGestWeeks 1 "<=29wks gest. @ delivery" 2 "30-34 wks gest @ 
delivery " 3 "35-37 wks gest @ delivery " 4 ">38 wks gest @ delivery" /// 
.u "unk wks preg@delivery" .d "declined response" 
label values GestWeeks labelGestWeeks 
*Now check to see recoding makes sense 
tab Gestation GestWeeks, miss 
*It does! 
tab GestWeeks Site, col 
tab GestWeeks FluvaxPreg, col chi 
*Generate new variable for severe prem babies born under 30 weeks 
gen Prem30=1 if GestWeeks==1 
replace Prem30=0 if GestWeeks==4 
label var Prem30 "<=29wks gest. @ delivery" 
label define labelPrem30 0 ">38 wks gest @ delivery" 1 "<=29wks gest. @ 
delivery" 
label values Prem30 labelPrem30 
tab GestWeeks Prem30 , miss 
cs Prem30 FluvaxPreg 
**Generate new variable for prem babies born under 35 weeks 
gen Prem35=1 if GestWeeks==1 | GestWeeks==2 
replace Prem35=0 if GestWeeks==4 
label var Prem35 "<35wks gest. @ delivery" 
label define labelPrem35 0 ">38 wks gest @ delivery" 1 "<35wks gest. @ 
delivery" 
label values Prem35 labelPrem35 
tab GestWeeks Prem35 , miss 
cs Prem35 FluvaxPreg 
 
*BIRTHWEIGHT (in grams) Q14.03 
*References for low birthweight are from AIHW website accessed 18Dec2014 
codebook B1Wgt 
hist B1Wgt 
mean B1Wgt  
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tabstat B1Wgt, by (Site) stat (n mean min p25 p50 p75 max) 
tabstat B1Wgt, by (FluvaxPreg) stat (n mean min p25 p50 p75 max) 
summ B1Wgt, detail 
*Need to make categorical variable for <2500g =2500-3999g >=4000g 
gen Lbwt=0 if B1Wgt==0  
replace Lbwt=1 if B1Wgt<2500 
replace Lbwt=2 if B1Wgt>=2500 & B1Wgt<=3999 
replace Lbwt=3 if B1Wgt>=4000 & B1Wgt<=6000 
*Birthweight needs to be a minimum of 400g 
tab B1Wgt Lbwt if B1Wgt<401, miss 
replace Lbwt=.u if B1Wgt<401  
replace Lbwt=.d if B1Wgt==100 
tab B1Wgt Lbwt if B1Wgt<401, miss 
label var Lbwt "Low birth weight at delivery" 
label define labelLbwt 1 "<2500g bweight " 2 ">=2500g-<=3999g bweight " 3 
">=4000g bweight " /// 
.u "unk birthweight" .d "declined response" 
label values Lbwt labelLbwt 
* now cross check recoding makes sense 
*It does yay! 
tab Lbwt Site, miss 
tab Lbwt FluvaxPreg, miss 
tab Lbwt FluvaxPreg, col chi*LOW BIRTHWEIGHT-Infants less than 2500g 
gen LowBwt=1 if B1Wgt<2500 
replace LowBwt=0 if B1Wgt>=2500 & B1Wgt<6000 
replace Lbwt=.u if B1Wgt<401 
replace Lbwt=.d if B1Wgt==100 
label var LowBwt "Infant less than 2500g" 
label define labelLowBwt 0 ">2500g bweight" 1 "<2500g bweight" .u "unk 
birthweight" .d "declined response" 
label values LowBwt labelLowBwt 
tab LowBwt FluvaxPreg, col chi 
cs LowBwt FluvaxPreg 
*VERY LOW BIRTHWEIGHT-Infants less than 1500g 
gen VLowBwt=1 if B1Wgt<1500 
replace VLowBwt=0 if B1Wgt>=1500 & B1Wgt<6000 
replace VLowBwt=.u if B1Wgt<401 
replace VLowBwt=.d if B1Wgt==100 
label var VLowBwt "Infant less than 1500g" 
label define labelVLowBwt 0 ">1500g bweight" 1 "<1500g bweight" .u "unk 
birthweight" .d "declined response" 
label values VLowBwt labelVLowBwt 
tab VLowBwt FluvaxPreg, col chi 
cs VLowBwt FluvaxPreg 
*EXTREMELY LOW BIRTHWEIGHT-Infants less than 1000g 
gen ELowBwt=1 if B1Wgt<1000 
replace ELowBwt=0 if B1Wgt>=1000 & B1Wgt<6000 
replace ELowBwt=.u if B1Wgt<401 
replace ELowBwt=.d if B1Wgt==100 
label var ELowBwt "Infant less than 1000g" 
label define labelELowBwt 0 " >1000g bweight" 1 "<1000g bweight" .u "unk 
birthweight" .d "declined response" 
label values ELowBwt labelELowBwt 
tab ELowBwt FluvaxPreg, col chi 
cs ELowBwt FluvaxPreg 
cs ELowBwt FluvaxPreg, exact 
 
*LARGE FOR GESTATIONAL AGE->4000G 
gen LGA=0 if B1Wgt<4000 
replace LGA=1 if B1Wgt>=4000 & B1Wgt<=6000 
replace LGA=.u if B1Wgt<401 
replace LGA=.d if B1Wgt==100 
label var LGA "LGA" 
label define labelLGA 0 "<4000g bweight " 1 ">=4000g bweight " .u "unk 
birthweight" .d "declined response" 
label values LGA labelLGA 
tab LGA FluvaxPreg, col chi 
cs LGA FluvaxPreg 
*NORMAL FOR GESTATIONAL AGE-2500-3999g 
gen NGA=1 if B1Wgt>=2500 & B1Wgt<=4000 
replace NGA=0 if B1Wgt>=4000 | B1Wgt<=2500 
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replace NGA=.u if B1Wgt<401 
replace NGA=.d if B1Wgt==100 
label var NGA "NGA" 
label define labelNGA 0 ">=4000g bweight & <2500g " 1 "Normal birthweight " .u 
"unk birthweight" .d "declined response" 
label values NGA labelNGA 
tab NGA FluvaxPreg, col chi 
cs NGA FluvaxPreg 
 
*GENDER (infant) Q14.04 
codebook B1Sex 
label var B1Sex "Gender of infant" 
replace B1Sex="0" if B1Sex=="I" 
replace B1Sex="1" if B1Sex=="M" 
replace B1Sex="2" if B1Sex=="F" 
replace B1Sex="10" if B1Sex=="Dcl" | B1Sex=="Declined" 
destring B1Sex, replace 
label define labelB1Sex 0 "Indeterminate" 1 "Male" 2 "Female" 10 "Declined" 
label values B1Sex labelB1Sex 
tabstat B1Sex, by (Site) stat (n mean min p25 p50 p75 max) 
tab B1Sex FluvaxPreg, col 
 
gen InfantSex=0 if B1Sex==0 
replace InfantSex=0 if B1Sex==1 
replace InfantSex=1 if B1Sex>1 & B1Sex<.  
label var InfantSex "Sex of infant" 
label define labelInfantSex 0 "Male" 1 "Female" 2 "Other/unspecified" 
label values InfantSex labelInfantSex 
* now cross check recoding makes sense 
tab InfantSex FluvaxPreg, col chi 
cs InfantSex FluvaxPreg 
 
*IF YES, NAME OF IMMUNE DISORDER Q14.09 
*Lots of different text responses for this variable, not sure whether will 
need to include or not 
codebook B1ImmuneName 
*tab B1ImmuneName, miss 
*tab B1ImmuneName 
 
*IF YES, REASON GIVEN STEROIDS Q14.11 
*as above 
codebook B1Steroid_reason 
 
*BABY ILLNESS REQUIRIING MEDICAL FOLLOW-UP OR HOSP Q14.12 
codebook B1HighRisk 
 
*IF YES, NAME OF MEDICAL CONDITION Q 14.13 
*as above 
codebook B1HighRiskName 
*tab B1HighRiskName 
 
**MATERNAL RISK FACTORS Q'S 17.01-17.11, Q17.13, Q18.03,18.06   
*MOTHER EVER BEEN TOLD SHE HAS THE FOLLOWING CONDITIONS 
foreach var of varlist Heart-ImmuneMedspreg PregSmoker AustralianBorn English2 
DayCare IndoorSmoke{ 
 codebook `var' 
 replace `var'="0" if `var'=="No" 
 replace `var'="1" if `var' =="Yes" 
 replace `var'="9" if `var' =="Unknown" | `var'=="Unk" 
 replace `var'="10" if `var'=="Declined" | `var'=="Dcl"  
 destring `var', replace 
 label values `var' labelYesNo 
 codebook `var' 
 tab `var' FluvaxPreg,miss 
 tab `var' FluvaxPreg, col 
} 
label var Heart "Heart disease" 
label var Hypertension "Hypertension" 
label var Pneumonia "Severe pneumonia requiring hospitalisation during 
pregnancy" 
label var Bronchitis "Chronic resp condition" 
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label var Immune "Immunosuppressive condition" 
label var Cancer "Cancer" 
label var Diabetespreg "Diabetes in pregnancy" 
label var ImmuneMedspreg "Immunosuppressive meds in pregnancy" 
label var PregSmoker "Cigarette smoking in pregnancy" 
label var AustralianBorn "Australian born" 
label var English2 "Is English main language spoken at home?" 
label var DayCare "Any children who attend day care?" 
label var IndoorSmoke "Regularly exposed to indoor tobacco smoke during 
pregnancy" 
 
*RISK FACTORS (any condition listed in the Aust Immun Handbook, same as Q's 17 
in workbook) 
gen RiskFact=. 
label var RiskFact "Maternal Risk Factors (Co-morbidities)" 
foreach var of varlist Heart-ImmuneMedspreg { 
tab `var' RiskFact, miss  
replace RiskFact=0 if `var'<9 & RiskFact~=1 
replace RiskFact=1 if `var'==1 
tab `var' RiskFact, miss  
} 
label values RiskFact labelYesNo 
tab RiskFact FluvaxPreg, col chi 
cs RiskFact FluvaxPreg 
 
*MATERNAL SELF-REPORTED SMOKING IN PREG Q17.13 
codebook PregSmoker 
tab PregSmoker FluvaxPreg, col 
*MATERNAL SELF-REPORTED EXPOSURE TO INDOOR TOBACCO SMOKE IN PREG Q18.16 
codebook IndoorSmoke 
tab IndoorSmoke FluvaxPreg, miss 
tab IndoorSmoke FluvaxPreg, col 
cs IndoorSmoke FluvaxPreg 
 
*MOTHER IDENTIFIES AS ABORIGINAL AND/OR TORRES STRAIT ISLANDER Q.18.01 
*String variables need to change to numerical, then binary  
foreach var of varlist ATSIMum{ 
 codebook `var' 
 replace `var'="0" if `var'=="No" 
 replace `var'="1" if `var' =="AB" 
 replace `var'="2" if `var' =="TSI" 
 replace `var'="3" if `var' =="Both" 
 replace `var'="9" if `var' =="Unknown" | `var'=="Unk" 
 replace `var'="10" if `var'=="Declined" | `var'=="Dcl"  
 destring `var', replace 
 label define labelATSIMum 0 "No" 1 "Yes" 2 "TSI" 3 "Both" 9 "Unk" 10 
"Dcl" 
 label values `var' labelATSIMum 
 codebook `var' 
 tab `var',miss 
}  
*BABY IDENTIFIES AS ABORIGINAL AND/OR TORRES STRAIT ISLANDER Q.18.02 
foreach var of varlist ATSIBaby{ 
 codebook `var' 
 replace `var'="0" if `var'=="No" 
 replace `var'="1" if `var' =="AB" 
 replace `var'="2" if `var' =="TSI" 
 replace `var'="3" if `var' =="Both" 
 replace `var'="9" if `var' =="Unknown" | `var'=="Unk" 
 replace `var'="10" if `var'=="Declined" | `var'=="Dcl"  
 destring `var', replace 
 label define labelATSIBaby 0 "No" 1 "Yes" 2 "TSI" 3 "Both" 9 "Unk" 10 
"Dcl" 
 label values `var' labelATSIBaby 
 codebook `var' 
 tab `var',miss 
}  
*The following coding changes ATSIMum and ATSIBaby from categories into a 
binary yes/no outcome 
*ATSI Mum  
gen IndigMum=0 if ATSIMum==0 
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replace IndigMum=1 if ATSIMum>0 & ATSIMum<4 
label var IndigMum "Aboriginal and/or Torres Strait Islander" 
tab IndigMum 
tab IndigMum ATSIMum, miss  
tab IndigMum Birthyear 
tab IndigMum FluvaxPreg, col 
*ATSI Baby 
gen IndigBaby=0 if ATSIBaby==0 
replace IndigBaby=1 if ATSIBaby>0 & ATSIBaby<4 
label var IndigBaby "Aboriginal and/or Torres Strait Islander" 
tab IndigBaby 
tab IndigBaby ATSIBaby, miss  
tab IndigBaby FluvaxPreg, col 
cs IndigBaby FluvaxPreg 
 
*NUMBER OF HOUSEHOLD SMOKERS Q18.15 
codebook HouseholdSmoker 
gen HouseExp=0 if HouseholdSmoker==0  
replace HouseExp=1 if HouseholdSmoker>=1 & HouseholdSmoker<99 
replace HouseExp=.u if HouseholdSmoker==99 
replace HouseExp=.d if HouseholdSmoker==100 
label var HouseExp "Exposure to household smoke" 
label define labelHouseExp 0 "Is not exposed to household smoke" 1 "Exposed to 
household smoke" /// 
.u "unknown" .d "declined response" 
label values HouseExp labelHouseExp 
* now cross check recoding makes sense 
tab HouseholdSmoker HouseExp, miss 
tab HouseExp FluvaxPreg, col chi 
 
*EDUCATION QUALIFICATIONS OF MOTHER Q19.01 
codebook Education 
label define labelEducation 1 "Did not finish high school" 2 "High school" 3 
"Certificate" 4 "Diploma" 5 "Degree" /// 
6 "Post grad degree" 10 "Declined" 
label values Education labelEducation 
tab Education FluvaxPreg if Consent==1, col 
*Create a categorical variable for Education that differentiates "Diploma & 
under " from "Degree or higher"  
gen EducationCat=0 if Education==0  
replace EducationCat=0 if Education>0 & Education<=4 
replace EducationCat=1 if Education>=5 & Education<7 
replace EducationCat=.m if Education==10 
label var EducationCat "Education Level of mother" 
label define labelEducationCat 0 "Diploma & Under" 1 "Degree or higher" .d 
"declined" 
label values EducationCat labelEducationCat 
* now cross check recoding makes sense 
tab EducationCat Education, miss 
tab EducationCat FluvaxPreg, col chi 
cs EducationCat FluvaxPreg 
 
tab Site FluvaxPreg if Consent==1 
bysort Enrolled: tab Site FluvaxPreg, row 
 
*Mean Gestation at 1st Antenatal care presentation 
tabstat MeanGest, stat (n mean min p25 p50 p75 max) 
tabstat MeanGest, by (FluvaxPreg) stat (n mean min p25 p50 p75 max) 
*Following variables used for comparison with FluvaxPreg  
foreach var of varlist MatILI IndigMum IndigBaby PregSmoker English2{ 
 codebook `var' 
 tab `var' FluvaxPreg if Consent==1, col miss 
 tab `var' FluvaxPreg,miss 
} 
***UNIVARIATE ANALYSIS 
*t-tests for continuous variables with normally distributed data. 
ttest Gestation, by (FluvaxPreg) 
ttest B1Wgt, by (FluvaxPreg) 
ttest MatAge, by (FluvaxPreg) 
ttest Antenatal, by (FluvaxPreg) 
ttest Mat1FluWeeks, by (FluvaxPreg)  
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ttest Gestation, by (MatILI) 
ttest B1Wgt, by (MatILI) 
ttest MatAge, by (MatILI) 
 
**Chi-square analysis and 95% CI for binary variables 
foreach var of varlist PlaceScreened PlaceBirth MatILI SiteCity B1Sex Heart-
ImmuneMedspreg PregSmoker AustralianBorn English2 AntenatalBy16 DayCare-
Education Birthyear Gest37-HouseExp{ 
 tab `var' FluvaxPreg, col chi 
} 
*For 95% CI for the remainder of the binary variables (within cohort 
*comparisons if required) 
bysort FluvaxPreg: ci PlaceBirth 
bysort FluvaxPreg: ci MatILI 
bysort FluvaxPreg: ci B1Sex 
bysort FluvaxPreg: ci Heart-ImmuneMedspreg 
bysort FluvaxPreg: ci PregSmoker 
bysort FluvaxPreg: ci AustralianBorn 
bysort FluvaxPreg: ci AntenatalBy16 
bysort FluvaxPreg: ci DayCare-EducationCat 
bysort FluvaxPreg: ci Gest37-HouseExp 
 
cs Heart FluvaxPreg 
cs Hypertension FluvaxPreg 
cs ImmuneMedspreg FluvaxPreg 
cs Cancer FluvaxPreg 
cs Pneumonia FluvaxPreg 
cs Bronchitis FluvaxPreg 
cs Immune FluvaxPreg 
cs English2 FluvaxPreg 
cs DayCare FluvaxPreg 
 
**Crude and relative risks with 95% confidence intervals & p-values. 
foreach var of varlist IndigMum Diabetespreg RiskFact PregSmoker MatILI Gest37 
Education{ 
 cs `var' FluvaxPreg  
} 
*What proportion of women had a flu vaccine in their 1st trimester? 
gen FluvaxPregweeks=(DeliveryDate-Date1Given)/7 if DeliveryDate~=. & 
Date1Given~=. 
*Check for logic  
sort FluvaxPregweeks 
br FluvaxPregweeks Date1Given DeliveryDate if DeliveryDate~=. & Date1Given~=. 
 
gen GestWeeksFluvax =Gestation-FluvaxPregweeks if Gestation~=. & 
FluvaxPregweeks~=. 
*generate categorical variable showing trimester when flu vaccine was given in 
pregnancy 
gen GestTrimFluvax=1 if GestWeeksFluvax >0 & GestWeeksFluvax <14 
replace GestTrimFluvax=2 if GestWeeksFluvax>=14 & GestWeeksFluvax<29 
replace GestTrimFluvax=3 if GestWeeksFluvax>=29 & GestWeeksFluvax<=43 
replace GestTrimFluvax=.u if GestWeeksFluvax==. & FluvaxPreg==1 
label var GestTrimFluvax "Trimester in which flu vaccine given" 
label define labelGestTrimFluvax 1 "1st trimester fluvax" 2 "2nd trimester 
fluvax" 3 "3rd trimester fluvax" /// 
.u "unknown trimester" .d "declined" 
label values GestTrimFluvax labelGestTrimFluvax 
 
*Look at primary birth outcomes (gestation & birthweights)between those mums 
who /// 
*had a flu vax in 1st trimester compared to those mums who didn't have a flu 
vaccine in pregnancy 
ttest Gestation if GestTrimFluvax==1 | FluvaxPreg==0, by (FluvaxPreg) 
ttest B1Wgt if GestTrimFluvax==1 | FluvaxPreg==0 , by (FluvaxPreg) 
 
*The proprtion of women who had a flu vaccine in the 1st trimester is... 
tab GestTrimFluvax FluvaxPreg, col 
 
*Are infants born in Jan-March more likely to have a mother who was vaccinated 
in their /// 
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*1st trimester compared to infants born in Apr-Dec? 
tab Birthmonth Consent, miss 
gen Birthmonthvax=0 if Consent==1 & Birthmonth<=12 
replace Birthmonthvax=1 if Birthmonth<4 
tab Birthmonthvax Consent, miss 
label var Birthmonthvax " Infants born 1=Jan-March, 0= Apr-Dec" 
tab GestTrimFluvax Birthmonthvax  
bysort Birthmonthvax: tab GestTrimFluvax FluvaxPreg, col miss 
 
*Need to make Gestation & B1Wgt catagorical variables before being able to 
calculate relative risks 
*foreach var of varlist Gestation B1Wgt{ 
* cs `var' FluvaxPreg if GestTrimFluvax==1 | FluvaxPreg==0 
*} 
 
* I want to know the birth outcomes of the mum's who 
*a) self-reported having a flu vaccine during pregnancy vs those who didn't 
(done) 
*b) had an ILI (done) see t-test results above 
*c) had an ILI & had a test to describe trimester & flu season 
*d) had an ILI and DID NOT have a test  
 
* did NOT have an ILI (MatILI==0) 
 
log close 
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Appendix 2.3.  Communicable Disease Control (CDC) 
conference presentation, Brisbane, June 2015 
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3. Data analysis: Laboratory Confirmed Pertussis 
Notifications in Queensland 1997-2014 
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Prologue 
Background 
It is known notification data are generally not used for analytical assumptions but 
rather as an indication of how effective a surveillance system is operating or for quality 
assurance purposes. They provide important opportunities to observe trends and 
responses to interventions such as immunisation programs. Pertussis has been a 
notifiable disease in Queensland since 1997.The aim of this project was to present a 
case series analysis of all pertussis notifications in Queensland since this date. 
My role 
I conducted all of the data analysis required of this project. This included; applying and 
acquiring ethics approvals, designing a data analysis plan, preparing the data by 
cleaning and coding in a Stata do-file as well as all data analyses. I also merged two 
major datasets and calculated rates as well as construct graphs to present the results. 
Lessons learned 
Rates, rates, rates. I never knew how much time was involved in calculating average 
annual notification rates by year of notification or age or sex. I also learned a great 
deal about presenting data in this project. After generating so many results from so 
much data I found it challenging to determine which data to present and how. It was 
also a learning experience merging two Stata do-files. Learning how to achieve this in 
courseblock was quite different to putting it into practice in a real life scenario. This 
was fun, gratifying and challenging. 
Public Health Impact 
Pertussis remains endemic in most parts of the world and continues to be difficult to 
control. In these analyses, infants under 6 months of age recorded the highest 
notification rates of 196.5 per 100,000 populations. Rates declined sharply once 
infants reached over 12 months of age. There is evidence suggesting maternal 
pertussis vaccination administered during the last trimester of pregnancy has a 
protective effect in infants in the first few months of life. It will be worth observing the 
data that arises from the Queensland maternal pertussis vaccination program which 
commenced on 01 August 2014 regarding pertussis notifications in infants less than 
four months of age.  
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Abstract 
Introduction 
Pertussis is a highly contagious disease which has epidemic cycles. Outbreaks occur 
regularly every three to four years with varying degrees of severity.Treatment of 
pertussis is based on clinical findings and diagnosis and control is a high public health 
priority. Morbidity and mortality is highest in infants under six months of age and 
control efforts focus on preventing disease in this age group by minimizing exposure by 
other infected cases. Despite ongoing immunisation programs, pertussis was the most 
commonly reported vaccine preventable disease (VPD) in Australia in 2010 and 
accounted for over half of all VPD notifications. The aim of this project was to present 
case series analysis of all pertussis notifications in Queensland since this date. 
Methods 
I conducted a retrospective case series analysis of all notified cases of pertussis 
occurring in Queensland from 01 January 1997 to 31 December 2014. This was 
achieved by extraction of all valid (laboratory confirmed) and probable (clinical) 
notified cases of pertussis in Queensland according to the current case definition. 
Descriptive epidemiology and temporal trends of pertussis notifications in Queensland 
over time were examined. Results are presented as baseline demographic 
characteristics and summary statistics in the form of proportions, counts and average 
annual rates, by year of notification, age and sex. 
Results 
There were 53,901 unique notified laboratory confirmed pertussis cases and 46,998 
laboratory testing results examined. Over the 18 year observation period (1997-2014), 
the median age of persons notified with pertussis was 35.2 years. There were more 
females compared to males for each year of notification and an over representation of 
Aboriginal and Torres Strait Islander persons (10%) – albeit with proportion of records 
(69%) with missing data on Indigenous status. Amongst children less than three years 
of age, notifications of pertussis were most common amongst the youngest infants, 
that is those <4 months of age. The highest number of notifications recorded for a 
single year was in 2011 with 8,984 cases and the lowest number of notifications 
occurred in 2000 with 537 cases. Serology (66%) and PCR (33%) were the most 
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common test types for confirmation of a diagnosis with only 1% culture. The increase 
in pertussis notifications from 2009 coincided with a substantial increase in the 
number of cases diagnosed by PCR. 
Conclusions 
The results in this case series for notifications of pertussis by age are consistent with 
that of overseas literature. It will important to monitor the outcomes of the 
implementation of the Queensland maternal pertussis vaccination program which 
commenced on 01 August 2014 regarding pertussis notifications in infants less than 
four months of age. 
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Introduction 
Bordetella pertussis is a bacterial, vaccine-preventable infectious disease causing a 
condition known as ‘pertussis’ or ‘whooping cough’.1 Pertussis is a highly contagious 
disease, particularly in the first two weeks, that can result in significant morbidity and 
mortality.1 The incubation period ranges from 6-20 days with an average of 9-10 days.1 
According to the World Health Organization (WHO), global immunisation coverage of 
infants in 2014 who had received all three doses of pertussis vaccine was estimated at 
86%.2 In Australia this was greater than 90%.2 In 2010, pertussis was the most 
commonly reported vaccine preventable disease (VPD) in Australia and accounted for 
over 50% of all VPD notifications.3  
 
Pertussis is a disease that has epidemic cycles.4 Outbreaks occur regularly every three 
to four years with varying degrees of severity, despite ongoing immunisation 
programs. Those that acquire pertussis and are unvaccinated or only partially 
vaccinated have higher degrees of morbidity and mortality,5 particularly infants under 
six months of age. Disease severity is high in this age group with case fatality rates 
reportedly 1 in 200 infants.6 The epidemiology of pertussis in Australia shows a similar 
pattern.7 Generally, the most likely mode of transmission of pertussis is from exposure 
to other household members who are infected; particularly mothers, fathers and 
grandparents, followed by siblings, as well as exposure to children in child care and 
other health care settings.8 In the 2008-2012 pertussis epidemic in Perth, siblings were 
identified as being the highest source of infection to infants under six months of age, 
which was thought to be due to waning immunity amongst these siblings.9 
 
Treatment of pertussis is based on clinical findings and diagnosis. Control of pertussis 
is a high public health priority, with control efforts focusing on preventing disease in 
children under 6 months of age, particularly by minimizing exposure to this age group 
by other infected cases.10 
 
Pertussis is a nationally notifiable disease and has been a notifiable disease in 
Queensland since 1997. Clinicians and laboratories are required to notify public health 
units (PHU) within one working day of probable and confirmed diagnoses. The 
Queensland Notifiable and Other Conditions System (NOCS) records all notifications of 
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pertussis received from laboratories and clinicians. Public health units access these 
data for public health follow up. The NOCS system is a source of information regarding 
the incidence and prevalence of pertussis in Queensland and can provide information 
on disease acquisition, morbidity and mortality on the cases that are followed up by a 
PHU. Information assists in planning of Queensland’s Health (QH) services and is used 
for national and state reporting. De-identified notification data are forwarded to the 
Australian National Notifiable Disease Surveillance System (NNDSS). 
 
The primary aim of this project was to present descriptive epidemiological results of all 
notified cases of pertussis occurring in Queensland from 01 January 1997 to 31 
December 2014. To achieve this, the primary objective was to perform a descriptive 
case series analysis of these data by extraction of all valid (laboratory confirmed) and 
probable (clinical) notified cases of pertussis in Queensland.  
 
Methods 
Study design and population 
The study design for this data analysis project was a retrospective case series. The 
study population was formed using the population hierarchy shown in Figure 3.1. Here 
the source population was all cases of pertussis that occurred in Queensland from 
1997-2014, whereas the database population was limited to those cases of pertussis 
notified to a public health unit by a clinician or laboratory. The database population did 
not capture those cases of pertussis who did not present to a health care provider or 
were not notified to the public health authority by a health care provider/diagnostic 
laboratory. Notified cases of pertussis were entered into the NOCS system as being 
either valid or probable cases. This database population also included notifications that 
were later found to have not met the case definition (see below) or were duplicates 
which were removed. Following data cleaning, the study population was formed and 
became the final dataset, of which data in this project were analysed. 
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Figure 3.1:  Population hierarchy for laboratory confirmed pertussis data analysis, 
Queensland 1997-2014. 
 
 
 
Case definition 
The NNDSS case definition for pertussis was implemented by Communicable Diseases 
Network Australia (CDNA) in February 2009. Revisions in January 2013 and April 
2015,11 included components related to case management, follow-up of contacts, 
revision of the mechanism of transmission and antibiotic use. None of these revisions 
by CDNA affected the way a case was classified as probable or confirmed for these 
data analyses. 
 
The current national case definition for pertussis recommends both probable and 
confirmed cases should be notified. Guidance for reporting cases includes the 
consideration of laboratory, clinical and epidemiological evidence as outlined in Figure 
3.2 below. The case definition was used in preparation of data cleaning prior to 
analysis of the pertussis notifications.  
 
  
 
 
Study 
population 
Database population 
Pertussis notifications 
Source population 
Pertussis cases in QLD 
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Figure 3.2:  Matrix for reporting pertussis notifications using National Notifiable 
Disease Surveillance System case definition, 01 July 2013. 
 
 
Confirmed case 
-laboratory 
definitive evidence 
OR 
-laboratory 
suggestive evidence 
AND clinical 
evidence. 
Probable case 
-clinical AND epidemiological evidence 
required. 
 
Laboratory suggested evidence 
In the absence of recent vaccination  
-significant change (increase or decrease) in antibody level (IgG, IgA) to B. 
pertussis whole cell or B. pertussis specific antigen(s) OR 
-Single high IgG and/or IgA titre to Pertussis Toxin (PT) OR 
-Single high IgA titre to Whole Cell B. pertussis antigen. 
Epidemiological evidence (link established when there is) 
-Contact between two people involving a plausible mode of transmission at a time 
when: 
-one of them is likely to be infectious (from the catarrhal stage, approximately one 
week before, to three weeks after onset of cough) AND 
-the other has an illness which starts within 6 to 20 days after this contact AND 
-at least one case in the chain of epidemiologically linked cases (which may 
involve many cases) is a conﬁrmed case with either laboratory definitive or 
laboratory suggestive evidence. 
Laboratory definitive evidence 
-isolation of Bordetella pertussis OR 
-detection of B. pertussis by nucleic acid 
testing OR 
-Seroconversion in paired sera for B. pertussis 
using whole cell or specific B. pertussis 
antigen(s) in the absence of recent pertussis 
vaccination. 
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Data extraction 
De-identified data were extracted from the Queensland NOCS database by senior data 
managers of the Communicable Diseases Branch (CDB), Queensland Government 
Department of Health. These data were then made available to me electronically in the 
form of a password protected Microsoft Excel spreadsheet containing two separate 
spreadsheets; one containing demographic characteristics and the other laboratory 
confirmed cases of pertussis from 01 January 1997- 31 December 2014. Stata v.12 
(StataCorp, Texas, USA) was the statistical software package used to complete all 
analyses. 
 
The extracted data included all valid (laboratory confirmed) and probable (clinical and 
epidemiological) cases of pertussis according to the Australian National Notifiable 
Disease Surveillance System (NNDSS) case definition.11  
 
Study variables 
Table 3.1 contains the demographic characteristics and laboratory notification 
variables included in the pertussis data analysis. These variables were pre-existing data 
fields in the NOCS database specified in the ethics application. 
 
  
Chapter 3                                                                                                                   Data analysis 
92 
 
Table 3.1:  Study variables included in pertussis data extraction for proposed 
analysis. 
 
Demographic characteristics variables Laboratory notification variables 
Notification reference number*  
Person reference number 
Date of birth 
Notification date 
Date of onset of illness  
Diagnosis date 
Age at onset of illness 
Sex 
Indigenous status † 
Public health unit 
Died of condition 
Deceased date 
Validity 
Number of lab tests performed  
Notification reference number* 
Date of onset of illness 
Laboratory name 
Specimen 
Collection date 
Test ID 
Test type 
Result 
Organism 
  
* Unique identifier used for merging of the two datasets, † People who identified as being of Aboriginal 
and or Torres Strait Islander origin. 
 
Data cleaning 
Variables were examined individually for logic, whilst missing data were coded as such. 
Data cleaning, recoding, labelling and final analyses were all conducted using a do-file 
that I wrote in the statistical data analysis package Stata version 12.1 (Appendix 3.1). 
 
Cases were excluded that showed negative ages in years at onset of illness. These 
negative ages in the dataset were unable to be clarified, validated or corrected due to 
the nature of the project and the length of time since original data collection.  
 
The number of days from the onset of illness to notification date were calculated but 
were not utilised for the purposes of analysis due to substantial inconsistencies in the 
variable generated resulting in illogical numbers of days in some circumstances. For 
the vast majority of records where an onset of illness date was included, this was the 
same date as the notification date. Therefore the recorded onset of illness date was 
considered unreliable and was not included in the analysis. The variables ‘Organism’, 
‘Serogroup’, ‘Serotype’ and ‘Subtype’ contained no data and were therefore excluded.  
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The ‘notification reference number’ variable was used as the unique study identifier to 
merge the two Microsoft Excel datasets (clinical and laboratory) and then the data 
were examined for duplicate entries. Duplicate results that were identified were 
subsequently deleted by recoding in the Stata do-file. 
 
Analysis 
Statistical methods 
Age in years at the date of notification was recorded in the NOCS database as a 
continuous variable, from which age groups were created. Following data cleaning, 
remaining string variables were recoded as categorical or binary and dates formatted 
into DMY.  
 
As the data were not normally distributed, the median age rather than mean age were 
calculated for the various age strata. Age-specific notification rates were calculated for 
all age groups using Australian Bureau of Statistics’ estimated Queensland resident 
population data as the denominator.12 For children less than three years old, where 
disease severity is high, age-specific notification rates were also calculated for age 
groups; 0-<6months, 6-<12months and 1-3 year olds. Age groups for all ages were 
created in Stata then exported to a Microsoft Excel worksheet to calculate average 
annual notification rates per 100,000 total populations for each age group.  
 
Descriptive epidemiology and temporal trends of pertussis notifications in Queensland 
over time were examined. Results are presented as baseline demographic 
characteristics and summary statistics in the form of proportions, counts and average 
annual rates, by year of notification, age and sex. Graphs and figures were created in 
Stata v12.1 and Microsoft Excel. 
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Ethics approval 
Unconditional ethics approval was received for this data analysis project by the Human 
Research Ethics Committee of Queensland Department of Health approval number 
HREC/14/QRCH/367. Research Governance authorisation was also obtained from 
Queensland Health. 
 
Results 
Study population  
There were 53,944 pertussis notifications recorded as confirmed and 82,247 
laboratory test entries extracted from the NOCS database from 01 January 1997 to 31 
December 2014. There were 22 cases where dates of birth were illogical due to data 
entry error. These resulted in negative ages and were excluded. Once the two datasets 
were merged and cleaned, there were 53,901 unique notified laboratory confirmed 
pertussis cases and 46,998 laboratory testing results (Figure 3.3). There were 43 
duplicate entries found in the notification dataset which were subsequently deleted. 
There were multiple laboratory entries found for some cases and these were managed 
in the analysis by coding in the Stata do-file. Notifications were managed by ten of the 
public health units (PHU) within Queensland. Metropolitan South PHU recorded the 
most notifications over the period with 12,740 (24%) individual cases (Table 3.2). 
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Figure 3.3:  Final study population from merger and cleaning of clinical and 
laboratory datasets for pertussis notifications, Queensland, 1997-
2014.  
 
 
 
Most notifications occurred in the month of November (11 %). The range for other 
months was 7-10% with April recording the lowest percentage of notifications at 6%. 
 
Baseline characteristics of study population 
Over the 18 year observation period (1997-2014), the median age of persons notified 
with pertussis was 35.2 years, most (56%) were female and there was an over 
representation of Aboriginal and Torres Strait Islander persons (10%) – albeit with a 
very large proportion of records (69%) with missing data on Indigenous status (Table 
3.2). All of the notifications in the final dataset had an accompanying record of 
laboratory confirmation consistent with the case definition.  
 
The number of pertussis notifications rose markedly in 2009 (Figure 3.4) and remained 
elevated until 2013 when notifications began to decline. The highest number of 
notifications recorded for a single year was in 2011 with 8,984 cases and the lowest 
number of notifications occurred in 2000 with 537 cases. There were more females 
compared to males for each year of notification (Figure 3.5) and across almost all age 
groups when expressed as age-specific rates (Figure 3.6).  
Clinical dataset 
53,944 notifications 
Merged with laboratory dataset 
82,247 records 
22 excluded for date of birth errors 
(negative age years) 
43 duplicate notifications excluded 
Clinical and laboratory dataset 
53,901 unique notification records 
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Table 3.2:  Baseline characteristics of laboratory confirmed pertussis cases 
Queensland, Australia (1997-2014). 
 
* People who identified as being of Aboriginal and or Torres Strait Islander origin. 
 
Characteristics Total cases  
N= 53,901 (%) 
Age, median in years (range) 35.2 (<1-99) 
Sex 
Males 
 
23,864 (44%) 
Indigenous status * N= 16,454 
 
1,632 (10%) 
Public Health Units (PHU’s) 
 
Metro South PHU 
Metro North PHU 
Sunshine Coast PHU 
Gold Coast PHU 
Darling Downs PHU 
Townsville PHU 
Cairns PHU 
West Moreton PHU 
Rockhampton PHU 
Wide Bay PHU 
N= 53,799 
 
12,740 (24%) 
11,029 (20%) 
5,121 (10%) 
4,998 (9%) 
4,915 (9%) 
4,331 (8%) 
3185 (6%) 
3126 (6%) 
2305 (4%) 
2049 (4%) 
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Figure 3.4:  Epidemiologic curve showing individual laboratory confirmed notified cases of pertussis notified in Queensland, 1997-
2014.  
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Figure 3.5:  Pertussis notifications in Queensland by year and sex, 1997-2014 
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Figure 3.6:  Average annual pertussis notification rates per 100,000 population in Queensland by age and sex, 1997-2014 
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Infants and Children 
Amongst children less than three years of age, notifications of pertussis were most 
common amongst the youngest infants, in particular those <4 months of age (Figure 
3.7). The average annual age-specific notification rates over the period from 1997-
2014 were highest amongst infants under 6 months, 196.5 per 100,000 population 
(Table 3.3). This age-group also had the highest age-specific notification rates 
throughout the period of observation peaking in 2002, 2005 and 2010-2011 consistent 
with epidemic cycles (Figure 3.8).  
 
Table 3.3:  Baseline characteristics and rates of 2,911 children <3 years, with 
laboratory confirmed pertussis in Queensland, 1997-2014 
 
Characteristics 
 
Infants <6months Infants 6-<12 
months 
Children 1yr-
<3yrs 
N (%) 1,009 (35%) 392 (13%) 1,510 (52%) 
Notification rate per 
100,000 population* 
 
196.5 
 
74.7 
 
47.4 
Sex  
Male 
 
494 (49%) 
 
199 (51%) 
 
684 (45%) 
Indigenous Status†   163 (21%) 48 (19%) 104 (11%) 
Deaths‡ 6 (100%) 0 0 
* Average annual notification rates 1997-2014 
†  Infants who have been identified as being Aboriginal and/or Torres Strait Islander 
‡ Deaths as a direct result of pertussis infection 
 
The average annual age specific notification rates for all age-groups (Figure 3.9) show 
the same epidemic cycle evident amongst the youngest children (Figure 3.8) with 
peaks in notification rates in 2001-2002, 2005-2006, and 2009-2012. Of note, the 
period coinciding with the most recent epidemic period is on top of a much higher 
baseline (Figure 3.9). 
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Figure 3.7:  Confirmed cases of pertussis in Queensland children less than 3 years, 1997-2014 
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Figure 3.8:  Age specific notification rates of laboratory confirmed pertussis in children under 3 years per 100,000 population, 
Queensland, 1997-2014.  
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Figure 3.9:  Average annual notification rates of Pertussis in Queensland by year of notification and age group, 1997-2014 
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Laboratory  
Of 46,998 specimens obtained for confirmation of diagnosis of pertussis, most (65%) 
were blood samples, 30% were swabs of unknown origin, whilst nasopharyngeal 
aspirate (NPA) (4%) was the most common of the remainder (Table 3.4). There were 
no testing data available from 1997-2000. Of 49,145 individual results where the test 
type was known, serology (66%) and polymerase chain reaction (PCR) (33%) were the 
most common test types for confirmation of a diagnosis with only 1% culture. The 
increase in pertussis notifications from 2009 coincided with a substantial increase in 
the number of cases diagnosed by PCR (Figure 3.10). 
 
Table 3.4: Specimen types and test types of laboratory confirmed pertussis 
positive cases Queensland, Australia (1997-2014). 
 
 
 
Specimen type 
Blood sample 
Swab-undefined 
NPA 
Sputum  
Bronchial lavage 
Urine 
Faeces 
Other 
N= 46,998 
30, 5084 (65%) 
14,012 (30%) 
1,971 (4%) 
67 (0.1%) 
6 (0.1%) 
1 (0.1%) 
7 (0.1%) 
426 (0.1%) 
Confirmation of diagnosis by test type 
Serology positive 
PCR 
Culture  
Other positive test 
N= 49,145 
32,522 (66%) 
16,120 (33%) 
468 (1%) 
35 (0%) 
Chapter 3      Data analysis 
 
105 
 
Figure 3.10:  Pertussis notifications in Queensland by test type, 1997-2014 
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Test type by age groups 
There were no testing data available from 1997-2000. Test type from 2001-2007 was 
predominantly PCR for the 0-12 month and 1-4 years age groups, and predominantly 
IgA (serology) for the remaining age groups (Figure 3.11). Testing type from 2008-2014 
showed an increase in PCR in all age groups under 15 years, and an increasing trend of 
PCR use for testing in all remaining age groups (Figure 3.12). 
 
Deaths 
Whilst death due to a notifiable condition is itself not notifiable, there were six deaths 
in total directly related to pertussis infection recorded in NOCS. All deaths occurred in 
infants under six months of age and one child was identified as being of Aboriginal or 
Torres Strait Islander origin. There were 5 male infants (83%) and one female infant. 
There were two deaths in 2001, two in 2002, one in 2005 and one in 2012. 
Geographically, two deaths occurred in the South East area of Queensland in separate 
years, two deaths in Far North Queensland in different years, one death in the Darling 
Downs area and one death in the West Moreton region. 
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Figure 3.11:  Type of test for diagnosis of pertussis by age group, Queensland  
2001-2007 
 
 
NB: Other N=35 excluded 
 
Figure 3.12:  Type of test for diagnosis of pertussis by age group, Queensland  
2008-2014 
 
 
NB: Other N=35 excluded 
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Discussion 
Notifications for pertussis in Queensland rose markedly from 2009-2012. Outbreaks of 
pertussis occur regularly in Australia8 and there were increases in notification rates 
nationally during this time period.3 Australian Bureau of Statistics data for 
communicable diseases in 2010 showed pertussis was the most commonly notified 
VPD accounting for 56% of total VPD notifications.3  
 
There were more laboratory confirmed pertussis notifications in females compared to 
males in all age categories apart from the infants in the 6-12 month age group. The 
current literature reports pertussis incidence, morbidity and mortality are all higher in 
females than males,5 and this is consistent with these data apart from mortality.  
In Queensland, five out of the six deaths that were identified over this period as being 
directly as a result of pertussis infection were male infants and all of the deaths 
occurred in children under six months of age. This is an age at which infants are 
particularly vulnerable to severe outcomes from pertussis infections, especially if 
unvaccinated or have not yet received all the recommended scheduled doses of the 
vaccine.5  
 
Interpretation  
In Queensland, three major pathology providers service more than 90% of the market. 
All three providers notify electronically, resulting in efficient and timely notification of 
laboratory notifiable conditions. Notification data in this report are presented based 
on the population health case definitions in use over the period as described in the 
Queensland Health Disease Control Manual (Notifiable diseases report 2002-2006) and 
the Australian NNDSS surveillance case definition.11 Available national notification data 
for pertussis for the years 2006-2012 showed Queensland notifications were slightly 
higher to those nationally.13 This increase in Queensland notifications may be due in 
part to the type of laboratory testing used.  
 
Average annual notification rates 
The highest average annual notification rates across all age groups were in those under 
6 months of age, which was most evident during epidemic peaks and is consistent with 
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the international literature.14 Whilst age-specific notification rates increased for all age 
groups from 2009, school-aged children (those aged 5-14 years) were particularly high.  
 
I found no evidence of seasonality in pertussis notification data with only a very 
narrow range of differences in percentages by month of notification. Most 
notifications were reported in the month of November (11%), with remaining months 
recording similar percentages (range 7-10%). April recorded the lowest number of 
notifications at 6%. Others, using Queensland notification and laboratory testing data 
from 2008 and 2011, have been able to show that the notification data masks testing 
trends. The authors found by having access to all tests undertaken rather than just 
those found to be positive that both the proportion of PCR tests that were positive and 
the proportion of serology tests that were positive both provided evidence that 
pertussis is a seasonal illness in Queensland with annual peaks in the summer 
months.15  
 
Laboratory testing 
PCR use has increased as the testing type for pertussis infections over time which may 
have led to increased detection of cases.16 From 2008-2014 these data showed an 
increasing trend in PCR testing in all age groups however this was a sustained epidemic 
period and this increased trend in testing is possibly a result of actual increases in 
cases. Increases in PCR testing are however consistent with national and increasingly 
global trends for PCR usage as the type of test to detect pertussis infections, 
particularly as a dominant test type in children under 15 years old.16 
 
Vaccine type 
Acellular pertussis vaccine has been in use for almost the entire period of observation 
for this study, 1997-2014. First introduced in Queensland in July 1997, acellular 
pertussis vaccine replaced the whole cell pertussis vaccine.17 Over this time period, 
infants aged <6 months and particularly those aged <4 months have carried the 
highest burden of pertussis in Queensland - both in terms of notifications of pertussis 
and of death directly due to pertussis. For most of these young infants, pertussis 
occurs before they have had the opportunity to be protected by at least two doses of a 
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pertussis containing vaccine.1 The United Kingdom recommended routine pertussis 
vaccination in pregnancy as a direct response to their high pertussis burden in early 
infancy and have shown that the program has been highly effective in reducing 
pertussis burden during early infancy.18 In August 2014, Queensland introduced a 
funded pertussis vaccination program in pregnancy,19 which became a national 
recommendation in Australia in 20151 and has now been funded by every state and 
territory across the country.19 
 
Limitations 
Missing data 
Hospitalisation and vaccination data were not available within the dataset. 
Hospitalisation is an indicator of severity, whilst vaccination status is critical for 
assessment of vaccine failures. 
 
Data for the variable ‘Indigenous status’ were missing in 70% of cases in the 
Queensland NOCS database from 1997-2014. Available data for ‘Indigenous status' 
showed 10% of cases identified as being of Aboriginal and or Torres Strait Islander 
origin. This could be interpreted as an over representation of Aboriginal and Torres 
Strait Islander people in these data as the latest ABS figures estimates 3% of the total 
Australian population in 2013 identified as being Indigenous.20 Care should therefore 
be taken when attempting to infer meaningful results from these data. Anecdotal 
reports by unpublished researchers suggest adding ‘Indigenous status’ to all laboratory 
request forms may improve under-identification in Aboriginal and Torres Strait 
Islander peoples.  
 
In Queensland, deaths that occur directly as a result of a notifiable disease are not 
required to be formally notified and this is reflected in the data for the variable ‘Died 
of condition’. Of the 53,901 individually notified cases, 97% of data were missing or 
unknown for this variable. Of the six deaths that were recorded, all were infants less 
than 6 months of age. It is difficult to make assumptions about these findings due to 
the lack of available data, however, other literature also support these results with 
most fatalities occurring in infants under 6 months of age.5 
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The results in this case series for notifications of pertussis by age are consistent with 
that of overseas literature. In these analyses, infants under 6 months of age recorded 
the highest notification rates of 196.5 per 100,000 populations. Rates declined sharply 
once infants reached over 12 months of age. This is consistent with an observational 
study of pertussis notifications by Carlsson et al.,14 Their data collected on 1803 infants 
over a fifteen year period reported notification rates in those under 6 months of age to 
be 193 per 100,000 population with rates sharply declining once the infants were over 
12 months old.  
 
Conclusion 
Although notification data are generally not used for analytical assumptions, they are 
an important indicator of how effective a surveillance system is operating or for quality 
assurance purposes. When the data are of high quality they provide important 
opportunities to observe trends and responses to interventions such as immunisation 
programs. 
 
Whilst missing data provided some limitations for interpretability, the results in this 
case series for notifications of pertussis by age are consistent with that of overseas 
literature. As is the case globally, the increase in pertussis notifications has often 
coincided with a substantial increase in the number of cases being diagnosed by PCR 
method. 
 
 
 
 
 
 
 
 
 
Chapter 3                                                                                                                   Data analysis 
112 
 
References 
 
1. National Health and Medical Research Council, The Australian Immunisation 
Handbook, 2013, Australian Government Department of Health and Ageing: 
Canberra.10th edition. Website last accessed:16 November 2015. Available from: 
http://www.immunise.health.gov.au/internet/immunise/publishing.nsf/Content/H
andbook10-home 
2. World Health Organization. Global and regional immunization profile. Geneva, 
Switzerland. Website last accessed: 20 October 2015. Available from: 
http://www.who.int/immunization/monitoringsurveillance/data/gs_gloprofile.pdf?
ua=1 
3. Australian Bureau of Statistics. Health Communicable Diseases, May 2012. Website 
last accessed 16 October 2015. Available from: 
http://www.abs.gov.au/ausstats/abs@.nsf/Lookup/by%20Subject/1301.0~2012~M
ain%20Features~Communicable%20diseases~232 
4. World Health Organization. Programs. Immunization, Vaccines and Biologicals. 
Estimates of disease burden and cost-effectiveness. Website last accessed 16 
October 2015. Available from: 
http://www.who.int/immunization/monitoring_surveillance/burden/vpd/surveilla
nce_type/passive/big_dtp3_map_coverage.jpg?ua=1 
5. Heymann DL. Control of communicable diseases manual.19th ed. Washington DC: 
American Public Health Association, 2008. 
6. Wood N, Quinn H, McIntyre P and Elliott E. Pertussis in infants: Preventing deaths 
and hospitalisations in the very young. Journal of paediatrics and child health.2008; 
available online DOI: 10.1111/j.1440-1754.2008.01292.x 
7. National Centre for Immunisation Research and Surveillance of Vaccine 
Preventable Diseases. Vaccine Preventable Diseases in Australia, 2005 to 2007. 
Commun Dis Intell 2010;34(Suppl ):S1-S167. 
8. Wiley KE, Zuo Y, Macartney KK, McIntyre PB. Sources of pertussis infection in young 
infants: a review of key evidence informing targeting of the cocoon strategy. 
Vaccine,2013;31:618–625. 
Chapter 3                                                                                                                   Data analysis 
113 
 
9. Bertilone C, Wallace T, Selvey LA. Finding the ‘who’ in whooping cough: vaccinated 
siblings are important pertussis sources in infants 6 months of age and under. 
Commun Dis Intell 2014;38(3 ):E195-E200 
10. World Health Organization. Weekly epidemiological record. Pertussis vaccines: 
WHO position paper 28 August 2015;90:433-4360. Website last accessed 01 
September 2015. Available 
from:http://www.who.int/wer/2015/wer9035.pdf?ua=1 
11. Australian National Notifiable Disease Surveillance System surveillance case 
definitions. Website last accessed 01 September 2015. Available from: 
http://www.health.gov.au/internet/main/publishing.nsf/Content/cda-surveil-
nndss-casedefs-cd_pertus.htm  
12. Australian Bureau of Statistics. Estimated Resident Population By Single Year Of 
Age, Queensland June 2014. Australian Demographic Statistics. TABLE 53. Website 
last accessed September 2015. Available from:  
http://www.abs.gov.au/AUSSTATS/abs@nsf/DetailsPage/3101.0Mar%202014?Ope
nDocument 
13. Pillsbury A, Quinn HE and McIntyre PB. Australian vaccine preventable disease 
epidemiological review series: pertussis, 2006–2012. Commun Dis Intell 2014;38(3 
):E179-E194. 
14. Carlsson RM, von Segebaden K, Bergstrom J, Kling AM, Nilsson L. Surveillance of 
infant pertussis in Sweden 1998–2012; severity of disease in relation to the national 
vaccination programme. Euro Surveill. 2015;20(6):pii=21032. Available from: 
http://www.eurosurveillance.org/ViewArticle.aspx?ArticleId=21032 
15. Kaczmarek M, Ware RS, Nimmo GR, Robson JMB and Lambert SB. Pertussis 
Seasonality Evident in Polymerase Chain Reaction and Serological Testing Data, 
Queensland, Australia. Journal of the Pediatric Infectious Diseases Society Advance 
Access.2015; available from: 
http://jpids.oxfordjournals.org/content/early/2015/01/28/jpids.piu144.abstract 
16. Kaczmarek M, Ware RS and Lambert SB The contribution of PCR testing to influenza 
and pertussis notifications in Australia. Epidemiol. Infect.,2015:1-9 
17. National Health and Medical Research Council, The Australian Immunisation 
Handbook, 2008, Australian Government Department of Health and Ageing: 
Canberra.9th edition. 
Chapter 3                                                                                                                   Data analysis 
114 
 
18. Amirthalingam G et al., Effectiveness of maternal pertussis vaccination in England. 
The Lancet, 2014;384(9953):1521-8. 
19. Beard F. Pertussis immunisation in pregnancy: A summary of funded Australian 
state and territory programs. Commun Dis Intell short report [in press] 2015;39 
(3):E329-336. 
20. Australian Bureau of Statistics. Estimates of Aboriginal and Torres Strait Islander 
Australians, June 2011. Website last accessed 01 September 2015. Available from: 
http://www.abs.gov.au/ausstats/abs@.nsf/latestProducts/3238.0.55.001Media%2
0Release1June%202011 
 
Appendix 3.1                                                                                                             Data analysis  
115 
 
Appendix 3.1  Stata do-file for Pertussis data analysis  
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*this do file was created by Lisa McHugh 02May2015 for MAE Pertussis data 
analysis project 
*Last updated 26Oct2015 
*The do file labels, cleans and, where necessary, recodes the data with 
outputs to various log files  
capture log close 
version 12.1 
clear 
set more off 
 
* Change working directory in STATA, for me that's 
cd "C:\MAE for uni\Pertussis data analysis\Data\ 
log using PertussisALL.log, replace 
 
import excel "C:\MAE for uni\Pertussis data 
analysis\Data\Pertussis\Pertussis_1997_2014_All _Stata.xlsx", 
sheet("data_1997_2014") firstrow 
 
*import excel "C:\MAE for uni\Pertussis data 
analysis\Data\Pertussis_1997_2014_deidentified_Stata.xlsx", sheet("lab_data") 
firstrow 
*import excel "S:\QCMRI-RiOAR\FluMum Study National\MAE for uni\.xlsx", 
sheet("data_1997_2014") firstrow 
 
**DATA CLEANING** 
*NOTES: THERE ARE NO HOSPITALISATION DATA 
*Check for duplicates 
duplicates report 
 
foreach var of varlist AGE_AT_ONSET-ASSIGNED_PHU{ 
 codebook `var' 
}  
tab ASSIGNED_PHU 
 
*Changing string variables to numerical 
* GENDER 
tab GENDER, miss 
replace GENDER = "1" if GENDER == "F" 
replace GENDER ="0" if GENDER =="M" 
destring GENDER, replace 
label define GENDERlbl 0 "Male" 1"Female"  
label values GENDER GENDERlbl 
tab GENDER 
 
*INDIGENOUS STATUS 
tab indig_status, miss 
replace indig_status="1" if indig_status=="Indig" 
replace indig_status="0" if indig_status=="Not Indigenous" 
replace indig_status="." if indig_status=="Not Stated" 
destring indig_status, replace 
label define indig_statuslbl 0 "Not ATSI" 1 "Aboriginal & TSI"  
label values indig_status indig_statuslbl 
tab indig_status 
 
*VALIDITY 
tab VALIDITY, miss 
replace VALIDITY="1" if VALIDITY=="VALID" 
replace VALIDITY="0" if VALIDITY=="PROBABLE" 
destring VALIDITY, replace 
label define VALIDITYlbl 0 "Probable" 1 "Valid"  
label values VALIDITY VALIDITYlbl 
tab VALIDITY 
 
*DATES-CHANGING FROM "MDY" TO "DMY" 
foreach var of varlist Birthdate NOTIFICATION_DATE ONSETDATE DIAGNOSIS_DATE{ 
 codebook `var' 
 format `var' %td 
 codebook `var' 
} 
*DECEASED_DATE is a string variable & needs to be changed to numeric 
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codebook DECEASED_DATE  
gen DeceasedDate=. 
replace DeceasedDate=date(DECEASED_DATE,"DMY", 2015) 
format DeceasedDate %d 
label variable DeceasedDate "Deceased Date" 
tab DeceasedDate 
 
*GENERATE NOTIFICATION YEAR & MONTH 
*create year and month of notification 
gen Notifyear = year(NOTIFICATION_DATE) 
label var Notifyear "Notification year" 
drop if Notifyear==2015 
gen Notifmonth = month(NOTIFICATION_DATE) 
label var Notifmonth "Notification Month" 
label define labelmonth 1 "Jan" 2 "Feb" 3 "Mar" 4 "Apr" 5 "May" 6 "Jun" 7 
"Jul" 8 "Aug" 9 "Sep" 10 "Oct" 11 "Nov" 12 "Dec" 
label values Notifmonth labelmonth 
gen Notifyrmth = Notifyear + (Notifmonth*0.01) 
label var Notifyrmth "Year month of notification"  
tab Notifyear, miss 
tab Notifmonth, miss 
tab Notifyrmth, miss 
hist Notifyear, discrete freq 
tab indig_status Notifyear, miss 
tab indig_status Notifyear, col 
 
* AGE_AT_ONSET 
tab AGE_AT_ONSET, miss 
hist AGE_AT_ONSET,normal 
summ AGE_AT_ONSET 
*Create a variable to calculate age at time of onset of pertussis 
gen Age=(ONSETDATE-Birthdate)/365.25  
hist Age, normal 
summ Age 
br Age 
*exclude cases where negative age numbers exist 
drop if Age<0 
br Age 
*Age is not normally distributed so will need to use median instead of mean 
summ Age, detail 
*Look at median ages by notifcation year 
tabstat Age, by (Notifyear) stat (n mean min p25 p50 p75 max) 
 
*CREATE AGE GROUPS 
egen Agegps=cut(Age), at (0,1,5,10,15,20,30,40,50,60,70,80,90,100)  
label define Agegps /// 
0 "0 years" /// 
1 "1-4 years" /// 
5 "5-9 years" /// 
10 "10-14 years" /// 
15 "15-19 years" /// 
20 "20-29 years" /// 
30 "30-39 years" /// 
40 "40-49 years" /// 
50 "50-59 years" /// 
60 "60-69 years" /// 
70 "70-79 years" /// 
80 "80-89 years" /// 
90 "90-99 years" /// 
100 "100+ years" 
tab Agegps 
 
label var Agegps "Age groups" 
tab Agegps indig_status 
tab Agegps GENDER, col miss 
tab Agegps Notifyear, col miss 
hist Agegps 
bysort GENDER: tab Notifyear Agegps 
tab Notifyear Agegps, col miss  
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*Look at DISEASE BURDEN in WOMEN OF CHILD BEARING AGE (19-49 yrs?) 
gen Childbearing=Age if Age>19 & Age <50 & GENDER==1 
label var Childbearing "Childbearing" 
sum Childbearing  
gen men=GENDER if GENDER==0 & Age>19 & Age <50 
label var men "Men 19-50yrs" 
tab men, miss 
gen women=GENDER if GENDER==1 & Age>19 & Age <50 
label var women "Women childbearing age" 
tab women 
 
*Cases in 0-3 yr olds  
gen Under3yr= Age if Age>0 & Age <=3.0 
label var Under3yr "Children under 3yrs" 
summ Under3yr 
gen Agedays3yr = Age*365 if Under3yr<3 
hist Under3yr 
 
gen Agemonths3yr = Agedays3yr/30.5 
label var Agemonths3yr "Child's age in months if under 3yrs" 
format Agemonths3yr %12.1fc 
tab Agemonths3yr 
 
*Proportion of indig kids in this age group 
tab indig_status if Under3yr<3 
 
*Cases in 0-1 yr olds  
gen Under1yr= Age if Age>0 & Age <=1.0 
label var Under1yr "Children under 1yr" 
summ Under1yr 
hist Under1yr, normal 
*To calculate number of days 
gen Agedays1yr = Age*365 if Under1yr<1 
summ Under1yr 
summ Agedays1yr 
*Proportion of indig kids in this age group 
tab indig_status if Under1yr<1, miss 
tab indig_status if Under1yr<1 
 
graph box  Agedays1yr if Notifyear==1997 
*Possibly do this for each year of notification then consolidte into the one 
graph 
 
*Cases in 0-6month old infants 
gen Under6m= Age if Age>0 & Age <=0.6 
label var Under6m "Infants under 6 months" 
summ Under6m 
hist Under6m, normal 
* To calculate number of days 
gen Agedays6m = Age*365 if Under6m 
*Proportion of indig kids in this age group 
tab indig_status if Under6m<=0.6, miss 
 
*Infant Age Groups 
gen InfantAge=3 if Under3yr<3 
replace InfantAge=2 if InfantAge==3 & Agedays1yr<365.25 
replace InfantAge=1 if InfantAge==2 & Agedays1yr<182.75 
label define labelInfantAge 1 "<6mths" 2 "6mths-<1yr" 3 "1yr-3yrs" 
label values InfantAge labelInfantAge 
tab InfantAge 
tab Notifyear InfantAge, col 
tab GENDER InfantAge, col 
tab indig_status InfantAge, col 
 
*br VALIDITY Agegps Under3yr Under1yr Under6m 
tab VALIDITY Agegps, col miss 
 
*DAYS FROM ONSET OF ILLNESS TO NOTIFICATION DATE 
gen Daysill=(NOTIFICATION_DATE-ONSETDATE) 
*br Daysill NOTIFICATION_DATE ONSETDATE 
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*Some cases have illogic numbers of days (+ & -)  
summ Daysill if Daysill>=0 & Daysill <215 
tabstat Daysill, by (Agegps) stat (n mean min p25 p50 p75 max) 
drop if Daysill<0 
tabstat Daysill, by (Agegps) stat (n mean min p25 p50 p75 max) 
drop if Daysill >215 
tabstat Daysill, by (Agegps) stat (n mean min p25 p50 p75 max) 
* These results may not be meaningful  
 
*DIED OF CONDITION 
tab Died_of_condition, miss 
replace Died_of_condition = "1" if Died_of_condition == "Yes" 
replace Died_of_condition ="0" if Died_of_condition =="No" 
replace Died_of_condition =".u" if Died_of_condition =="Unknown" 
destring Died_of_condition, replace 
label define Died_of_conditionlbl 0 "No" 1"Yes"  
label values Died_of_condition Died_of_conditionlbl 
tab Died_of_condition Agegps, col miss 
tab Died_of_condition Agegps 
tab Died_of_condition InfantAge, col 
*br Died_of_condition DeceasedDate Agegps Age indig_status Notifyear 
Notifmonth Notifyrmth  
*Note: ab(xx)is abbreviate to xx 
bysort Died_of_condition: list Agegps Age indig_status Notifyear Notifmonth 
Notifyrmth if Died_of_condition==1, ab(21) 
sort NOTF_ref 
 
save Pertussis_ALL.dta, replace 
log close 
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*this do file was created by Lisa McHugh 12June2015 for MAE Pertussis LAB data 
analysis project 
*Last updated 26August2015 
*The do file labels, cleans and, where necessary, recodes the data with 
outputs to various log files  
capture log close 
version 12.1 
clear 
set more off 
* Change working directory in STATA, for me that's 
cd "C:\MAE for uni\Pertussis data analysis\Data\ 
log using PertussisLabAll.log, replace 
 
*import excel "C:\MAE for uni\Pertussis data 
analysis\Data\Pertussis_1997_2014_deidentified_Stata.xlsx", 
sheet("data_1997_2014") firstrow 
*import excel "S:\QCMRI-RiOAR\FluMum Study National\MAE for uni\.xlsx", 
sheet("data_1997_2014") firstrow 
import excel "C:\MAE for uni\Pertussis data 
analysis\Data\Pertussis\Pertussis_1997_2014_All _Stata.xlsx", 
sheet("Pertussis_lab_data") firstrow 
 
**DATA CLEANING** 
*NOTES: MMPL is a unit measurement micro moles per litre used for this 
particular lab test 
 
*Check for duplicates 
duplicates report 
*NOTF_ref is not unique here (multiple results for a single notification) 
*bysort NOTF_ref: assert [_N]==1 
 
*the following variables contain no data or are irrelevant so will be dropped 
drop SIGN NUM_VALUE UNIT ORGANISM SEROGRP SEROTYPE SUBTYPE  
 
tab RESULT 
gen tagresult=1 if RESULT=="POSITIVE" | RESULT=="REACTIVE" | RESULT=="PCR 
DETECTED" | RESULT== "BORDETELLA PERTUSSIS PCR DETECTED" 
replace tagresult=2 if RESULT=="EQUIVOCAL" | RESULT=="BORDERLINE" 
replace tagresult=3 if RESULT=="NEGATIVE" 
replace tagresult=4 if RESULT=="" 
tab RESULT tagresult, miss 
 
* sort NOTF_ref so that multiple entries of a given NOTF_ref show the positive 
result first  
sort NOTF_ref tagresult 
 
*now create tags to show the lab records that are here more than once so you 
can see 1 of 3, 2 of 3, 3 of 3 etc 
bysort NOTF_ref: gen tagn=[_n] 
bysort NOTF_ref: gen tagN=[_N] 
br if tagN>1 
*now drop missing RESULT if we have another lab record in the dataset for that 
notification 
list NOTF_ref TEST_TYPE RESULT tagresult tagn tagN if tagresult==4 & tagN>1, 
noobs 
drop if tagresult==4 & tagN>1 
 
*repeat tagging of data now those records are dropped  
drop tagn tagN 
sort NOTF_ref tagresult 
bysort NOTF_ref: gen tagn=[_n] 
bysort NOTF_ref: gen tagN=[_N] 
 
*now drop NEGATIVE RESULT if we have another lab record in the dataset for 
that notification 
drop if tagresult==3 & tagN>1 
 
*repeat tagging of data now those records are dropped  
drop tagn tagN 
sort NOTF_ref tagresult 
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bysort NOTF_ref: gen tagn=[_n] 
bysort NOTF_ref: gen tagN=[_N] 
 
*now drop BORDERLINE/EQUIV RESULT if we have another lab record in the dataset 
for that notification 
drop if tagresult==2 & tagN>1 
 
*repeat tagging of data now those records are dropped  
drop tagn tagN 
sort NOTF_ref tagresult 
bysort NOTF_ref: gen tagn=[_n] 
bysort NOTF_ref: gen tagN=[_N] 
 
bysort RESULT:tab tagn tagN 
 
*not sure whether to drop this one record or not, suggest keep until after 
merge with notification data 
*drop if RESULT=="NEGATIVE" 
 
foreach var of varlist ONSET_DATE-RESULT{ 
 codebook `var' 
}  
*DATES-CHANGING FROM "MDY" TO "DMY" 
foreach var of varlist ONSET_DATE{ 
 codebook `var' 
 format `var' %td 
 codebook `var' 
} 
*COLLECTDATE is a string variable & needs to be changed to numeric 
gen CollectionDate=. 
replace CollectionDate=date(COLLECTDATE,"DMY", 2015) 
format CollectionDate %d 
label variable CollectionDate "Collection Date" 
codebook CollectionDate 
br CollectionDate COLLECTDATE 
 
*GENERATE ONSET YEAR & MONTH 
*create year and month of onset of illness  
gen Onsetyear = year(ONSET_DATE) 
label var Onsetyear "Onset year" 
gen Onsetmonth = month(ONSET_DATE) 
label var Onsetmonth "Onset Month" 
label define labelmonth 1 "Jan" 2 "Feb" 3 "Mar" 4 "Apr" 5 "May" 6 "Jun" 7 
"Jul" 8 "Aug" 9 "Sep" 10 "Oct" 11 "Nov" 12 "Dec" 
label values Onsetmonth labelmonth 
gen Onsetyrmth = Onsetyear + (Onsetmonth*0.01) 
label var Onsetyrmth "Year month of onset"  
tab Onsetyear, miss 
codebook Onsetmonth 
codebook Onsetyrmth 
hist Onsetyear, normal 
hist Onsetyear, discrete frequency 
hist Onsetmonth, discrete frequency 
 
*GENERATE SPECIMEN COLLECTION YEAR & MONTH 
*create year and month of collection dates of specimens 
gen SpecimenCollection = year(CollectionDate) 
label var SpecimenCollection "Year of specimen collection" 
gen Specimenmonth = month(CollectionDate) 
label var Specimenmonth "Month of specimen collection " 
label define labelmonth1 1 "Jan" 2 "Feb" 3 "Mar" 4 "Apr" 5 "May" 6 "Jun" 7 
"Jul" 8 "Aug" 9 "Sep" 10 "Oct" 11 "Nov" 12 "Dec" 
label values Specimenmonth labelmonth1 
gen Specimenyrmth = SpecimenCollection + (Specimenmonth*0.01) 
label var Specimenyrmth "Year month of specimen collection"  
tab SpecimenCollection, miss 
codebook Specimenmonth 
codebook Specimenyrmth 
hist SpecimenCollection, normal 
hist SpecimenCollection, discrete frequency 
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hist Specimenmonth, discrete frequency 
 
*DAYS FROM ONSET OF ILLNESS TO SPECIMEN COLLECTION DATE 
gen DaysillSpec=(CollectionDate-ONSET_DATE) 
br DaysillSpec 
 
*TYPE OF SPECIMEN 
replace SPECIMEN = "1" if SPECIMEN == "Blood Sample" 
replace SPECIMEN ="0" if SPECIMEN =="Nasopharyngeal aspirate" | 
SPECIMEN=="Aspirate" | SPECIMEN=="Saliva" 
replace SPECIMEN="2" if SPECIMEN =="Sputum" 
replace SPECIMEN="3" if SPECIMEN =="Bronchial Washings" | SPECIMEN== "Lavage" 
| SPECIMEN=="Tissue" 
replace SPECIMEN="4" if SPECIMEN =="Swab" 
replace SPECIMEN="5" if SPECIMEN =="Urine" 
replace SPECIMEN="6" if SPECIMEN =="Faeces" 
replace SPECIMEN="7" if SPECIMEN =="Other"  
replace SPECIMEN="." if SPECIMEN =="" 
destring SPECIMEN, replace 
label define labelSPECIMEN 0 "NPA" 1"Blood sample" 2 "Sputum" 3 "Bronch 
lavage" 4 "Swab-undefined" /// 
5 "Urine" 6 "Faeces" 7 "Other" 
label values SPECIMEN labelSPECIMEN 
tab SPECIMEN, miss 
tab SPECIMEN 
*bysort SPECIMEN: tab Agegps once datasets are merged 
 
*TYPE OF TEST 
replace TEST_TYPE = "2" if TEST_TYPE == "Nucleic Acid Method" 
replace TEST_TYPE ="3" if TEST_TYPE =="Serol IgA"  
replace TEST_TYPE="4" if TEST_TYPE =="Serol IgG" | TEST_TYPE== "Serol IgM" | 
TEST_TYPE=="Serol" 
replace TEST_TYPE="1" if TEST_TYPE =="Isolation" 
replace TEST_TYPE="5" if TEST_TYPE =="Antigen"  
replace TEST_TYPE="." if TEST_TYPE =="." 
destring TEST_TYPE, replace 
label define labelTEST_TYPE 1 "Culture" 2"PCR" 3 "Serol IgA" 4 "Serol(IgA 
unspecified)"  5 "Other" 
label values TEST_TYPE labelTEST_TYPE 
tab TEST_TYPE, miss 
*bysort TEST_TYPE: tab Agegps once datasets are merged 
tab TEST_TYPE tagN, miss 
 
*now drop TEST_TYPE if test type is "Other" where there is another test result 
for that case 
list NOTF_ref TEST_TYPE RESULT tagn tagN if TEST_TYPE==5 & tagN>1, noobs 
sort NOTF_ref 
drop if TEST_TYPE ==5 & tagN>1 
*repeat tagging of data now those records are dropped  
drop tagn tagN 
sort NOTF_ref TEST_TYPE 
bysort NOTF_ref: gen tagn=[_n] 
bysort NOTF_ref: gen tagN=[_N] 
*now drop TEST_TYPE if test type is "Serology other than IgA" where there is 
another test result for that case 
br NOTF_ref TEST_TYPE RESULT tagn tagN if TEST_TYPE==4 & tagN>1 
sort NOTF_ref 
tab TEST_TYPE tagN, miss 
drop if TEST_TYPE ==4 & tagN>1 
tab TEST_TYPE tagN, miss 
drop tagresult tagN tagn 
*repeat tagging of data now those records are dropped  
sort NOTF_ref TEST_TYPE 
bysort NOTF_ref: gen tagn=[_n] 
bysort NOTF_ref: gen tagN=[_N] 
tab TEST_TYPE tagN, miss 
 
*If duplicate results for the same test then keep the first record (sorted by 
DaysillSpec)  
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list NOTF_ref ONSET_DATE COLLECTDATE DaysillSpec SPECIMEN TEST_TYPE RESULT 
tagn tagN if DaysillSpec<0 & tagN>1 | NOTF_ref=="N01415", noobs 
drop if DaysillSpec<0 & tagN>1 
 
drop tagn tagN 
*now search for exact duplicates of SPECIMEN, TEST_TYPE and RESULT 
sort NOTF_ref SPECIMEN TEST_TYPE RESULT DaysillSpec 
bysort NOTF_ref SPECIMEN TEST_TYPE RESULT: gen tagn=[_n] 
bysort NOTF_ref SPECIMEN TEST_TYPE RESULT: gen tagN=[_N] 
*br if tagN>1 
*now dropping exact duplicates of SPECIMEN, TEST_TYPE and RESULT for the same 
NOTF_ref 
drop if tagN>1 & tagn>1 
drop tagn tagN 
 
*now recheck how many records there are with more than 1 lab result in the 
database  
sort NOTF_ref DaysillSpec 
bysort NOTF_ref: gen tagn=[_n] 
bysort NOTF_ref: gen tagN=[_N] 
tab TEST_TYPE tagN, miss 
tab TEST_TYPE tagN 
 
drop tagN tagn 
*keeping tagn to use as part of the reshape wide command in the 
PertussisMaster.do file 
*ask Ross about reshaping positive results into a single line per NOTF_ref 
save PertussisLab_ALL.dta, replace 
log close 
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*this do file was created by Lisa McHugh 12June2015 for MAE Pertussis 
notifiations data analysis project 
*Last updated 24Oct2015 
*This master do file merges the Pertussis notification do file with the 
Pertussis Lab data do file. 
*It was painful to understand and work out and am glad it's over! 
 
capture log close 
version 12.1 
clear 
set more off 
* Change working directory in STATA, for me that's 
cd "C:\MAE for uni\Pertussis data analysis\Data\ 
 
*First run both do files right through to make sure there are no errors 
do Pertussis_ALL 
do PertussisLab_ALL 
clear 
log using PertussisMaster_ALL.log, replace 
*reshape PertussisLab_ALL into a single unique record per line 
use PertussisLab_ALL.dta 
*confirm more than 1 lab result in PertussisLab.dta  
sort NOTF_ref DaysillSpec 
bysort NOTF_ref: gen tagn=[_n] 
 
drop COLLECTDATE TEST_ID 
* i is the index variable to sort the data by 
reshape wide LAB_NAME SPECIMEN TEST_TYPE RESULT CollectionDate /// 
SpecimenCollection Specimenmonth Specimenyrmth DaysillSpec, i(NOTF_ref) 
j(tagn) 
 
bysort NOTF_ref: assert [_N]==1 
save PertussisLabmin.dta, replace 
use Pertussis_ALL.dta 
merge 1:1 NOTF_ref using PertussisLabmin.dta 
tab _merge 
*check merge results by notification year 
tab Notifyear _merge 
 
drop if Notifyear==2015 
 
*br ONSETDATE Notifyear 
bysort indig_status: tab Notifyear Agegps,miss 
bysort Notifyear: tab GENDER Agegps, col 
 
*GENERATING TYPES OF TESTS 
gen PCRposTest=1 if (TEST_TYPE1==2 & RESULT1=="POSITIVE") | (TEST_TYPE2==2 & 
RESULT2=="POSITIVE")| (TEST_TYPE3==2 & RESULT3=="POSITIVE") 
label values PCRposTest labelPCRposTest 
label var PCRposTest"PCR positive test" 
*br PCRposTest TEST_TYPE1 RESULT1 TEST_TYPE2 RESULT2 TEST_TYPE3 RESULT3 if 
PCRposTest==1 
tab PCRposTest Notifyear if PCRposTest==1 
 
gen CultureposTest=1 if (TEST_TYPE1==1 & RESULT1=="POSITIVE") | (TEST_TYPE2==1 
& RESULT2=="POSITIVE") | (TEST_TYPE3==1 & RESULT3=="POSITIVE") 
label values CultureposTest labelCultureposTest 
label var CultureposTest"Culture positive test" 
*br CultureposTest TEST_TYPE1 RESULT1 TEST_TYPE2 RESULT2 TEST_TYPE3 RESULT3 if 
CultureposTest==1 
tab CultureposTest Notifyear if CultureposTest==1 
 
gen IgAposTest=1 if (TEST_TYPE1==3 & RESULT1=="POSITIVE")| (TEST_TYPE2==3 & 
RESULT2=="POSITIVE") | (TEST_TYPE3==3 & RESULT3=="POSITIVE") 
label values IgAposTest labelIgAposTest 
label var IgAposTest"Serology IgA positive test" 
*br IgAposTest TEST_TYPE1 RESULT1 TEST_TYPE2 RESULT2 TEST_TYPE3 RESULT3 if 
IgAposTest==1 
tab IgAposTest Notifyear if IgAposTest==1 
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gen SerologyposTest=1 if (TEST_TYPE1==4 & RESULT1=="POSITIVE")| (TEST_TYPE2==4 
& RESULT2=="POSITIVE")| (TEST_TYPE3==4 & RESULT3=="POSITIVE") 
label values SerologyposTest labelSerologyposTest 
label var SerologyposTest"Serology unspecified positive test" 
*br SerologyposTest TEST_TYPE1 RESULT1 TEST_TYPE2 RESULT2 TEST_TYPE3 RESULT3 
if SerologyposTest==1 
tab SerologyposTest Notifyear if SerologyposTest==1 
 
gen OtherposTest=1 if (TEST_TYPE1==5 & RESULT1=="POSITIVE") | (TEST_TYPE2==5 & 
RESULT2=="POSITIVE") | (TEST_TYPE3==5 & RESULT3=="POSITIVE") 
label values OtherposTest labelOtherposTest 
label var OtherposTest"Other positive test" 
*br OtherposTest TEST_TYPE1 RESULT1 TEST_TYPE2 RESULT2 TEST_TYPE3 RESULT3 if 
OtherposTest==1 
tab OtherposTest Notifyear if OtherposTest==1 
 
tabstat PCRposTest CultureposTest IgAposTest SerologyposTest OtherposTest, by 
(Notifyear)  stat (n) 
 
*Look at type of test by age groups. 
*NB: no data before 2000 
tab Agegps TEST_TYPE1 if Notifyear>2000 
tab Agegps TEST_TYPE1 if Notifyear>2007 
tab Agegps TEST_TYPE1 if Notifyear>2000 & Notifyear<2008 
 
save PertussisMasterALL.dta, replace 
log close 
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Prologue 
Background 
Kim Bap sushi is a form of sushi also known as ‘Gimbap’ or ‘kimbap’; it will be referred 
to as Kim Bap throughout the remainder of this chapter. Kim Bap is similar to the 
Japanese variety of sushi however it originates from Korea. Kim Bap is literally 
‘seaweed rice’, the two main ingredients of the dish; it is often served with multiple 
variations of fillings and pickled radish. Unlike traditional Japanese sushi that uses rice 
vinegar to season the rice, Korean sushi uses sesame oil and salt.1 The common fillings 
used in Kim Bap sushi are fish cakes, imitation crab meat, ham, eggs, seasoned beef, 
cucumbers, carrots and spinach.1  
My role 
My placement was based at the Communicable Diseases Branch of Queensland Health. 
There were many foodborne outbreak investigations occurring in Brisbane at the 
particular time of my placement. Under the guidance of the Acting Director of the 
Metropolitan South public health unit and one of the senior epidemiologists I led a 
high profile outbreak investigation assessing causes of Salmonella Typhimurium.  I was 
involved in the response from the outset of this investigation and my tasks included 
interviewing cases, creating a line list, management of laboratory specimen results, 
data entry, data analysis, interpretation of the data and report writing.  
Lessons Learned 
This outbreak investigation was a valuable learning opportunity in many ways. It was 
my first experience working inside a public health unit and the warm welcome I 
received was encouraging and appreciated. I gained skills in transforming concepts 
learned in courseblock into practice, and quickly became aware of the reality of the 
speed of the response to a public health crisis, which was not a sequential ten step 
plan but involved implementing all steps at the same time!  
 
Observing how community concerns were responded to throughout the outbreak 
investigation and the way media attention was managed by professional and 
respectful communication within the public health unit was insightful and refreshing. 
 130 
 
During the outbreak all staff co-ordinated efforts during a particularly frantic period 
where multiple outbreaks within the public health unit were being managed. 
Public Health Implications 
This outbreak affected over 100 members of the Korean community in greater 
Brisbane and the degree of illness experienced was severe. There were twenty-two 
hospitalisations of adults and children, and a perinatal event causing a premature 
birth. These factors precipitated wide spread media interest in the outbreak coverage. 
 
Efforts to control this outbreak were successful in that prompt and effective actions 
were taken to stop further members of the community from falling ill. This included 
the implementation of an effective communication strategy developed and 
implemented by the Metropolitan South public health unit to deal with the media and 
those concerned in the wider Brisbane community. As a result of the outbreak, 
awareness of food safety measures was raised within the Korean community and food 
retailers. Food retailers were provided with advice regarding food safety matters and it 
was recommended that they ensure ongoing compliance with the Food Safety 
Standards and the Food Act 2006. 
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Abstract 
Introduction 
On Thursday 15 January 2015 the Metropolitan South Public Health Unit in South 
Brisbane received notification that multiple people had presented with signs and 
symptoms of a gastrointestinal illness to health care facilities. All patients had 
experienced symptoms consistent with gastroenteritis following consumption of Kim 
Bap sushi purchased from multiple food outlets in Brisbane. The dates of onset of 
illness initially occurred over a three-day period from 13 to 16, January 
2015.Laboratory analysis of faecal samples confirmed Salmonella Typhimurium was 
the organism with MLVA patterns consistent for all cases.   
Methods 
This outbreak investigation was a descriptive study involving epidemiological, 
laboratory and environmental investigations. Information was collected using a 
working case definition and hypothesis generating interviews. Data analysis included 
calculating medians, frequencies and proportions of implicated food exposures. All 
food samples and environmental swabs were tested using culture for Salmonellae 
species and other bacterial organisms at the QHFSS laboratory at Coopers Plains  
Results 
There were 85 confirmed cases of Salmonella Typhimurium who completed a 
questionnaire and provided faecal samples. Most were female, 51 (60%) and 34 were 
male. The median age of cases was 31 years (range <1 – 66 years).Twenty-two cases 
were hospitalised, 7 of these (32%) were children. All cases reported a history of 
diarrhoea. Laboratory analyses identified as the agent of infection.  
Conclusions 
There was enough evidence to indicate the aetiological agents responsible for illness in 
this outbreak were Salmonella Typhimurium MLVA 03-12-11-12-524 and MLVA 03-13-
11-12-524. The likely vehicle of transmission of infection for this outbreak was Kim Bap 
sushi which was distributed by one producer to multiple food retail outlets in Brisbane. 
Supply of this product ceased on Friday 16 January, 2015 and there were no further 
reported cases of illness. I was unable to determine any associations between food 
exposures and illness due to the absence of a comparison group.  
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Introduction 
Salmonella are Gram-negative bacteria ubiquitous in the environment.2 Infection in 
humans is usually brought about by consumption of contaminated food via the faecal-
oral route. Multiple potential food sources, generally of animal origin, have been 
implicated.2 Most Salmonella arise from a single species, Salmonella enterica, sub 
species enterica, from which there have been over 2,500 serotypes identified to date.2 
Over 99% of all Salmonellae infections in humans are caused by this species.2 
Salmonella Typhimurium are a serovar of the sub species enterica and are considered 
highly prevalent globally and within Australia.2 The five year mean annual case 
notification rate of Salmonellosis in Australia (2007-2011) was 46.6 per 100,000 
population per year, with the Salmonella Typhimurium serotype accounting for 
approximately 40% of notifications in Victoria and Queensland.3 Human infection with 
Salmonella Typhimurium has been linked with multiple animal hosts and in Western 
Australia in particular is linked to certain flocks of chicken and chicken meat.4  
 
The incubation period for Salmonella is 6 to 72 hours.2 Those infected typically present 
with a sudden onset of gastrointestinal symptoms such as nausea and vomiting, 
diarrhoea, fever and abdominal pain with symptoms sometimes persisting for weeks.2 
Outbreaks of Salmonellosis are common, although 60-80% of known cases are 
considered to occur sporadically.2  
 
Salmonella infections are notifiable in all jurisdictions in Australia.5Only confirmed 
cases are notifiable. Confirmation requires definitive laboratory evidence of isolation 
or detection of Salmonellae species excluding Salmonella typhi which is a separate 
notification.5 Confirmation of diagnosis in Queensland is predominantly attained 
through the testing of faecal specimens using a range of laboratory-based techniques 
such as culture or nucleic acid amplification tests (NAAT’s), for example polymerase 
chain reaction (PCR) testing. Isolates are then sent for serotyping, phage-typing or 
Multiple Locus Variable-number tandem repeat Analysis (MLVA) to further 
characterise the pathogen. Rates of Salmonella notifications have risen steadily in 
Queensland over time, particularly from December 2014 6 when over 55% of cases 
were serotyped as Salmonella Typhimurium. Salmonella Typhimurium was the serovar 
identified in the outbreak presented in this chapter. 
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Identification of an outbreak 
On Thursday 15 January 2015 the Metropolitan South Public Health Unit (MSPHU) in 
South-East Brisbane received notification of five people who had presented with 
gastrointestinal symptoms to an astute General Practitioner (GP) at Eight Mile Plains. A 
further four people had presented to the Queen Elizabeth II Hospital emergency 
department (also located in South Brisbane), with signs and symptoms of a 
gastrointestinal illness. The GP and the clinician treating the hospitalised people 
notified the public health unit. A food-borne illness outbreak was hypothesised after 
reports confirmed that all patients had experienced symptoms of abdominal cramps, 
diarrhoea and vomiting following consumption of Kim Bap sushi purchased from 
multiple food outlets in Brisbane. The dates of onset of illness initially occurred over a 
three-day period from 13 to 16, January 2015. 
 
On 15 January, 2015 an outbreak control team (OCT) meeting was initiated at MSPHU 
and outbreak investigation team members were identified. The outbreak investigation 
was led by the Acting Director of the public health unit (PHU) and the team included a 
Public Health Physician, epidemiologists, laboratory scientists, environmental health 
officers (EHO), public health nurses, an OzFoodNet epidemiologist and myself. Early in 
the outbreak, after reviewing verbal and written reports from the GP and other 
clinicians attending to the cases, we ascertained that all people with illness had eaten 
Korean sushi (Kim Bap) from a number of Asian retailers, Korean grocers and Asian 
supermarkets. Concurrently a statement from the Queensland Health Forensics and 
Scientific Services (QHFSS) laboratory confirmed the MLVA patterns from faecal 
specimens were consistent with all cases.   
 
The purpose of the outbreak investigation was to determine the source of Salmonella 
Typhimurium infection and instigate control measures to prevent further illness from 
occurring in the community. The focus was also on identifying factors contributing to 
contamination, growth or survival of the responsible pathogen. There were also 
concerns from medical practitioners attending to the cases and from scientists at the 
QHFSS regarding the virulence of this particular strain due to the severity of symptoms. 
A communication strategy was devised and initiated by the Acting Director of the 
MSPHU to deal with interest from the media and those concerned about the outbreak 
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in the wider Brisbane community. This strategy included providing daily updates to the 
media on the progress of the outbreak investigation. This chapter describes the 
ensuing outbreak and the public health response to the investigation.  
Methods 
Epidemiological investigation 
After reviewing the initial data, the outbreak investigation team developed a working 
hypothesis that the consumption of a variety of Kim Bap Korean style sushi was 
responsible for illness. This sushi was being sold by multiple Asian grocers across the 
south Brisbane metropolitan area.  
 
Case definition 
A case was defined as any person who consumed Korean style Kim Bap sushi from 13 
to 21 January 2015 and who subsequently developed diarrhoea and/or vomiting 
and/or stomach cramps within 72 hours of consuming the sushi. The case definition 
date of 13 January 2015 was chosen based on discussions with retailers who stocked 
Kim Bap sushi. These discussions revealed the product had not been delivered over the 
Christmas and New Year period and deliveries resumed 13 January 2015.  
 
Study design  
The study design for this outbreak investigation was a descriptive study. A decision was 
made by the Acting Director of the facilitating public health unit early in the outbreak 
not to conduct an analytic study due to the numerous other outbreaks that were 
occurring in the public health unit at the time.  
 
Data collection 
A line list was developed in a Microsoft Excel spreadsheet. The line list was based on 
incoming notification data from the Queensland Health Forensic Scientific Services 
(QHFSS) laboratory and clinicians. People who met the case definition were 
interviewed by trained public health staff. I was also involved with interviewing cases. 
Cases were interviewed using the Queensland Health suspected food borne illness 
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outbreak hypothesis generating questionnaire. A three-day food diary was used as a 
prompt in the hypothesis generating interview process. The study variables included in 
the dataset are shown in the box below, including a list of food items consumed by the 
cases, which were gathered from the interview process and then categorised.  
 
Outbreak identification #  
Notification date  
Diagnosis date 
Interview date 
Date of onset of illness 
Date of birth 
Age at onset of illness 
Sex 
Suburb  
Postcode 
Public health unit  
Epi linked case 
Outbreak venue 
Attendance date  
Nausea 
Vomiting 
Diarrhoea 
Abdominal cramps 
Blood in stools 
Fever 
Duration of illness (in days) 
Hospitalisation 
Days hospitalised 
Food items consumed  
 Rice 
 Egg 
 Tuna 
 Carrot 
 Pickled radish  
 Cucumber 
 lettuce 
 Ham 
 Seafood extender 
 Crab 
 Sesame seeds 
 Seaweed 
 Sesame oil 
 
Analysis 
Data were analysed using Stata version 12.1 (StataCorp, Texas, USA) to conduct 
descriptive analyses. I calculated frequencies and proportions of implicated food 
exposures and calculated medians for continuous variables. In Stata, dates were 
formatted and remaining variables were coded as either categorical or binary. Age 
groups were created. I was unable to determine any associations between food 
exposures and illness due to the absence of a comparison group. 
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Outbreak identification number 
Notification date 
Diagnosis date 
Date of onset of illness 
Date of birth 
Public health unit 
Laboratory number 
Specimen type 
Collection date of specimen 
Organism 
Serotype 
Subtype 
Laboratory investigation 
Faecal specimens were collected from cases 
requesting isolation or detection of Salmonellae 
species. All faecal samples were sent directly to 
QHFSS or indirectly to QHFSS from private 
pathology providers. Samples that were positive 
for Salmonella by culture were typed by PCR 
method and subsequently MLVA tested and 
genotyped. The QHFSS laboratory variables 
included in the analysis are shown in the adjacent 
box. 
 
Environmental investigation 
The environmental health investigation included joint inspections by MSPHU and 
Brisbane City Council (BCC) to a number of retail food outlets. This involved food 
sampling and multiple environmental swabbing of surfaces such as kitchens and 
benches by environmental health officers (EHO) from the retail food outlets. A joint 
inspection of the residential home of the Kim Bap sushi operator was conducted by 
BCC, MSPHU and Queensland Police Service (QPS) officers as it was suspected that 
sushi was being prepared in the kitchen of his private residential house. Food samples 
and environmental swabs were also obtained from these premises and student 
flatmates living at the premises were interviewed. 
 
All food samples and environmental swabs were tested using culture for Salmonellae 
species and other bacterial organisms at the QHFSS laboratory at Coopers Plains, 
Brisbane. 
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Results 
Epidemiological investigation 
There were 100 cases identified in this outbreak with onset dates from 13 to 21 
January 2015. All cases ate some type of Kim Bap sushi. 
Person 
There were 100 known people who consumed Kim Bap sushi between 13 and 16 
January 2015 and developed gastrointestinal symptoms. A total of 96 (96%) were of 
Korean ethnicity with English as a second language. Of these 100 people with known 
gastrointestinal symptoms, 85 (85%) were interviewed and 58/85 (68%) provided 
faecal specimens to QHFSS for analysis. Of the 58 faecal specimens provided and 
tested, 100% were positive for either Salmonella Typhimurium MLVA 03-12-11-12-524 
(91%) or MLVA 03-13-11-12-524 (9%). A further 27 faecal specimens provided by the 
cases had been sent to and tested by other laboratories. Confirmation from these 
laboratories that the faecal samples were positive for Salmonella Typhimurium was 
provided.  Initially it was difficult to contact people for further information due to the 
severity of their illness and language difficulties. There were a remaining 15/ 100 (15%) 
who refused to be interviewed or refused to provide a specimen or were unable to be 
recontacted. 
 
Of the 85 people who completed a questionnaire, 51 were female (60%) and 34 were 
male. The median age of cases was 31 years (range <1 – 66 years). 
The majority of cases (37%) occurred in the 30-39 year old age group (Figure 4.1).   
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Figure 4.1:  Age group of 85 patients with Salmonella Typhimurium, South Brisbane, January 
2015  
 
 
Twenty-two cases were hospitalised, seven of these (32%) were children. Two cases 
were pregnant women, one of whom delivered prematurely at 31 weeks gestation 
once gastroenteritis symptoms began and one who was 38 weeks gestation and 
birthed her infant immediately upon becoming ill. 
Time 
Six cases reported that the date of onset of their illness commenced on 13 January 
2015. There were 44 cases who reported illness commencing on the 14 January 2015 
with the last known recorded cases reporting illness commencing on the 20 January, 
(Figure 4.2). 
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Figure 4.2:  Confirmed cases of Salmonella Typhimurium by date of onset of illness, 
South Brisbane, January 2015 
 
  
The median incubation period for this outbreak was 17 hours (range 6 to 51 hours). 
The median duration of illness was difficult to determine due to ongoing illness; at the 
time of interview all but two cases were still experiencing symptoms. The duration of 
illness for these two cases was 6 and 10 days.  
Place 
All cases purchased Kim Bap sushi products from a total of 22 Korean food retailers 
throughout Brisbane in January 2015. Cooked rice and sesame oil was contained in all 
of the pre-packaged sushi. Apart from the rice and sesame oil (where 100% of cases 
consumed these food items), egg was the next most commonly consumed food item 
(45; 69%), followed by tuna (42; 65%) and a variety of vegetables (41; 63%)(Table 4.1).   
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Table 4.1:  Kim Bap sushi food items consumed by 70 cases with Salmonellosis, South 
Brisbane 2015 
 
Food item consumed  N (%)  
Rice 70/70 (100%) 
Egg 45/65   (69%) 
Tuna 42/70   (65%) 
Vegetables including carrot, pickled radish, cucumber, lettuce 41/70   (63%) 
Ham 34/70   (52%) 
Seafood extender 7/70   (10%) 
NOTE: denominators differ due to missing data 
Clinical features 
All cases (100%) reported a history of diarrhoea and 57/62 (92%) reported stomach 
cramps. The remaining symptoms reported by cases are listed in Table 4.2. Laboratory 
scientists from QHFSS indicated this strain of Salmonella Typhimurium appeared to be 
particularly virulent (personal communication: QHFSS, January 2015).     
 
Table 4.2:  Symptoms of 65 people with Salmonellosis who consumed Kim Bap sushi, 
Brisbane, 2015  
 
Symptoms N (%) 
Diarrhoea 65/65 (100%) 
Stomach cramps 57/62   (92%) 
Fever 56/64   (88%) 
Headache 52/61   (85%) 
Nausea 39/58   (67%) 
Vomiting 33/64   (52%) 
Blood in stools 1/52     (2%) 
NOTE: denominators differ due to missing data 
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Laboratory investigation 
A total of 58 cases provided faecal specimens. All returned positive results for 
Salmonella Typhimurium and were further characterised to have MLVA patterns 03-
12-11-12-524 or 03-13-11-12-524. Fifty three specimens (91%) were MLVA pattern 03-
12-11-12-524 and five (9%) were MLVA pattern 03-13-11-12-524. 
 
Leftover food samples of Kim Bap sushi collected from one retail food outlet were 
positive for Salmonella Typhimurium MLVA 03-12-11-12-524 (Figure 4.3). Pre-prepared 
Korean sushi was not found at the owner/operator’s residential premises at the time 
of the inspection. Commercial quantities of food were found however, that would 
normally be used to prepare Kim Bap sushi. These food samples obtained from the 
owner/operator’s residential premises did not contain any positive results for 
Salmonella. An unknown quantity of environmental swabs detected Bacillus cereus.  
 
Figure 4.3:  Sample of pre-packaged Kim Bap sushi implicated in the Salmonella 
Typhimurium outbreak, South Brisbane, 2015 
 
 
Source: http://www.ninemsm.com/en-au/video/watch/sushi-salmonella-scandal 
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Environmental Health Investigation 
Results from the environmental health inspections led to the suspension of the licence 
of one premise due to the identification of poor food hygiene practices. Another 
premise did not have a food licence from BCC. Another one Asian grocer surrendered 
their food licence following an interview. The environmental health investigation 
identified that ten staff members from another premise experienced symptoms of 
gastroenteritis during the outbreak. However, none of them sought medical treatment 
and they all stated that they did not wish to be interviewed or supply a faecal sample.  
 
Upon interview, student flatmates of the owner denied that any food preparation took 
place at the owner’s residence. Flatmates would not reveal where food was prepared 
nor the whereabouts of the owner. The owner/operator who manufactured the Kim 
Bap sushi was unable to be located, despite repeated attempts to contact him. 
 
The owner/operator was a Korean student living in Brisbane who held a student visa. 
He worked in a local food retail company who supplied produce to the Korean food 
retailers in Brisbane. These were the same retailers that he was supplying Kim Bap 
sushi to. A Korean community spokesperson indicated that many individuals were keen 
to find and speak with the owner/operator as they were angry and were 
contemplating legal action. It was alleged that the owner/operator had left Australia. 
The MSPHU attempted to confirm this information with the Department of 
Immigration and Border Protection but were unsuccessful. The owner/operator was 
unable to be located, therefore he was unable to be issued with notices and MSPHU 
were unable to obtain any further information to instigate a traceback of food 
suppliers. There were no further reported cases of Salmonella Typhimurium from 
consumption of Kim Bap sushi in the Brisbane city following the environmental 
investigation. 
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Discussion 
A Queensland OzFoodNet Enteric Disease Surveillance Report for the 24 January 2015 
recorded 7 outbreaks of Salmonella Typhimurium infection that required investigation 
in South East Queensland from mid-December 2014 (personal communication: Russell 
Stafford, QH 2015). According to this report, Salmonella notifications were 2.2 times 
higher than the preceding 5-year mean for this time period, with 55% of cases 
serotyped as Salmonella Typhimurium. It is thought possible that the use of PCR to 
diagnose Salmonella Typhimurium has had a role in diagnoses over time.10 Testing 
faeces using PCR commenced in private laboratories and public laboratories in the last 
five years (2009-2014). 11  
 
The time period when the outbreak occurred was considered a particularly hot 
summer with higher than average daily temperatures for a longer numbers of days 
(personal communication: John Bates QHFSS, January 2015). Records for mean 
maximum daily temperatures in Queensland from the Australian Bureau of 
Meteorology, 7showed November 2014 was the hottest month since before 1999 
when online data became available.9 December 2014 also recorded the highest mean 
maximum temperature in 3 years.9 In January 2015 when the outbreak occurred, mean 
maximum temperatures were highest for the third consecutive year in a row.9  Other 
Salmonella outbreak reports in Australia that have noted highly virulent serovar strains 
have also occurred during or following particularly hot summers.3 Recent literature 
from Adelaide also demonstrated that there are more notifications of Salmonella 
Typhimurium when higher temperatures are recorded. 10 
 
The MLVA pattern for 6 out of 7 of the outbreaks that occurred in Brisbane mentioned 
above was Salmonella Typhimurium MLVA 03-12-11-12-524 which was the same MLVA 
pattern noted in this outbreak. Scientists from the QHFSS stated this particular serovar 
was showing high virulence and as a result, this factor combined with the actual 
outbreak itself caused intense media scrutiny, requiring the Acting Director of MSPHU 
to provide regular updates regarding the progress of the investigation.  
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The same Queensland Health suspected food borne illness outbreak questionnaire was 
used by trained public health personnel for each case when conducting the interviews. 
This will contribute to minimising any potential measurement bias. This is also true for 
the validity of laboratory results for the faecal samples tested.  
 
Final results from the epidemiological investigation for this outbreak were written and 
presented in a report to the MSPHU. The report described the management and 
analyses of data obtained through interviews; the report also contained the results 
from the laboratory and environmental investigations. 
 
Kim Bap sushi is sold pre-made and pre-packaged.1 The sushi contains multiple high-
risk food items known to contribute to Salmonellosis.2 Cross contamination is a strong 
possibility and could have occurred during the preparation process. That combined 
with the fact that each sushi roll contains multiple ingredients meant that it was not 
possible to determine the primary source of the contaminated food.  
Limitations 
 
Conducting the interviews for the cases proved difficult due to the severity of their 
illness and English as a second language for the majority of Korean speaking 
participants. Interpreters were not used during the interview process due to the 
limited available financial resources and the time constraints incurred due to other 
outbreaks in the PHU at the time. It is therefore possible that some misinterpretation 
may have occurred during the interview process.  Despite these difficulties, recall error 
for the cases is unlikely due to the severity of their symptoms, the pre-packaged and 
clearly labelled sushi containers, and the minimal time frame from the onset and 
notification of illness to being interviewed by public health staff. The intense media 
coverage (Figure 4.4) may have prompted more people with symptoms of 
gastroenteritis to seek medical attention and this may have potentially identified more 
cases.  
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Figure 4.4:  Media coverage of Salmonella outbreak related to consumption of Kim Bap 
sushi, South Brisbane, 2015 
 
 
Source: http://www.ninemsm.com/en-au/video/watch/sushi-salmonella-scandal 
 
Whilst an analytical study such as a case-control study would have been the preferred 
method of study design for this outbreak, it was not practical, nor cost-effective to do 
so, given other competing health priorities. It was clear from early on in this outbreak 
that consumption of Korean sushi was generating the illness experienced by cases, 
however there were limited samples of the remaining product to conduct any further 
testing. 
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Conclusion 
On balance there was enough evidence to indicate the aetiological agents responsible 
for illness in this outbreak were Salmonella Typhimurium MLVA 03-12-11-12-524 and 
MLVA 03-13-11-12-524. The likely vehicle of transmission of infection for this outbreak 
was Kim Bap sushi which was distributed by one producer to multiple food retail 
outlets in Brisbane. Supply of this product ceased on Friday 16 January, 2015 and there 
were no further reported cases of illness. 
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Prologue 
A core component of the MAE field program is to evaluate a local surveillance system. I 
evaluated the Notifiable and Other Conditions System for hepatitis A notifications in 
Queensland. This chapter follows the structure of the framework used by Teutsch and 
Churchill (2000) and the Centers for Disease Control updated guidelines for evaluating a 
public health surveillance system (2001). As such, this chapter does not contain a traditional 
discussion section; instead I have opted to include the discussion within the results section. I 
have done so to enhance the readability of the evaluation, which included a substantive 
case series analysis of hepatitis A notifications in Queensland 1988-2014. I was invited to 
give an oral presentation of preliminary results of the data analysis component of this 
project at the Communicable Disease Control conference in Brisbane June 2015 (Appendix 
5.1). 
My role 
I completed a detailed data analysis of all hepatitis A notifications in Queensland for the 
period 1988-2014. I designed questionnaires for the purpose of conducting stakeholder 
interviews of current users of the surveillance system. I appraised the responses to gain 
insights into the way the current surveillance system was performing. I examined five 
surveillance system attributes and developed recommendations to improve the functioning 
of the system. I also played a role in the multi state hepatitis A outbreak related to frozen 
berries, March 2015. This involved conducting case control interviews and data entry into 
NetEpi. 
Lessons Learned 
This project was a huge learning opportunity regarding the many elements involved in 
conducting an evaluation of a public health surveillance system. I found it a complex process 
bringing all these components of the project together into one final report. I also learned 
that you cannot die from giving an oral presentation despite feeling like this is quite possibly 
going to happen. 
Public Health Impact 
Adequately functioning public health surveillance systems are essential in order to recognise 
outbreaks and changes in trends of infectious diseases. For the current hepatitis A 
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surveillance system to perform at its desired level, regular ongoing evaluations of the data 
and systems are necessary. As with all systems, some aspects function at a higher level than 
others and it is a matter of trying to get the balance right. Hopefully the limitations 
identified from this evaluation will be useful. The timely identification and control of 
hepatitis A infections is critical in reducing the transmission of this preventable disease and 
is a strength of the current surveillance system in Queensland. 
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Abstract 
Introduction 
Hepatitis A virus (HAV) in Australia remains a nationally notifiable disease and control is 
considered to be a high public health priority. Hospitalisations for HAV amongst Aboriginal 
and Torres Strait Islander children had been more than 100 times more common than 
amongst other children. The evidence now suggests that the gap has been closed, and 
indeed reversed in regards to hospitalisations and notifications. Queensland has played a 
pivotal role in this success.  
Methods 
This evaluation was conducted using the framework by Teutsch and Churchill (2000) and the 
Centers for Disease Control updated guidelines for evaluating public health surveillance 
systems. Short open ended Stakeholder questionnaires were employed to determine 
acceptability and timeliness of the system. A retrospective case series and genotype analysis 
was conducted to determine sensitivity, representativeness and data quality of the current 
system.  
Results 
There were 6748 single laboratory notified HAV cases extracted from the NOCS database for 
the period 1 January 1988 to 1 May 2014. OzFoodNet enhanced surveillance data for 192 
laboratory confirmed notified cases of HAV from 2006-2014 were included in the analyses.  
Age and sex data were 99% complete. The median age of cases was 25 years (range: less 
than one year to 97 years), 58% of all notifications were male. The age-sex profile was 
typical of what would be expected in a setting where endemic HAV transmission has been 
interrupted, suggesting that the notification data are representative of the HAV cases in 
Queensland for this time period. Risk factor data were largely incomplete. Data quality for 
travel history, post exposure prophylaxis vaccination, Indigenous status, mechanism of 
infection and hospitalisations were poor.  
Conclusions 
There has been a change in the landscape over time for HAV notifications in Queensland. 
Most cases are now acquired as a result of overseas travel or exposure to a returning 
overseas traveller. Improved vaccination rates in prospective overseas travellers in all areas 
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of health care provider service could reduce current case numbers even further. Regarding 
the current HAV surveillance system’s functionality; the timeliness of all aspects of the 
current system is reassuring as notifications are managed and processed within appropriate 
time frames. There needs to be a sustained improvement in completeness of data at every 
step for identification of Aboriginal and Torres Strait Islander people and for risk factor data.  
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Introduction 
Hepatitis A (HAV) is a picornavirus.1 The virus is considered an enteric pathogen, primarily 
transmitted person to person by the faecal-oral route, with infection affecting the liver.1 
Hepatitis A infections can be asymptomatic. Mild symptoms of infection with HAV such as 
fever, malaise, nausea, anorexia and abdominal pain are predominantly reported more in 
children whereas significant morbidity is reported more frequently among adults.2 Jaundice, 
dark urine and pale coloured stools may also occur with any degree of severity.1 Hepatitis A 
has a long incubation period from 15 - 50 days though most commonly 28-30 days. 
Treatment is based upon clinical findings.1 The case-fatality rate for HAV is considered to be 
low at 0.1%-0.3% although slightly higher (1.8%) in adults over the age of 50 years.1  
 
The diagnosis and control of HAV is a world-wide public health priority. In 2010 the global 
burden of disease related to deaths from acute HAV for both sexes of all ages was estimated 
to be 102,850 people and 4,351,760 disability-adjusted life years.2 In 2014, the World Health 
Organization (WHO) estimated that there were 1.4 million people infected with HAV every 
year worldwide.3 Exposure to a common source of contaminated food or water or exposure 
to sewerage are important environmental health factors related to HAV transmission in 
developing countries.1 Globally, endemicity of HAV is separated into three levels; high, 
intermediate and low, with each level being  directly related to sanitation and hygiene 
conditions.3 Australia is currently (2015) considered to be in a low endemicity period. 3 
 
In Australia, hospitalisations for hepatitis A amongst Aboriginal and Torres Strait Islander 
children had been more than 100 times more common than amongst other children, but the 
evidence now suggests that the gap has been closed, and indeed reversed in regards to 
hospitalisations and notifications.4 Queensland has played a pivotal role in this success. In 
June 1988, HAV became notifiable in Queensland in accordance with State legislation.5 In 
1999, a hepatitis A vaccine program was introduced for Aboriginal and Torres Strait Islander 
children under two years of age in North Queensland (hepatitis A vaccine was introduced 
into Australia in 1993).6 Hanna et al.7 showed the roll-out of this vaccination program 
significantly reduced HAV notification rates in the target population group. In 2005, this 
prompted an extension of the vaccination program to include Aboriginal and/or Torres 
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Strait Islander children less than two years of age in other Australian States and the 
Northern Territory. Hepatitis A virus in Australia remains a nationally notifiable disease and 
control is considered to be a high public health priority.8 
 
The public health concern around HAV in Australia is particularly directed toward those at 
greater risk of acquiring the virus.3 At-risk groups, (listed in Table 5.1) are a priority target 
group for HAV vaccination. The recommended doses and schedules for the hepatitis A 
vaccine are included in the 2013 Australian Immunisation Handbook.6 
 
Table 5.1:  Known risk groups for acquisition of hepatitis A virus, in the Australian 
context 
 
Travellers to an area where hepatitis A is highly endemic, particularly without prior 
vaccination 
Aboriginal and Torres Strait Islander peoples 
People who live in areas of poor sanitation and unsafe drinking water 
Intravenous drug users 
Men who have sex with men 
Immunocompromised peoples 
Persons who live or come into close contact with an infected person  
Child care workers, aged care workers or others who reside or work in institutional facilities 
 
Evaluation Objectives  
In this chapter I describe an evaluation of the performance of the current HAV surveillance 
system in Queensland. The objectives of this evaluation were to: 
 Describe the current epidemiology of HAV in Queensland and its public health 
importance; 
 Analyse genotype data to determine whether there was a circulating endemic HAV 
strain in Queensland;  
 Outline how the existing surveillance system supports the requirements for reporting 
and managing cases of HAV in Queensland; 
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 Assess the surveillance system attributes based on the Centers for Disease Control (CDC) 
updated guidelines for evaluating public health surveillance systems;9  
 Present recommendations to improve the current HAV surveillance system in 
Queensland if applicable. 
 
Ethics 
Ethics approval for this evaluation was granted by the Human Research Ethics Committee of 
Queensland Department of Health, approval number HREC/14/QRCH/61/AM01. Research 
governance authorisation and site specific authorisation was obtained from Queensland 
Health (QH), as well as ethics approval from the Australian National University Human 
Research Ethics Committee.  
 
Epidemiology and public health importance of hepatitis A in Queensland  
1988-2014 
From 1992-1999, there were in excess of 400 notifications of HAV per year in Queensland 
but since 2009 there have been less than 50 notifications per year (Figure 5.1). There has 
been a substantial decline in HAV notifications coinciding with the introduction of the 
vaccine program for Aboriginal and Torres Strait Islander children in North Queensland in 
1999. In 2009 there was a multi-state outbreak of HAV related to consumption of semi-dried 
tomatoes, however this had minimal impact on overall HAV notifications.   
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Figure 5.1:  Hepatitis A notifications in Queensland, 1988-2014. 
 
 
 
My analysis of the data indicated the most common age group affected from HAV in 
Queensland to date are those between five and 40 years old. Previously the most likely 
mode of HAV transmission in Queensland to children was from common source outbreaks in 
childcare facilities.7 My analysis (see Results section) found that most notified cases in 
Queensland now occur following international travel or contact with a returned traveller. 
Over time there has been a definite shift in the mode of transmission of acquiring HAV from 
that of common source outbreaks to overseas travel. 
 
Current hepatitis A surveillance system in Queensland 
The Queensland Notifiable and Other Conditions System (NOCS) operates as a passive 
surveillance system. Clinicians and laboratories are required to notify public health units 
(PHU) of probable and confirmed diagnoses of HAV under the Queensland Public Health Act 
2005.5 Once the HAV notifications are received from laboratories and clinicians, they are 
recorded in the NOCS. All HAV notifications are actively followed-up by the Public health 
Units (PHU), which all have access to NOCS. There are three major pathology providers who 
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manage more than 90% of HAV notifications in Queensland. All three providers notify HAV 
to Queensland Health electronically, resulting in efficient and timely reporting.  
 
Case definition 
The Australian National Notifiable Disease Surveillance System (NNDSS) provides the case 
definition for HAV which was implemented and updated by the Communicable Diseases 
Network Australia (CDNA) on 01 January 2013.10 The current national case definition is 
outlined in Table 5.2 below.  
 
The CDNA developed this case definition to enable a nationally standardised approach in 
Australia for the surveillance of HAV.10 The data are collected by all states and territories in 
Australia under their own jurisdictional public health legislation, and are reported to state 
and territory notifiable surveillance systems. OzFoodNet (OFN) is a national collaboration for 
enhanced surveillance and follow-up of enteric pathogens, which includes HAV. Hepatitis A 
positive cases are followed up by the jurisdictional health authorities with regular uploads of 
de-identified data from the state and territory-based databases provided directly to the 
NNDSS. Data are collected, analysed and reported back to relevant stakeholders on a 
fortnightly basis with quarterly reports documenting trends from notified cases of HAV in 
Australia. 
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Table 5.2:  National Notifiable Disease Surveillance System case definition for  
hepatitis A, 2013. 
 
Confirmed 
case 
 
Laboratory definitive evidence  
OR Laboratory suggestive AND clinical evidence 
OR Laboratory suggestive evidence AND epidemiological evidence 
 
Probable case A probable case requires clinical evidence AND epidemiological evidence 
 
Laboratory 
definitive 
evidence 
Detection of hepatitis A virus by nucleic acid testing 
 
Laboratory 
suggestive 
evidence 
Detection of hepatitis A-specific IgM, in the absence of recent vaccination 
Clinical 
evidence 
Child less than 5 years of age OR acute illness with discrete onset of at 
least two of the following signs and symptoms: fever; malaise; abdominal 
discomfort; loss of appetite; nausea 
AND 
Jaundice or dark urine or abnormal liver function tests that reflect viral 
hepatitis. 
 
Epidemiological 
evidence 
Contact between two people involving a plausible mode of transmission 
at a time when: 
a. one of them is likely to be infectious (from two weeks before the onset 
of jaundice to a week after onset of jaundice) AND 
b. the other has an illness that starts within 15 to 50 (average 28 – 30) days 
after this contact 
AND 
At least one case in the chain of epidemiologically linked cases (which may 
involve many cases) is laboratory conﬁrmed. 
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Purpose and objectives of the HAV surveillance system 
The purpose and objectives of the current HAV surveillance system in Queensland are not 
specifically stated. I have assumed that the purpose is to capture complete data on HAV 
notifications in Queensland in a useful way to then inform policy and practice. In order to 
achieve this, the NOCS system needs to be able to:  
 Monitor trends in a timely way; 
 Detect changes that may indicate any increase in disease among high-risk groups and 
or any change in risk factors for the disease; 
 Assess the success of prevention and control measures; or 
 Instigate further research on the disease.11 
 
In the absence of documented objectives of the current HAV surveillance system in 
Queensland, I set the following specific objectives for my evaluation: 
 Assess the surveillance system attributes of NOCS in relation to HAV; 
 Appraise current stakeholder engagement with the NOCS system;  
 Analyse and describe HAV notification data in order to 1) monitor trends over time 
and 2) establish whether the surveillance system had the capacity to assess whether 
endemic HAV transmission had been interrupted in Queensland;  
 Describe the limitations of the current system and provide recommendations. 
 
Methods 
This chapter follows the structure of the framework used by Teutsch and Churchill11 and the 
Centers for Disease Control updated guidelines for evaluating a public health surveillance 
system.9 As such, this chapter does not contain a traditional discussion section; instead I 
have opted to include the discussion within the results section and a summary post results. I 
have done so to enhance the readability of the evaluation.  
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System attributes 
Due to the scope of this project, the key system attributes assessed for this evaluation were: 
sensitivity and acceptability; timeliness; representativeness and data quality (Table 5.3). 
Other surveillance system attributes are also shown in Table 5.3 and were considered in the 
evaluation.  
 
In relation to sensitivity, I focused on the sensitivity of the HAV surveillance system as 
opposed to sensitivity of testing methods or sensitivity of genotyping (a test which has high 
sensitivity and specificity). Sensitivity of the HAV surveillance system is a measure of how 
well the proportion of true HAV cases in Queensland are being identified by the HAV 
surveillance system.12 
 
Reviewing characteristics of the population from multiple sources of data can assist in 
measuring trends, in revealing important findings and can be used as an indicator of the 
representativeness of the HAV surveillance system data. Notification data from the NOCS 
system and OFN dataset were analysed according to person, place and time. Completeness 
of data (data quality) was assessed as part of the detailed data analysis for the NOCS 
system, OFN database and genotype dataset (received from QHFSS laboratory). An audit 
was conducted comparing paper based case report forms with existing data fields in the 
NOCS database. Enhanced HAV surveillance data from OFN and genotype data from QHFSS 
provided further details on locally acquired cases.  
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Table 5.3:  Hepatitis A surveillance system attributes in Queensland 
 
Attribute Description of attribute and questions asked in stakeholder 
interviews 
 
Simplicity Whether the structure of the system flows easily and is operationally 
uncomplicated. Low resource requirements for case follow up and 
contract tracing. 
 
Flexibility Adaptable to any changing reporting requirements or novel methods 
of data collection and analysis such as laboratory methods and 
genotype data. 
 
Acceptability Whether stakeholders are engaged in the system. This will be 
reflected in high rates of hepatitis A being reported in a timely way as 
well as completeness of questionnaires from interviews and report 
forms.  
 
Sensitivity Are case reports being completed in order for the system to detect 
changes in disease occurrence in the community? Is the system 
designed to detect hepatitis A outbreaks? 
 
Predictive value 
positive (PVP) 
Whether the system provides confidence by precluding low false-
positive results, avoiding overestimating the level of immunisation 
coverage or using valuable resources. 
 
Representativeness Analysis of hepatitis A notifications from the NOCS system that 
specifies time, place and person data to determine whether the 
sample is representative, in particular Aboriginal and Torres Strait 
Islander identity.   
 
Timeliness Whether data are available in a timely way or are there delays in any 
steps from data notification to receiving reports? How acceptable is a 
delay in notification? 
 
Data quality Who is responsible for the quality of data? How are inconsistencies of 
data managed? Are validation checks of the data performed at any 
stage? 
 
Stability Whether there are adequate resources, such as costs associated with 
staff as well as the collection and maintenance of the operational 
system. 
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Stakeholder Engagement and Consultation 
Stakeholder interviews were conducted with current HAV surveillance system users 
identified in Table 5.4. The purpose of these interviews was to determine the level of 
engagement with the system, seeking opinions about the system attributes including 
acceptability and timeliness. A short questionnaire with a series of closed and open ended 
questions was developed for this task and responses were categorised into common 
themes. 
 
Table 5.4:  Stakeholders involved in evaluating the hepatitis A surveillance system in 
Queensland 
 
National Notifiable Diseases Surveillance System (NNDSS) 
OzFoodNet (national and Queensland epidemiologists) 
The following Queensland Health employees: 
Epidemiologists 
Immunisation providers 
Data managers (providers and users) 
Public health practitioners, physicians and nurses  
Acting director of a public health unit 
Queensland Health Forensic Scientific Services laboratory 
scientists 
Queensland Health Public Health Virology  
NOCS users 
NetEpi data users   
 
Stakeholders approached for interviews were those responsible for: (a) conducting case 
interviews, (b) data collection and entry of data, (c) data generation from NOCS for the 
purposes of producing reports, (d) interpretation and dissemination of the data. Other 
relevant stakeholders approached for interview consisted of personnel responsible for; 
managing the reference laboratory in Queensland where HAV positive samples are tested, 
genotyped and entered into an international database. OzFoodNet epidemiologists and 
Queensland Health (QH) epidemiologists were also interviewed. 
Data analysis 
I analysed retrospective HAV notification data for the period 1988 to 2014. I analysed three 
datasets: (a) the NOCS dataset on HAV notifications, and (b) the OFN enhanced surveillance 
data and c) the QHFSS genotype data. I used summary statistics (counts, proportions) to 
describe HAV epidemiology using available demographic and risk factor data. These 
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included age, sex, vaccination status, Indigenous status, mechanism of infection, history of 
travel or exposure to a returned traveller, exposure to a known case, child care or school 
attendance or living with a child who attends childcare or school (Table 5.5). Where 
relevant, I also determined the prevalence of risk factors known to be associated with 
increased HAV risk.  
 
Table 5.5:  Retrospective case series data available for analysis of hepatitis A 
notifications, Queensland 1988-2014 
 
Study population All probable and confirmed cases of hepatitis A infections from 
the Queensland NOCS System database and OzFoodNet 
enhanced surveillance data from January 1st 1988 to 10th May 
2014 
 
Risk factors Travel history, exposure to a known case, child care and/or 
school attendance, living with a child who attends child care 
and/or school, mechanism of infection, MSM, IVDU and food 
exposure, vaccination status, Indigenous status 
 
Outcome measures Hepatitis A virus notifications (i.e. PCR, serum) genotype, locally 
acquired, overseas acquired country of acquisition, Indigenous 
status, NHIG recipients, hospitalisations, deaths 
 
Covariates Sex, age, Indigenous status, vaccination status 
 
 
I merged the OFN enhanced surveillance data with the NOCS database using the v-look up 
function in Microsoft Excel. I arranged the data so that each notification was recorded in a 
single row together with OFN enhanced surveillance data where applicable. Further data 
cleaning was conducted to identify duplicate results and illogical data entries such as dates, 
ages and other outliers. This final dataset of 6748 unique notifications was then manually 
audited for accuracy of merged data. Missing data were coded as such.  
 
In addition, I analysed the available genotyping data to assess whether Queensland was in 
an elimination phase of HAV transmission – that is, if there is the absence of a common 
circulating genotype of HAV in Queensland. Genotyping of HAV notification data is now 
performed routinely through the Queensland Health Public Health Virology (QHPHV) 
laboratory in Brisbane. Genotyping data were provided by QHPHV laboratory from January 1 
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2002 to December 31 2014 in the form of a phylogenetic tree. I entered the data from the 
phylogenetic tree into Microsoft Excel in order to sort by genotype, year and country of 
acquisition. I recoded and grouped the country of acquisition data into world regions 
according to the World Health Organization (WHO) classification. The methods for 
conducting the genotyping are outlined in Table 5.6.  
 
Table 5.6:  Hepatitis A genotyping methods undertaken at Queensland Health Public 
Health Virology laboratory, Brisbane, 2002-2014 
 
 
Samples 
2002-
2006 
2006-
2013 
2014-
2015 
Samples at FSS extracted with:    
 QIAamp® Viral RNA Mini Kit (Qiagen)    
 Qiagen Universal Biorobot® system using the QiaAmp One-for-all 
Nucleic Acid kit or the Qiagen EZ1, using the EZ1 Virus mini kit v2.0 
   
RT-PCR performed using:    
 a 2-round assay using primers published by Grinde et al 1997    
 a single round of PCR with primers published by Faber et al 2009.    
PCR products screened using:    
 gel electrophoresis, with the expected size of 397bp    
 QIAxcel® and any detected were run on gel electrophoresis    
 Bands were excised from the gel and purified using the QIAquick® 
Gel Extraction kit. 
   
Sequencing:    
 set primers HAV8 and HAV9 using the Big Dye terminator kit v3.0    
 performed on an ABI 3130xl Genetic Analyser    
 set primers HAV6a, HAV6b, HAV17a and HAV17b, using the 
GenomeLab DTCS Quick Start kit 
   
 performed on the CEQ8000 genetic Analysis System using the 
standard LFR-1 program 
   
 Contigs assembled in Sequencher 5.0 and phylogenetic analysis 
conducted using the MEGA5 program 
   
Source: Judy Northill QHPHV, May 2015 
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Results 
System attributes 
Results from analyses of stakeholder interviews were incorporated within the assessment of 
the system attributes. These include results from the detailed data analysis of notification 
and OFN enhanced surveillance data.  
 
Sensitivity  
The true sensitivity of the HAV surveillance system is unknown. Stakeholders who were 
interviewed stressed that as a passive surveillance system with low numbers of HAV 
infections each year, the key aspect with regard to sensitivity was the capacity to monitor 
increases in locally acquired HAV notifications in Queensland. In the event that a locally 
acquired HAV case is identified, the standard protocol for follow-up by public health units 
includes active case ascertainment.  
 
The results from the data analyses of HAV notifications in Queensland from 1988-2014 
showed that, where there has been a risk factor recorded in the NOCS dataset, the majority 
of notifications indicate disease acquisition was associated with overseas travel or exposure 
to a returned traveller. These overseas acquired infections ensued from travel to countries 
where HAV is still endemic. However, a considerable proportion of HAV cases in the NOCS 
system have either missing data or no risk factors recorded for the source of locally acquired 
infections (Figure 5.2). Known risk factors include intravenous drug use (IVDU), men who 
have sex with men (MSM) and exposure and consumption of high risk foods such as 
shellfish. The analysis indicates the sensitivity of the surveillance system is compromised 
because poor data quality inhibits the capacity to adequately identify risk factors for locally-
acquired HAV infections and to monitor changes in trends over time.  
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Figure 5.2:  Identified risk factors recorded for hepatitis A infections, Queensland  
2001-2014 
 
 
 
Acceptability 
Whether stakeholders are engaged in the system is reflected in high rates of HAV being 
reported in a timely way, as well as completeness of questionnaires from interviews and 
report forms. OzFoodNet staff reported that the current system works very efficiently. At a 
national level, reports are received from Queensland OFN members fortnightly, quarterly 
and annually in addition to reports received at face to face meetings. Queensland system 
users report to NNDSS with case information as necessary and there is direct liaison with the 
state reference laboratory (QHFSS) when there are outbreak investigations occurring.  
 
During stakeholder discussions, concerns were raised from some users regarding the 
security and privacy of currently uploading all HAV genotype sequencing data into the 
international HAV.net database. Other concerns were raised regarding the level of 
communication between the different sections of Queensland Health who utilise the HAV 
surveillance system. There have been regular changes in virology laboratory personnel. This 
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has impacted on the communication between the virology laboratory and public health 
units and OzFoodNet. Staff will need to be updated with who the relevant virology 
laboratory personnel are in order to establish and continue the sharing of relevant 
information. Re-establishment of these relationships is required. Data quality regarding 
travel history in case report forms is another concern. The current variable for capturing 
travel history is inconsistent between case report forms (questionnaires) and required fields 
in the NOCS database. Travel information is also not being exchanged between the PHU, 
laboratory and OFN therefore important travel history is being lost. This makes the travel 
history data unreliable and inaccurate.  
 
An important finding was considerable inconsistencies between the questions on the case 
report form and data fields in the NOCS database. Based on my analysis of the HAV 
notification data it was apparent that there were large amounts of missing data in the NOCS 
database for some variables, including dates in particular. However the questions related to 
these missing data were not actually included on the case report forms so the issue is not 
that the data were missing but that the data had no systematic way of being collected. 
 
Timeliness 
Timeliness is critical in a surveillance system to minimise ongoing transmission of HAV 
illness. Figure 5.3 summarises the key phases beginning from the presentation for medical 
care by the person infected with HAV. Stakeholders reported minimal delays between these 
steps and in the case of an outbreak or other urgency, time frames for particular steps of 
the notification process can be dramatically reduced to allow a timely and well informed 
public health response. OzFoodNet stakeholders email surveillance reports to relevant users 
of the HAV system fortnightly to ensure accountability and thorough follow up of cases. The 
phases where timeliness is considered fundamental to the surveillance system’s success for 
HAV in Queensland are highlighted in Figure 5.3. 
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Figure 5.3:  Flowchart of hepatitis A surveillance system in Queensland demonstrating key phases in timeliness  
 
 
Presentation to health care facility following development of symptoms of 
hepatitis A. Treating physician orders pathology testing  
Laboratory tests conducted. Results 
referred back to treating physician  
Notification to PHU of probable and 
confirmed cases  
Data entered into NOCS database  
Data entered into 
NetEpi and NNDSS 
databases 
Weekly epi report 
generated  
Case interviews conducted. Case 
report forms completed  
Results of genotype 
sequence entered into 
Auslab and Hav.net 
international database 
  
+/- Genotyping at FSS 
Data analysis 
Case test positive (confirmed case) 
OzFoodNet Qld 
notified  
OFN produce fortnightly, 
quarterly and annual reports 
Contact tracing and 
offer of vaccine if 
appropriate or 
Immunoglobulin if 
appropriate  
HAV cases not identified 
(asymptomatic and not tested)  
or  
(symptomatic and do not seek 
medical care/are not tested) 
OzFoodNet Qld report 
confirmed cases to 
National OzFoodNet 
epidemiologist 
*Shaded boxes indicate key phases of timeliness in hepatitis A notification 
process 
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Discussions with laboratory stakeholders centred around the timeliness of genotyping data. 
The QHFSS reference laboratory in Brisbane is one of two laboratories in Australia who 
perform polymerase chain reaction (PCR) testing and genotyping for HAV. Methods are not 
standardised between the two laboratories. Victorian Infectious Diseases Reference 
Laboratory (VIDRL) are the other laboratory and this laboratory does not use the same 
sequences or target the same genes for genotyping as QHFSS, however QHFSS do the same 
sequencing as all international laboratories so that comparisons can be made between 
countries.13 Queensland Health Forensic Scientific Services enter all HAV positive results 
that have been genotyped from returned overseas travellers into the international HAV 
database where comparisons of sequences can be made. Some private laboratories and 
interstate laboratories refer samples for genotyping or PCR testing to QHFSS.  
 
Some faecal samples are referred to QHFSS for diagnostics purposes (for PCR and 
genotyping) or from public health medical officers as part of an outbreak investigation 
looking for epidemiologically linked cases. Not every sample will be genotyped, particularly 
if there are several members from the same family with clear epidemiological links. This is 
due to the cost of testing and the amount of time and resources required to perform the 
testing.  
 
Most genotyping is done in batches. Urgent requests from a public health unit for 
genotyping and PCR of single samples can be completed within 24 hours from receipt of the 
sample. Typically, the genotyping and sequencing data become available one to four weeks 
following specimen receipt at QHFSS. The batching process alone can take up to one week 
to complete but is preferred due to the costs and human resources required to complete 
testing. Results are reported to OFN and to PHU’s in an ad-hoc fashion. The data are entered 
into the NOCS and OFN databases “irregularly”.  
  
Chapter 5  Surveillance System Evaluation   
 
172 
 
Data quality and representativeness 
Data analysis 
There were 6748 single laboratory notified HAV cases extracted from the NOCS database for 
the period 1 January 1988 to 1 May 2014. OzFoodNet enhanced surveillance data for 192 
laboratory confirmed notified cases of HAV from 2006-2014 were included in the analyses. 
These notifications came from a total of 16 PHUs within Queensland. 
 
Age and sex data were 99% complete. The median age of cases was 25 years (range: less 
than one year to 97 years), 58% of all notifications were male. The age-sex profile was 
typical of what would be expected in a setting where endemic HAV transmission has been 
interrupted, suggesting that the notification data are representative of the HAV cases in 
Queensland for this time period.2 
 
In contrast to age and sex, the risk factor data were largely incomplete. Examples of 
incompleteness of data are provided below. Data quality for travel history, post exposure 
prophylaxis (PEP) vaccination, Indigenous status, mechanism of infection in the form of risk 
factor data and hospitalisations were poor.  
 
Travel 
There are currently no routinely collected data by the NOCS system for interstate travel. 
Data on overseas travel is collected but entered as free text and not easily analysable, 
particularly with cases often travelling to one or more countries where HAV endemicity is 
high. OzFoodNet collects detailed information on overseas and interstate travel, however 
the format of data entered into their database is also free text and not easily analysable. 
The available data indicated that of 608 people who provided information on travel, 286 
(47%) had travelled overseas. Of 147 cases from the OFN enhanced surveillance database 
with information on interstate travel, 14 (8%) reported interstate travel in the incubation 
period.  
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Post Exposure Prophylaxis 
In Australia, PEP for HAV includes the administration of Normal Human Immunoglobulin 
(NHIg) or hepatitis A vaccine given within two weeks of last exposure from an infectious 
case or source of infection.14,15 If NHIg is given according to these recommendations it is of 
more benefit in controlling community wide outbreaks particularly if given as soon as 
possible.16 In the NOCS database, 436 (6%) of HAV positive cases received one or more 
doses of NHIg but, due to incomplete data, the reason why NHIg was given, or not given, 
remains unclear. 
 
Mechanism of infection/risk factors for infection 
The HAV surveillance system seeks to ascertain mechanisms of infection as potential factors 
for acquiring HAV: childcare workers, person-to person and foodborne-related infections. Of 
the 6748 HAV notifications, a maximum of only 570 had any data recorded on these risk 
factors: 
 Childcare worker 45/570 (8%);  
 Person-to-person transmission 63/524 (12%); and  
 Foodborne related infections 125/501 (25%). 
 
Intravenous drug use (IVDU) 
Data collection for IVDU was poor within the HAV notification dataset. Of the 6748 
notifications to PHU across Queensland, 91% had data missing for this variable. Of the 559 
cases where the data were collected, only 1% identified as using intravenous drugs. Other 
Australian data suggest close to 25% of HAV infected persons are intravenous drugs users.17-
19 
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Men who have sex with men 
Data collection on MSM was poor for HAV notifications. Of the 6748 notifications to the 
PHU across Queensland, 92% had data missing for this variable. Data were collected in 543 
cases and of these cases, 3% of men identified as being a MSM. Other Australian data 
suggest close to 60% of male cases with HAV infections have sex with other men.17-19 
 
Indigenous status 
A process evaluation on the quality of the NOCS system data for HAV from 1991-2001 was 
conducted in 2002.20 The report expressed concern regarding the large volume of missing 
data (89%) for the Indigenous status identifier. My analyses showed that missing data 
remained a major issue with 69% of the 6748 notifications to the public health units across 
Queensland having missing data on Indigenous status for the period 1988-2014. Of the 2084 
cases where Indigenous status data were collected, 28% of people identified as being 
Aboriginal and or Torres Strait Islander (Figure 5.4). It is unclear whether there is a real over-
representation of Aboriginal and Torres Strait Islander people in these notifications due to 
the large volume of missing data for this variable. This percentage (28%) is substantial, 
particularly considering Aboriginal and Torres Strait Islander people make up 3% of the total 
Australian population and 4% of the total Queensland population.21 The establishment of 
the funded vaccine program in North Queensland for Indigenous children is likely to have 
contributed to a reduction in cases of HAV in the Aboriginal and Torres Strait Islander 
population, particularly in North Queensland.7 Data quality has improved slightly for the 
variable Indigenous status since 2002 which is reflected in Figure 5.4 below.   
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Figure 5.4:  Aboriginal and/or Torres Strait Islander status of confirmed hepatitis A, Qld 
1988-2014 
 
* Absolute values of missing data are shown in this figure 
 
Morbidity and mortality 
Prior to 2001, there were no recorded hospitalisations in NOCS associated with HAV 
infection. Morbidity and burden of disease for hospitalisations as a direct result of HAV 
infection was therefore not quantifiable for that period. From 2001 onwards, most data are 
missing for the variable ‘hospitalisations’ and ‘deceased date’. For the available data, total 
hospitalisations recorded were 158/450 (35%) and there were a total of 15 deaths recorded. 
Mortality in Australia from HAV is low.22 In Queensland, deaths that occur directly as a result 
of a notifiable disease such as HAV are not required to be formally notified. As a result, the 
combination of these two factors is reflected in the large volume of missing data in NOCS for 
the variable ‘died of condition’.  
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Genotype data 
There are seven unique genotypes of HAV ranging from I to VII. Types IV, V and VI are 
believed to be isolated from simian species in captivity only and not in humans.13 There 
were data for 152 genotype samples analysed from laboratory confirmed HAV cases in 
Queensland. Analysis of the phylogenetic tree data showed there were two (out of the 
possible seven) unique genotype strains identified. These strains were I (A and B) and III (A). 
The most prominent genotype strain of HAV in Queensland since 2002 was IA (62%), 
followed by IB (26%) and 3A (12%) as shown in Figure 5.5.  
 
Figure 5.5:  Hepatitis A genotypes by year of notification in Queensland, 2002-2014 
 
 
 
Genotype data are analysed in the QHPHV laboratory. When stakeholder interviews were 
conducted, personnel indicated travel history data were often incomplete, missing or 
recorded as ‘unknown’. Where this was the case, the place of acquisition was auto-recorded 
as ‘Queensland’ regardless of accuracy. One limitation of the data is that they are not linked 
with the NOCS dataset so it is not possible to determine an accurate country of origin for 
each genotype result. Unique laboratory identification numbers are different to the unique 
identification number allocated through the NOCS system and a data linkage process would 
need to be undertaken for this type of analyses.   
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An analysis of country of acquisition of infection from these genotype data (Figure 5.6) 
demonstrated a combination of local and imported cases. However due to the inaccuracy of 
travel history data and allocation of ‘Queensland’ as the chosen source of acquisition in the 
absence of available travel history, the usefulness of these data must be questioned. 
 
Figure 5.6:  Hepatitis A genotypes by location of origin of infection, Queensland, 2002-
2014 
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Summary 
Adequately functioning public health surveillance systems are essential in order to recognise 
outbreaks and changes in trends of infectious diseases. The history of closing the gap with 
respect to the burden of hepatitis A amongst Aboriginal and Torres Strait Islander peoples in 
Australia is a good news story in which Queensland has played a pivotal role. As this disease 
burden appears to be declining, there are challenges for the current hepatitis A surveillance 
system in Queensland. Some key areas where there is scope for improvement include:  
 Streamlining the NOCS database to accurately reflect the questions being asked in 
the case report forms. 
 Quality assurance checks in the current NOCS database for completeness of data; 
particularly Aboriginal and Torres Strait Islander status, risk factor data and 
mechanism of infection. This includes following up and updating travel history data. 
 Inclusion of Aboriginal and Torres Strait Islander status on all laboratory and 
reporting request forms. There is not the capacity to collect these data on current 
forms therefore under-identification will continue to remain an issue.  
 
To perform at its desired level, the limitations observed as a result of this evaluation 
would need to be addressed. 
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Recommendations 
In order to improve the usefulness of the Queensland NOCS surveillance system for HAV 
notifications, the following actions are recommended: 
High priority 
1. Standardise the Queensland case report form for HAV to match the data fields in the 
NOCS database for consistency and accuracy of data. Ensure all options are available 
for responses so there is no room for personal interpretation and to minimise 
missing data. 
2. Create a continuous quality improvement feedback system to minimize missing data 
from case report forms and data fields in the NOCS system. Generating weekly lists 
for follow up of missing data for those responsible for data at all levels. 
Medium priority 
3. Improve the communication between PHU’s, OFN and QHPHV unit regarding 
updating details of travel history data in the current system. 
4. Advocate for the addition of Aboriginal and Torres Strait Islander status on all official 
documents related to notification data such as laboratory request forms.  
Lower priority 
5. Link the NOCS dataset with the genotype dataset to better distinguish between 
locally acquired and imported cases of HAV. There is potential for this to complete 
the surveillance loop if the results for the genotype data were to be systematically 
entered into the NOCS database. 
6. Develop and implement an education strategy for staff interviewing cases regarding 
risk factor data. Asking and recording the questions surrounding Indigenous status, 
IVDU and MSM status is imperative for improving data quality, particularly where 
the source of infection is unknown. 
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Conclusion 
There has been a change in the landscape over time for HAV notifications in Queensland. 
What were predominantly foodborne related infections and much higher numbers of 
Aboriginal and Torres Strait Islander people now have been replaced by a reduction in local 
endemicity where most cases are acquired as a result of overseas travel or exposure to a 
returning overseas traveller. The establishment of the funded vaccine program in North 
Queensland contributed to a reduction in cases of HAV in Aboriginal and Torres Strait 
Islander people. It is unclear what vaccine uptake is like in the private sector which was 
outside the scope of this evaluation, however improved vaccination rates in prospective 
overseas travellers in all areas of health care provider service could reduce current case 
numbers even further. 
 
Regarding the current HAV surveillance system’s functionality; the timeliness of all aspects 
of the current system is reassuring as notifications are managed and processed within 
appropriate time frames. There needs to be a sustained improvement in completeness of 
data at every step for identification of Aboriginal and Torres Strait Islander people and for 
risk factor data. Whether data from the current NOCS surveillance system is representative 
of cases occurring in Queensland is unreliable due to the large volumes of these missing 
data.  
 
Finally, this evaluation of retrospective case series data from the Queensland NOCS 
surveillance system may be of interest to clinicians, researchers and vaccine providers 
locally and interstate who may be further encouraged to continue to offer a targeted 
prevention strategy of vaccination in at risk populations. 
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cdi34suppl.htm~cda-cdi34suppl-3-vpd.htm~cda-cdi34suppl-3-vpd3.htm 
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6. Teaching: Lesson from the Field and Teaching 
session for the 2015 MAE cohort as part of the 
Outbreak Investigation course 
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Prologue 
A core competency of the MAE program is to conduct a teaching session on an aspect 
of epidemiology to the MAE cohort of the following year. This was completed during 
our third courseblock in March 2015. Collectively our MAE 2014 cohort assisted in the 
running of the “Outbreak Investigation” session which involved my half of the group 
acting as ‘roving helpers’ or tutors during the EpiInfo data analysis section. 
The other component of our teaching session competency centred on our cohort 
dividing into three groups of three in order to establish themes and structure for a 
more tailored teaching session to the MAE 2015 cohort. My group decided on bias, 
with a focus on Aboriginal and Torres Strait Islander health data as we all had existing 
knowledge regarding the limitations in this area.   
 
I didn’t realise how much planning and effort goes into a one-hour teaching session! 
Mahomed Patel provided us with valuable, constructive feedback for this teaching 
session and I would personally like to acknowledge and thank him for his enthusiasm 
and time in helping us with its refinement.  This was a really fun and worthy 
opportunity to engage with the next cohort of MAE scholars.  
 
During the data analysis component of my epidemiological project (FluMum birth 
outcomes), it became clear that there was an opportunity to use the results as part of 
my ‘Lesson from the Field’. 
There were numerous analyses showing highly statistically significant results however 
from clinical experience, I knew these were not clinically relevant and would not mean 
a change in public health practice.  
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Lesson from the Field 
Statistical significance versus clinical importance: The role of ‘absolute risk’ 
and ‘risk difference’ 
 
Learning Objectives 
a)  Describe ‘risk difference’ and the role it plays in the context of interpreting 
outcome results from a data analysis.  
b)  Calculate and interpret risk differences from Stata outputs using actual data 
analyses from a cohort study. 
c)  Discuss the relationship between statistical significance and clinical importance 
and how these can influence public health practice. 
 
Background 
Statistical significance and clinical significance are terms often used interchangeably 
but incorrectly.1 Statistical significance is intended to determine whether the 
probability of results calculated from a study are due to chance or are in fact ‘real’ and 
may be replicated if the same study were to be repeated.3 Clinical significance 
however, is determining whether results derived from a study are relevant enough to 
warrant a change in clinical practice or public health policy.3 Clinical significance or 
clinically meaningful results are not necessarily linked with statistically significant 
results. Of course they might be, but it is more important to review a combination of 
results from an analysis to appreciate the whole picture before making inferences. 
Significant p-values or 95% confidence intervals that do not cross one, on their own do 
not automatically mean that the result is clinically important or of great public health 
value.1 On the other hand, statistically insignificant results from data analyses do not 
necessarily mean the results are not clinically important or of great public health value 
either.1 
 
That is when examining absolute risk and risk differences may be more meaningful 
when used alongside the more traditional significance tests as well as looking at the 
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results in context. It is important to remember that a relative risk is a measure of the 
strength of the association between a factor and a disease or outcome, however the 
risk difference provides a measure of the public health impact of the risk factor,1 and 
traditionally focuses on the number of cases that could potentially be prevented by 
eliminating the risk factor.1 
 
Scenario 
The following scenario was provided to the 2014 MAE cohort. 
 
FluMum is a national study that has the largest cohort of mother-infant pairs in 
Australia to date. Researchers investigated whether there were any differences in birth 
outcomes between women who received an influenza vaccine during their pregnancy 
compared to women who did not receive an influenza vaccine during their pregnancy 
within this cohort of 7125 mother-infant pairs from 2012 to 2014 inclusive. The 
primary exposure of interest was self-reported receipt of an influenza vaccine in 
pregnancy, and the primary outcomes of interest were infant birthweight in grams and 
gestation in weeks at birth of the infant. 
 
Data analyses were performed using Stata v12 (StataCorp, Texas, USA). Data for both 
outcome variables were normally distributed hence two- sample t-tests were used for 
continuous variables and chi squares for categorical variables. Relative risks (RR) were 
calculated to determine any associations between the primary exposure of interest 
and each primary outcome. Levels of statistical significance were set apriori at p values 
of < 0.05 and 95% confidence intervals (CI’s) that did not cross 1. 
 
The baseline characteristics of study participants by receipt of vaccination during in 
pregnancy are presented in Table 6.1.  
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Table 6.1:  FluMum study participants, by self-reported maternal influenza vaccination in 
pregnancy status, Australia (2012-2014) 
 
Variable influenza vaccine in pregnancy  
(95% CI) 
P value 
 Yes 
 n= 2394 
No 
 n= 4732  
 
Maternal age (mean, in years)    32.1 
(31.9-32.3) 
31.5 
(31.3-31.6) 
0.000* 
Mother Aboriginal and/or Torres Strait 
Islander  
75 / 2393 
(3%) 
128 / 4725 
(2%) 
0.31 
Weeks pregnant 1
st
 Antenatal care 8.2 weeks 
(8.0-8.5) 
8.8 weeks 
(8.6-9.0) 
0.0005*  
Smoking in pregnancy 141 / 2392  
(6%) 
383 / 4726 
(8%) 
0.0009* 
Diabetes in pregnancy 229/ 2391 
(10%) 
364 / 4724 
(8%) 
 0.0061* 
Any co-morbidity/flu risk factor 558 / 2393 
(23%) 
969/ 4726  
(21%) 
 0.0063* 
Source: FluMum study data 01 April 2012-31 Dec 2014. CDC conference abstract, 2015  
 
A discussion was held amongst the investigators and a decision was made to go no 
further with any multivariate or regression analyses related to these univariable 
results. Results from the univariate analyses showed there was no indication to do so. 
 
The results of analyses of the primary outcomes were as follows: 
a) Babies born to mothers who had an influenza vaccine during pregnancy had a 
mean birth weight of 3325 grams, compared to babies of mothers who did NOT 
receive an influenza vaccine during pregnancy whose mean birth weights were 
3336 grams. This difference of 11 grams was not statistically significant or 
clinically important. 
b) Mothers who had an influenza vaccine during pregnancy and mothers who did 
NOT have an influenza vaccine during pregnancy both had a mean gestation at 
delivery of 38.7 weeks. Clearly this was not statistically different or clinically 
important either. 
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There were however, some statistically significant results when examining for potential 
confounding variables such as maternal co-morbidities and risk factors for influenza. 
Students were then asked to view the .ppt doc FluMum Stata output examples.  
  
Interpreting Stata outputs  
Students were sent Stata outputs resulting from actual data analysis from the FluMum 
cohort study and asked to describe the results. All six results were statistically 
significant in terms of pre-determined levels set at a p value of < 0.05, and 95% CI’s 
that did not cross 1. Some results were highly significant. Students were then asked to 
identify the risk difference in the Stata output, or alternatively calculate the risk 
difference using the calculation in Figure 6.1, and describe whether they thought the 
results were clinically meaningful, what the public health importance might be if any, 
and why.  
 
 
Figure 6.1: Calculation for risk difference 
 
 
 
  
Risk Difference (RD) = (Ie) - (Iu) 
where (Ie) = incidence among the exposed subjects,  
and (Iu) is the incidence among unexposed subjects. 
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The risk differences were calculated for the following six Stata examples: 
1. Mean maternal age in years at delivery of infant, by influenza vaccine 
given during pregnancy  
 
 
 
 
 
  
***FLUMUM UNIVARIABLE ANALYSIS FOR LFF 
 
. ttest Maternal age at delivery, by (Flu vaccine given in pregnancy ) 
 
Two-sample t test with equal variances 
------------------------------------------------------------------------------ 
   Group |     Obs        Mean    Std. Err.   Std. Dev.   [95% Conf. Interval] 
---------+-------------------------------------------------------------------- 
   (0)No |    4715    31.45961    .0788282    5.412808    31.30507    31.61415 
  (1)Yes |    2389    32.12061     .103395    5.053677    31.91785    32.32336 
---------+-------------------------------------------------------------------- 
combined |    7104     31.6819    .0629244    5.303601    31.55855    31.80525 
---------+-------------------------------------------------------------------- 
    diff |           -.6609931    .1329688               -.9216516   -.4003346 
------------------------------------------------------------------------------ 
    diff = mean((0)No) - mean((1)Yes)                             t =  -4.9710 
Ho: diff = 0                                     degrees of freedom =     7102 
 
    Ha: diff < 0                 Ha: diff != 0                 Ha: diff > 0 
 Pr(T < t) = 0.0000         Pr(|T| > |t|) = 0.0000          Pr(T > t) = 1.0000 
 
Risk difference = -0.66.What does this mean? 
 
ANSWERS: If we look at the p value and the 95% CI it certainly suggests there’s a 
statistically significant difference but the real difference is only ~6months of age which 
isn’t clinically important for this example. Large sample sizes are more likely to show a 
statistical significance between two groups particularly when numbers in the unexposed 
group are much less.2  
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2. Mean gestation in weeks at first presentation for antenatal care, by 
influenza vaccine given during pregnancy  
 
 
 
 
 
  
. ttest weeks pregnant at first presentation for antenatal care, by (FluvaxPreg) 
 
Two-sample t test with equal variances 
------------------------------------------------------------------------------ 
   Group |     Obs        Mean    Std. Err.   Std. Dev.   [95% Conf. Interval] 
---------+-------------------------------------------------------------------- 
   (0)No |    4727     8.80897    .0953766    6.557447    8.621987    8.995952 
  (1)Yes |    2394    8.248538    .1240679    6.070457    8.005246     8.49183 
---------+-------------------------------------------------------------------- 
combined |    7121    8.620559    .0758765    6.402913    8.471818    8.769299 
---------+-------------------------------------------------------------------- 
    diff |            .5604317    .1604915                .2458206    .8750428 
------------------------------------------------------------------------------ 
    diff = mean((0)No) - mean((1)Yes)                             t =   3.4920 
Ho: diff = 0                                     degrees of freedom =     7119 
 
    Ha: diff < 0                 Ha: diff != 0                 Ha: diff > 0 
 Pr(T < t) = 0.9998         Pr(|T| > |t|) = 0.0005          Pr(T > t) = 0.0002 
Risk difference = 0.56.What does this mean? 
 
ANSWERS: As with the 1st example, the p value and the 95% CI suggest there’s a 
statistically significant difference but the real difference is only part thereof a week, 
which again isn’t clinically meaningful for this example. Again, large sample sizes are 
more likely to show a statistical significance between two groups in this example, due to 
the exposed group being much smaller than the unexposed. 
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3. Diabetes in pregnancy, by influenza vaccine given during pregnancy  
 
 
 
 
 
  
Diabetes in pregnancy 
                 | Maternal flu vaccine   | 
                 | during pregnancy       | 
                 |   Exposed   Unexposed  |      Total 
-----------------+------------------------+------------ 
           Cases |       231         366  |        597 
        Noncases |      2162        4355  |       6517 
-----------------+------------------------+------------ 
           Total |      2393        4721  |       7114 
                 |                        | 
            Risk |  .0965316    .0775259  |    .083919 
                 |                        | 
                 |      Point estimate    |    [95% Conf. Interval] 
                 |------------------------+------------------------ 
 Risk difference |         .0190056       |    .0049274    .0330838  
      Risk ratio |         1.245152       |    1.064041    1.457088  
 Attr. frac. ex. |         .1968849       |    .0601869    .3136998  
 Attr. frac. pop |         .0761816       | 
                 +------------------------------------------------- 
                               chi2(1) =     7.46  Pr>chi2 = 0.0063 
Risk difference = 0.02. What does this mean? 
ANSWERS: 2% could be clinically important in such a large sample size. Is there potential 
bias though because women who are at risk (diabetics) will be targeted for flu vaccine in 
pregnancy anyway? This example could possibly be looked at more closely in a 
multivariable analysis or model. 
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4. Smoking in pregnancy, by influenza vaccine given during pregnancy 
 
 
 
 
 
  
Smoking in pregnancy 
                 | Maternal flu vaccine   | 
                 | during pregnancy       | 
                 |   Exposed   Unexposed  |      Total 
-----------------+------------------------+------------ 
           Cases |       142         383  |        525 
        Noncases |      2251        4338  |       6589 
-----------------+------------------------+------------ 
           Total |      2393        4721  |       7114 
                 |                        | 
            Risk |  .0593397    .0811269  |   .0737981 
                 |                        | 
                 |      Point estimate    |    [95% Conf. Interval] 
                 |------------------------+------------------------ 
 Risk difference |        -.0217871       |   -.0340453    -.009529  
      Risk ratio |         .7314436       |    .6071883    .8811267  
 Prev. frac. ex. |         .2685564       |    .1188733    .3928117  
 Prev. frac. pop |         .0903367       | 
                 +------------------------------------------------- 
                               chi2(1) =    11.03  Pr>chi2 = 0.0009 
Risk difference = - 0.02. What does this mean? Is there a reasonable explanation for this? 
ANSWERS: As above, -2% could indicate clinical importance in such a large sample size. Is 
there potential bias though because women who smoke are more at risk of respiratory 
illnesses and will be targeted for flu vaccine in pregnancy anyway? Or could there be a 
sample of participants who don’t consent to be in the study due to their smoking status 
so will be under represented? Could women who are non-smokers be over-represented 
due to healthy volunteer bias? Does it really matter? No, but it’s good to think about all 
possible reasons for your results, particularly potential selection bias! 
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5. Babies born prematurely, by influenza vaccine given during pregnancy 
 
 
 
 
 
  
Babies born prematurely (under 37 weeks gestation) 
           | Maternal flu vaccine   | 
                 | during pregnancy       | 
                 |   Exposed   Unexposed  |      Total 
-----------------+------------------------+------------ 
           Cases |       436         751  |       1187 
        Noncases |      1955        3961  |       5916 
-----------------+------------------------+------------ 
           Total |      2391        4712  |       7103 
                 |                        | 
            Risk |  .1823505    .1593803  |   .1671125 
                 |                        | 
                 |      Point estimate    |    [95% Conf. Interval] 
                 |------------------------+------------------------ 
 Risk difference |         .0229702       |    .0042947    .0416456  
      Risk ratio |         1.144122       |    1.027759    1.273659  
 Attr. frac. ex. |         .1259672       |    .0270095    .2148604  
 Attr. frac. pop |         .0462693       | 
                 +------------------------------------------------- 
                               chi2(1) =     6.01  Pr>chi2 = 0.0142 
Risk difference =  0.02. What does this mean? What might be a public health message 
here?  
ANSWERS: Some might report this as 18% of women who had a flu vaccine in pregnancy 
had a premature baby. Timely to remember it is always important to report what the 
comparison is to the unexposed group (16%), which is very similar to the exposed. Some 
vocal campaigners have employed scare tactics using similar results in their reports 
(without showing the comparator). 
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6. Mean gestation in weeks at delivery, by mothers who had an influenza 
vaccine during the first trimester of pregnancy 
 
 
 
 
 
*Look at primary birth outcomes (gestation & birthweights)between those mums who /// 
> *had a flu vax in 1st trimester(Yes) compared to those mums who didn't have a flu 
vaccine in pregnancy(No) 
. ttest Gestation in weeks at delivery if GestTrimFluvax==1 | FluvaxPreg==0, by 
(FluvaxPreg) 
Two-sample t test with equal variances 
------------------------------------------------------------------------------ 
   Group |     Obs        Mean    Std. Err.   Std. Dev.   [95% Conf. Interval] 
---------+-------------------------------------------------------------------- 
   (0)No |    4720    38.70169    .0344223    2.364891    38.63421    38.76918 
  (1)Yes |     142    38.29577    .1895767    2.259068    37.92099    38.67055 
---------+-------------------------------------------------------------------- 
combined |    4862    38.68984    .0338835    2.362633    38.62341    38.75627 
---------+-------------------------------------------------------------------- 
    diff |            .4059203    .2011646                .0115468    .8002938 
------------------------------------------------------------------------------ 
    diff = mean((0)No) - mean((1)Yes)                             t =   2.0179 
Ho: diff = 0                                     degrees of freedom =     4860 
 
    Ha: diff < 0                 Ha: diff != 0                 Ha: diff > 0 
 Pr(T < t) = 0.9782         Pr(|T| > |t|) = 0.0437          Pr(T > t) = 0.0218 
Risk difference = 0.40. What does this mean? What might be a public health message 
here?  
ANSWERS: This result is not clinically meaningful regarding mean gestation in weeks at 
delivery of infants of pregnant women who received an influenza vaccine during their 
first trimester in pregnancy. It is safe for pregnant women to receive an influenza 
vaccine during the first trimester of their pregnancy with regards to prematurity.  
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Discussion Questions 
The final part of the LFF was centred on discussion around our real life experiences 
related to publishing research.   
 
1. When it comes to trying to publish your research, how do you manage 
statistically insignificant results that are clinically important, having been told 
journals rarely publish ‘negative’ findings? 
Responses: Once having selected the most appropriate journal for the paper, 
submit anyway including a great summary of descriptive epidemiological 
statistics with risk differences and the importance of the potential public health 
benefits.  
2.  How do you react to senior researchers who say your results won’t get 
published unless you do multivariate analysis/modelling even though advice 
from your senior, experienced supervisors and a local biostatistician is that 
there is no indication to go ahead with any further analysis? 
Responses: a) In an ideal world you could change the study design to include a 
nested nested study and do a randomised controlled trial or case control study 
of that nested dataset 
b) do the multivariate/ modelling  anyway to appease the masses 
c) don’t do the multivariate/modelling and follow your supervisors’ advice 
d) scratch your head and look confused 
 
References used  
1. Sedgwick P. Clinical significance versus statistical significance, Endgames BMJ 
2014;348:g2130 doi: 10.1136/bmj.g2130 
2. Kirkwood B and Sterne J. Essential Medical Statistics 2nd Edition. Blackwell 
Publishing: Melbourne. 2008.pp150-155 
3. Statistical significance and clinical importance website accessed September 
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MAE Teaching Exercise 
Bias in interpreting Aboriginal and Torres Strait Islander health data  
 
Learning objectives: 
a) Describe and interpret graphs commonly used in health data reports 
b) Explain what bias is and the two major types of bias 
c) Identify biases in Aboriginal and Torres Strait Islander health data 
 
Appendix 6.1 includes slides used in this teaching session. 
 
Exercise 1: The session started with a PowerPoint presentation showing graphs of the 
latest ‘Close the Gap’ national statistics on Aboriginal and Torres Strait islander health.   
We reminded the group there are three key elements we should consider when 
interpreting epidemiological data; chance, bias and confounding. We advised we would 
be focussing on bias for this teaching session.  
 
We led the group through a refresher session on the two main types and potential 
sources of bias; selection bias and measurement bias to reinforce information the 
2015 MAE cohort had recently learned at their first course block. 
 
Exercise 2: The 2015 cohort were then split up into groups and asked to interpret the 
‘Close the Gap’ graphs and whether they thought the results were ’real’ with respect to 
being statistically significant. They were also asked to determine what types of biases 
were occurring in the Australian Bureau of Statistics (ABS) and Australian Institute of 
Health and Welfare (AIHW) child mortality graph provided and why. My MAE colleague 
Ana-Lena provided the graphs and data for this exercise and I was responsible for the 
development of the slides and proof reading. 
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Exercise 3: I was wholly responsible for the design and delivery of this third exercise. 
In this exercise we discussed the issue of under-reporting and incompleteness of 
Aboriginal and Torres Strait Islander status in health data and what are some of the 
implications when it comes to interpreting these data?  
 
We discussed why under-reporting occurs, in which areas it occurs and the need to be 
cognisant of potential biases when it comes to interpreting Aboriginal and Torres Strait  
Islander health outcome data. 
 
The group were led through two cases studies using real life examples of Stata 
outputs. These real life examples came from the data analysis component of two of my 
MAE projects and were: 
1. Hepatitis A positive cases in Queensland 1988-2014 (unpublished data, 2015). 
2. FluMum study; a national retrospective cohort study on birth outcomes, 2012-
2014 (unpublished data, 2015). 
 
These case studies were used to demonstrate poorly collected, incomplete data and an 
example of well collected complete data for the variable ‘Indigenous status’.  The 
group were asked whether these data are can be trusted, are they reliable and what 
are the implications of using these data in reports or in publishing them? 
 
We also discussed the various stages of a research study in which measurement and 
selection bias can occur and how that can influence the internal and external validity 
of the study and hence the results. A ‘tip of the iceberg’ pyramid (provided in the 
slides) was also shown to reveal the different steps at which the identification process 
for Aboriginal and Torres Strait Islander people fails.  
 
Recap: The group were asked to express key messages they had learned from our 
session and to list them from most important to least important. Following the 
responses we received from the 2015 cohort at the end of the session recap it was 
clear they had a firm grasp of how to interpret examples of health data and the 
concrete principles of bias. The 2015 MAE cohort also asked that a copy of our slides 
from the teaching session be uploaded onto their online learning platform ‘Wattle’. 
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Feedback: This area proved to be an eye opener for some of the students whose 
responses in summary were [they]: 
Had never really thought about the quality of health data presented in reports before, 
or that the data may in fact be incomplete which would lead to an under-
representation of the total Australian population. 
 
References used  
1.  Australian Government Close the Gap report, website accessed February 2015. 
https://www.humanrights.gov.au/sites/default/files/document/publication/CTG_ 
progress_and_priorities_report_2015.pdf    
2.  Australian Institute of Health and Wellbeing. National Mortality Database, 
accessed February 2015.  
http://aihw.gov.au/indigenous-statistics-quality-availability/#t2 
3.  Australian Bureau of Statistics website, accessed February 2015. 
http://abs.gov.au/ausstats/abs@.nsf/web+pages/statistics?opendocument#from- 
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Appendix 6.1- Presentation slides for MAE teaching exercise 
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7. Publication 
Outbreak investigation report of Salmonella Typhimurium 
following consumption of Korean style sushi in Southside 
Brisbane, January 2015. 
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Abstract 
 
On 15 January 2015 the Metro South Public Health Unit Brisbane, received notification 
of multiple people presenting to health care facilities with gastrointestinal illness 
symptoms. All patients experienced symptoms following consumption of Kimbap 
(Korean sushi) purchased from multiple food outlets in Brisbane. Laboratory analyses 
of faecal samples confirmed Salmonella Typhimurium as the organism with similar 
MLVA patterns consistent for cases. Twenty-two cases were hospitalised including 
seven children. Supply of the product ceased on Friday 16 January 2015 and there 
were no further reported cases of illness. This short report describes the 
epidemiological, laboratory and environmental health investigations from the 
outbreak.  
 
Chapter 7                                                                                                                     Publication 
220 
 
 
Background 
Identification of an outbreak 
 
On Thursday 15 January 2015 the Metro South Public Health Unit (MSPHU) in Brisbane 
received notification that five people had presented to one General Practitioner with 
gastrointestinal symptoms. A further four people with similar symptoms presented to 
a hospital emergency department in southern Brisbane. Verbal and written reports 
indicated all cases had experienced abdominal cramps, diarrhoea and vomiting 
following the consumption of Kimbap purchased from multiple food outlets in 
Brisbane. Faecal specimens were sent to the public health microbiology laboratory at 
Forensic and Scientific Services (QHFSS). Salmonella Typhimurium was confirmed and 
subsequently genotyped using Multiple Locus Variable-number tandem repeat 
Analysis (MLVA) demonstrating patterns were similar for all cases.   
 
The purpose of the outbreak investigation was to determine the source of Salmonella 
Typhimurium infection and instigate control measures to prevent further illness from 
occurring in the community. A communication strategy was devised to deal with 
interest from the media and those concerned about the outbreak in the wider 
Brisbane community.  
 
Methods 
 
A case was defined as any person who consumed Kimbap from 13 to 16 January 2015 
and subsequently developed diarrhoea and/or vomiting and/or stomach cramps within 
the incubation period for Salmonella. Cases were interviewed using Queensland Health 
‘Suspected’ and ‘Alleged’ Foodborne illness outbreak hypothesis generating  
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questionnaires.1 Three-day food histories were used in the hypothesis generating 
interview process. 
 
If Salmonella was cultured from faecal specimens they were serotyped. If subsequently 
identified as Typhimurium, they were genotyped using the MLVA method.  
 
The environmental health investigation included joint inspections by MSPHU and 
Brisbane City Council to numerous retail food outlets known to sell Kimbap. An 
inspection of the residential home of the Kimbap producer was conducted as it was 
thought the product was being prepared in the dwelling. These inspections involved 
food sampling and environmental swabbing of food preparation surfaces.  All food 
samples and environmental swabs obtained were sent to the laboratory for bacterial 
analysis. A descriptive data analysis was conducted on the case series using Stata 
version 12.1 (StataCorp, Texas, USA) and EpiInfo version 7. 
Description of outbreak 
 
There were 85 confirmed cases in this outbreak. Most cases (96%) were of Asian 
ethnicity and 98% resided in Brisbane. Initially it was difficult to contact people for 
further information due to severity of their illness and language difficulties. All had 
consumed Kimbap between Jan 13 and Jan 16 January 2015 and developed 
gastrointestinal symptoms with onset dates from 13 to 16 January 2015 (Figure 1). Five 
cases are excluded from this figure due to missing data.  
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Figure 1: Confirmed cases of Salmonella Typhimurium by date of onset of illness, 
South Brisbane, January 2015. 
 
The final median incubation period from consumption of the Kimbap to onset of illness 
was 15 hours (range 6 to 52 hours). Of the 85 confirmed cases, 44 provided faecal 
specimens that were positive for either Salmonella Typhimurium MLVA 03-12-11-12-
524 or MLVA 03-13-11-12-524. 
 
Of the 85 cases 60% were female and the median age was 31 years (range <1 – 66 
years).  Twenty-two were hospitalised including seven children. Symptoms reported by 
cases included; diarrhoea (100%), stomach cramps (91%), fever (86%), headache 74%) 
nausea (66%) and vomiting (54%). Three people reported bloody diarrhoea. 
 
Kimbap was known to be purchased from 22 Korean food retailers throughout 
Brisbane in January 2015. Cooked rice and sesame oil was contained in all pre- 
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packaged sushi. Other fillings in Kimbap reported by cases were eggs (69%), tuna (65%) 
a variety of mixed vegetables (63%), ham (52%) and seafood extender (10%).   
 
Laboratory and environmental investigations 
 
Leftover food samples of Kimbap collected from one retail food outlet were positive 
for Salmonella Typhimurium MLVA 03-12-11-12-524. Pre-prepared Kimbap was not 
found at the owner/operator’s residential premises during this inspection however 
commercial quantities of food items were obtained that would normally be used to 
prepare Kimbap.    
Results from the environmental health inspections led to a range of outcomes 
including; suspension and surrendering of food licences, identification of poor food 
hygiene practices and identification of premises with no food licences. 
The owner/operator was unable to be located therefore MSPHU was unable to obtain 
any further information to instigate traceback of food suppliers.  
 
Discussion 
Kimbap was sold pre-made, pre-packaged and contained multiple high-risk food items 
known to potentially cause Salmonellosis.2 Each Kimbap roll contained multiple 
ingredients 3 and since the producer was never able to be investigated it was not 
possible to determine the primary source of the contaminated food. Cross 
contamination during the preparation process was also a possibility. 
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Conducting interviews for cases in this outbreak proved challenging due to severity of 
illness and communication difficulties. Interpreters were not used during the interview  
 
process therefore it is possible some misinterpretation could have occurred during the 
completion of questionnaires.  Nevertheless, recall error for cases was unlikely due to 
the severity of symptoms experienced, consumption of food from pre-packaged and 
clearly labelled containers, and the minimal time frame between onset and notification 
of illness to being interviewed by public health staff. Media coverage4 may have 
prompted more people experiencing gastroenteritis symptoms to seek medical 
attention, potentially identifying more cases.  
 
This outbreak occurred at a time of increased background incidence of Salmonella:  the 
Queensland OzFoodNet Enteric Disease Surveillance Report for 24 January 2015 
indicates that notifications were 2.2 times higher than the preceding 5 year mean for 
this time period; 55% of cases serotyped as Salmonella Typhimurium and seven 
outbreaks of Salmonella Typhimurium infection requiring investigation had been 
recorded in South East Queensland from mid-December 20145. 
 
Public Health Implications 
 
This outbreak affected over 100 members of a Brisbane Asian community. The degree 
of illness experienced by cases was severe with multiple hospitalisations including 
seven children. These factors precipitated wide spread media interest in the outbreak. 
Final numbers of affected individuals from this outbreak are unknown as some cases 
refused an interview and/or specimen collection. 
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Efforts to control this outbreak were successful. Evidence indicated the aetiological 
agent responsible for illness was Salmonella Typhimurium. The likely vehicle of  
 
transmission of infection was Kimbap, distributed by one producer to multiple food 
retail outlets in Brisbane. Supply of product ceased on Friday 16 January, 2015 and no 
further reported cases of illness ensued. 
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